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Abstract 
Hepcidin, the critical iron regulatory factor, is a small peptide produced by the hepatocytes in 
response to increased body iron and inflammation. Circulating hepcidin controls both 
intestinal iron absorption and the release of iron from macrophages into plasma via a 
negative iron feedback system. 
I developed a novel competitive immunoassay for hepcidin using a polyclonal antibody 
produced against synthetic hepcidin. I validated the immunoassay and determined it was 
able to discriminate between healthy controls and selected disease groups. I compared the 
immunoassay against another established method of measuring hepcidin. I established that 
plasma hepcidin has a diurnal rhythm and that plasma hepcidin increases in response to 
intravenous iron in anaemic patients.  
Elevated levels of hepcidin in renal failure may have a role in the erythropoietin resistance 
observed in renal anaemia. In haemodialysis patients, hepcidin levels were significantly 
elevated, but there was no correlation with inflammatory markers. Elevated hepcidin was 
associated with anemia, but erythropoietin dose was negatively correlated with hepcidin, 
suggesting that erythropoietin suppresses hepcidin levels. This was confirmed in patients 
when hepcidin levels significantly decreased after erythropoietin treatment.  
The association between plasma hepcidin and other iron parameters were also examined in 
healthy controls after erythropoietin administration and venesection. Profound hepcidin 
suppression was observed after an erythropoietin dose, with peak levels reduced by 73.2%, 
and then gradually recovering over the following two weeks. A similar but more gradual 
change in hepcidin was observed after reducing hematocrit by removal of 250 mL blood. The 
studies suggested that the marrow–hepcidin axis is regulated by factors other than those 
specifically investigated. 
 
In summary, I have developed and validated a novel immunoassay for hepcidin which will 
allow further investigation of the vital role of this peptide in iron homeostasis and human 
physiology. 
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1.0 Iron 
 
1.1 Iron: essential and harmful 
 
Iron is the second most abundant metal and the fourth most abundant element of the earth‘s 
crust. The common presence of iron in rocky planets like Earth is due to its abundant 
production as a result of fusion in high-mass stars, where the production of nickel56  (Ni) 
(which decays to the most common isotope of iron) is the last exothermic nuclear fusion 
reaction. This causes radioactive nickel to become the last element to be produced before 
collapse of a supernova leads to the explosive events that scatter 
this precursor radionuclide of iron abundantly into space.   
 
Due to its position in the middle of the elements in the first transition series, iron has the 
possibility of various oxidation states, (from –II to + VI), the principal states being II (Ferrous) 
and III (Ferric). Ferrous (Fe2+) iron is extremely water soluble, whereas Ferric (Fe3+) iron is 
insoluble in water, (solubility equilibrium (Ksp
) = 10-39 M and at pH 7.0, [Iron3+] = 10-18 M), and 
significant concentrations of water-soluble Fe3+ species can only be attained by strong 
complex formations. These iron complexes readily undergo electron transfer and acid-base 
reactions, which explain the wide range and variety of catalytic functions of iron and its 
importance in biological systems (Crichton R 2009). 
 
All eukaryotic and most prokaryotic organisms‘ require iron as an essential metal as a 
constituent of oxygen binding haem proteins such as haemoglobin (Hb), Iron-sulfur proteins, 
and proteins that use iron in other functional groups; it is a component of the active sites of 
enzymes such as cytochrome oxidase, which is required for cellular proliferation. However, 
excess Iron accumulation causes organ dysfunction through production of reactive oxygen 
species (ROS). Fe2+ is capable of catalysing the generation of highly reactive hydroxyl 
radicals from hydrogen peroxide, described by the Fenton reaction (Crichton R 2009). In the 
22 
 
presence of trace amounts of iron, the superoxide radical then reduces Fe3+ to molecular 
oxygen and Fe2+. In the presence of catalytic amounts of iron, this reaction produces 
molecular oxygen, a hydroxyl radical and a hydroxyl anion from the superoxide radical and 
hydrogen peroxide. These free radicals play an important role in a number of biological 
processes, such as the intracellular killing of bacteria by phagocytic cells. Free radicals have 
also been implicated in certain cell signalling processes, known as redox signalling (Crichton 
R 2009). This means that free iron has the potential to generate free radicals which can 
cause widespread cellular damage.  
 
1.2 Maintenance of systemic iron homeostasis 
The total body iron content of adult humans is normally 3–5g (this corresponds to 40–50mg 
Iron/Kg body weight), with typically higher values in men than in women. The distribution of 
iron within the body is outlined in Figure 1.1. Circulating erythrocytes contain most of this 
iron bound in the haem prosthetic group of the oxygen transport protein Hb (about 30 mg 
Fe/Kg). Maintaining iron supply to the erythrocyte precursors is of paramount importance, as 
any prolonged drop in supply will result in decreased Hb production and result in the clinical 
condition of anaemia. A further 4 mg Fe/kg is found in muscle in the form of the oxygen 
storage protein myoglobin (Mb) and about 2mg Fe/kg in various tissues as other 
haemoproteins, iron–sulfur proteins and non-haem, non iron–sulphur proteins (Crichton R 
2009). Most of the remaining iron (10–12mg Fe/kg in men and around 5mg Fe/kg in woman) 
is stored as ferritin and haemosiderin, essentially in the liver, spleen, bone marrow and 
muscle. 
 
Iron status in humans may be evaluated by carrying out one or more biochemical tests to 
determine the amount of iron in the blood, the capacity of the blood to transport iron, and the 
amount of iron in storage. These tests may also help differentiate various causes of 
anaemia. Testing usually includes, (see Table 1.1); 
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 Serum iron – which measures the concentration of iron in the blood. 
 Transferrin (Tf) or total iron binding capacity (TIBC) – Tf is the primary transport 
protein to which iron is bound in the blood. TIBC is a measure of all the proteins in 
the blood that are available to bind with iron (including Tf). The TIBC test is an 
indirect measurement of Tf. The body produces Tf in relationship to the need for iron. 
When iron stores are low, Tf levels increase and vice versa. In healthy people, about 
one-third of the binding sites on Tf are used to transport iron. 
 Unsaturated iron binding capacity (UIBC) – measures the portion of Tf that has not 
yet been saturated with iron. UIBC also reflects Tf levels. This measurement may be 
combined with iron to calculate the TIBC. 
 Transferrin saturation (TSAT) - this is a calculation that represents the percentage of 
Tf that is saturated with iron. It can be calculated using either the Tf or TIBC value, 
when the serum iron concentration is known. 
 Serum ferritin - reflects the amount of stored iron in the body; ferritin is the main 
storage protein for iron inside of cells. It is the most useful indicator of iron deficiency, 
as ferritin stores can be significantly depleted before any fall in the serum iron 
concentration occurs. 
 
Table 1.1. Summary of the changes in iron tests seen in various diseases of iron status. 
Disease Iron TIBC/Tf UIBC TSAT Ferritin 
Iron deficiency Low High High Low Low 
Haemochromatosis High Low Low High High 
Chronic illness Low Low Low/Normal Low Normal/High 
Iron  poisoning High Normal Low High Normal 
 
TIBC; Total Iron Binding Capacity, Tf; Transferrin, UIBC; Unsaturated Iron Binding Capacity and TSAT; 
Transferrin Saturation. 
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Figure 1.1 Iron uptake and recycling. Most of the used body iron is recycled from senescent 
erythrocytes by macrophages, and returned to the bone marrow for incorporation in erythroid 
precursors. The liver and reticuloendothelial macrophages function as major iron stores. Importantly, 
the total amount of iron in the body can be regulated only by absorption, whereas iron loss occurs 
only passively from sloughing of skin and mucosal cells as well as from blood loss. This results in the 
absorption and loss of 1–2 mg iron every day. Hepcidin, a peptide produced in the liver, controls the 
plasma iron concentration by inhibiting Iron export by ferroportin from enterocytes and macrophages. 
As a consequence, an increase in hepcidin production leads to a decrease in plasma iron 
concentrations. Hepcidin expression is regulated by body Iron status, inflammation, erythroid iron 
demand and hypoxia via regulation pathways involving the expression of the genes HFE, transferrin 
receptor 2 (TFR2), and hemochromatosis type 2 (juvenile) (HFE2) (also known as HJV). (Adapted 
from Cuijpers et al. 2010). 
 
 
 
Only a small fraction of total body iron, around 3mg, circulates in the plasma and other 
extracellular fluids bound to the iron transport protein, transferrin (Tf) (Bothwell and Charlton 
1970). The system is highly efficient and only 1-2 mg/day of Iron (approximately 10% of the 
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iron ingested) is required to be absorbed from the duodenal enterocytes in the proximal 
duodenum to replace the small daily losses resulting from the desquamination of the 
intestinal epithelium, and from menstruation. However, iron absorption, transport and 
storage needs to be closely controlled to avoid iron overload, as there is no mechanism for 
active iron excretion. When failure of these control mechanisms occurs, excess iron is 
deposited in tissues where it can cause tissue injury and organ failure by promoting the 
generation of ROS, (Andrews 2004). 
 
1.2.1 Iron Absorption 
Dietary non-haem iron is generally found in the Fe3+ state and requires reduction to the Fe2+ 
state before absorption.  Fe3+ is reduced to Fe2+ by the membrane bound ferric reductase 
duodenal cytochrome b (Dcytb) (McKie et al. 2000) before absorption. The presence of a 
reducing agent, such as ascorbic acid, also facilitates this process. Fe2+ is then transported 
into enterocytes in the intestine by specific membrane transporter proteins found on the 
microvilli brush border. The divalent metal transporter-1 (DMT-1) and haem carrier protein 
(McGregor et al. 2005) transport Fe2+ and haem respectively from the intestinal lumen into 
the enterocyte. Within the cell, iron can follow four different routes; it can enter the labile iron 
pool (LPI), be stored within ferritin when in excess, be utilised for intracellular processes, or 
absorbed into the bloodstream by exiting the cell through the basolateral membrane. 
Hephaestin (Hellman et al. 2002;Vulpe et al. 1999), the transmembrane multicopper 
oxidase, oxidizes Fe2+ to Fe3+ for transport through the basolateral membrane into circulation 
via physical interaction with the membrane bound exporter, ferroportin (Fpn) and its plasma 
homolog ceruloplasmin (Cp) (Abboud and Haile 2000) (Donovan et al. 2000) (McKie et al 
2000). The Fpn-mediated efflux of Fe2+ from enterocytes into the plasma is critical for 
systemic Iron homeostasis. This process is negatively regulated by hepcidin, a liver-derived 
peptide hormone that binds to Fpn and promotes its phosphorylation, internalization, and 
lysosomal degradation (Fleming and Sly 2001). Iron is delivered to tissues by circulating Tf, 
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which captures iron released in plasma mainly from intestinal enterocytes or 
reticuloendothelial macrophages. Specifically, dietary iron excreted from enterocytes and 
reticulocytes binds to Tf in a process catalyzed by CP and is delivered to all organs and 
tissues. Two molecules of Iron3+ bind to each molecule of Tf, which transports Iron to all iron 
-requiring tissues, particularly the erythroid marrow for erythropoiesis. Figure 1.2 
summarises the mechanisms involved in the intestinal absorption of iron (Crichton R 2009). 
 
1.2.2 Iron distribution and recycling 
Essentially all circulating plasma iron is normally bound to the iron-binding protein Tf. This 
chelation of iron process has three purposes: 1) to render iron soluble under physiologic 
conditions; 2) to prevent iron -mediated free radical toxicity and 3) to facilitate transport into 
cells. As approximately 70% of body iron is found in Hb, most of the circulating iron is 
consumed for heme biosynthesis by immature bone marrow erythrocytes, which internalize 
Tf through the transferrin receptor-1 (TfR1). The liver stores 10%–20% of body iron in the 
form of ferritin, which can be easily mobilized when needed. About 10% of body iron is 
heme-bound to Mb in striated muscle; the rest is distributed in other tissues. The main iron 
supply for Hb synthesis comes from the iron recycled from senescent erythrocytes by 
macrophages in the liver and spleen. Hb-derived heme is transported in a still undefined 
manner to the cytoplasm, where it is catabolized by cytosolic heme oxygenase-1 (HO1) to 
release the iron that is subsequently exported into the circulation by Fpn  (Crichton R 2009). 
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Figure 1.2 Intestinal iron absorption. Iron absorption in the duodenal mucosa of the gut 
requires transport across the apical and basolateral membranes of duodenal enterocytes. 
The dietary non-heme iron in the duodenal lumen is reduced by an iron reductase, duodenal 
cytochrome B (Dcytb) and thus made available for divalent metal transporter 1(DMT1), 
which transports ferrous iron across the apical brush border membrane. The transporter(s) 
involved in heme iron absorption on the apical side have not been clearly identified or 
characterized. The iron not retained by the cell inside the iron storage protein ferritin is 
transferred to the bloodstream. The basolateral release of non-heme iron (which is also 
derived from heme catabolised by heme oxygenase, HO) is mediated by ferroportin (FPN), 
which transports the metal across the membrane, and hephaestin, which re-oxidizes iron as 
a necessary step for binding to the plasma carrier protein Tf. This step may be favoured by 
the presence of the soluble oxidase ceruloplasmin (Cp), and it is also possible that a portion 
of heme is released intact through the action of the heme exporter FLVCR (Feline 
Leukaemia Virus Subgroup C Receptor). The main proteins involved in iron absorption are 
controlled by iron regulatory proteins (IRPs), the activity of which is regulated by the levels of 
the metal in the labile iron pool (LIP). (Adapted from (Recalcati et al. 2010). 
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Heme can also be exported directly into the circulation via the feline leukaemia virus 
subgroup C receptor (FLVCR) on macrophage plasma membranes (Figure 1.3), which also 
plays a critical role in exporting excess heme from immature erythrocytes and hepatocytes. 
Under conditions of increased erythropoiesis (when there is an increase in Iron demand by 
erythropoietic bone marrow), Iron may be mobilized from hepatic storage sites (Crichton R 
2009). 
 
 
Figure 1.3 Macrophage iron metabolism. Macrophage iron homeostasis showing the 
most important molecules involved in iron traffic, most of which are controlled by iron 
responsive proteins (IRPs). Macrophages acquire iron through a variety of distinct and 
specialized systems: the major source is heme iron (derived from the phagocytosis and 
degradation of red blood cells (RBCs) or from haemopexin and haptoglobin scavenging), but 
the transferrin receptor-1 (TfR1)-mediated uptake of non-heme iron is also important. The 
iron that is not required by cells or stored in ferritin is mainly exported by ferroportin (FPN) 
but also by the feline leukaemia virus subgroup C receptor (FLVCR) (as heme iron). Iron 
traffic in the phagosome has not been fully characterised, although the natural resistance-
associated macrophage protein-1 (Nramp1) is used to pump iron across the phagosome 
membrane in the case of bacterial infection. (HO; haem oxygenase; LIP: labile iron pool). 
(Adapted from (Recalcati et al 2010). 
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1.2.2.1  Transferrin 
Human Tf is a glycoprotein with a molecular weight (MW) around 80 KDa, composed of a 
single polypeptide chain of 680 amino-acid residues with homologous N-terminal and C-
terminal Iron-binding regions, which will bind Fe3+ through the interaction of an obligate anion 
(usually bicarbonate) and four amino acids (Histidine, Asparate and Tyrosine) (Crichton R 
2009). Apotransferrin (Apo-Tf) (or Iron-free) will initially bind one atom of Iron at the C-
terminus and this is followed by subsequent Iron binding by the N-terminus to form 
holotransferrin (holo-Tf). Through its C-terminal iron-binding domain, holo-Tf will interact with 
the type 1 Tf-receptor (TfR1) on the surface of cells  (Crichton R 2009). Tf is synthesised in 
the liver and then secreted into the circulation, where it has a specific role of transporting 
Iron from sites of absorption (gastrointestinal tract (GI)) and haem degradation 
(reticuloendothelial system (RES)) to sites of function (for erythropoiesis, and incorporation 
into Iron containing proteins) and storage (in ferritin). The Tf gene is also expressed in other 
tissues including the central nervous system, testes, ovaries, spleen, kidney and the 
mammary glands (Lambert et al. 2005).  
Tf can only transport Iron in the Fe3+ state, therefore Fe2+ must be oxidised to Fe3+ before 
binding to Tf, this is facilitated by the protein Cp, which is the major copper-binding protein in 
circulation and is a member of the multicopper oxidase family of proteins which contains 
cation binding sites in two of the mononuclear copper sites (Lambert et al 2005). This protein 
also exhibits a copper (Cu)-dependant oxidase activity which is associated with the oxidation 
of Fe2+ to Fe3+ iron. At present it is not known whether apo-Tf interacts directly with CP, but a 
role for Cp in iron export from cells is now well established.  
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1.2.2.2  Transferrin Receptor 
Iron uptake from Tf is mediated by transferrin receptors (TfR) in all proliferating, 
differentiating and Hb synthesising mammalian cells. Two TfRs have been described, TfR1 
and TfR2. Both are homodimeric cell surface type II membrane glycoproteins which bind iron 
loaded Tf as part of the process of iron uptake. TfR1 is made up of two identical disulfide-
linked 90KDa subunits, each containing one threonine-linked and three asparagine-linked 
glycans. TfR1 is expressed by all Iron requiring cells, and is much more abundant than the 
more recently characterised TfR2. In humans, the gene for TfR1 is located on the long arm 
of the same chromosome 3, as are the genes for Tf, melanotransferrin and ceruloplasmin 
(Rabin et al. 1985). 
Hb-synthesising, immature erythroid cells, placental tissues and rapidly dividing cells, 
whether normal or malignant, obtain the Iron that they require via receptor-mediated uptake 
from Tf. The plasma pool in man is approximately 4mg, with the daily turnover greater than 
30mg: the Tf is normally only 30% saturated, so that the majority of the Tf lacks Iron at one 
or both sites  (Crichton R 2009). The binding of diferric-Tf to the TfR is summarised in Figure 
1.4. 
 
1.2.2.3  Ferritin 
Ferritin is a globular protein complex of 24 identical or similar subunits and is the primary 
intracellular Iron-storage protein, which forms a hollow protein shell capable of storing Iron in 
a water soluble, nontoxic, bioavailable form.  ferritin that is not combined with Iron is termed 
apoferritin  (Crichton R 2009). 
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Figure 1.4 Holotransferrin binds to transferrin-receptors (TFR) on the cell surface. The 
complexes localize to clathrin-coated pits, which invaginate to initiate endocytosis. Specialized 
endosomes form, and become acidified through the action of a proton pump. Acidification leads to 
protein conformational changes that release iron from Tf. Acidification also enables proton-coupled 
iron transport out of the endosomes through the activity of the divalent metal transporter 1 protein 
(DMT1). Subsequently, both APO-TF and the TFR return to the cell surface, where they dissociate at 
neutral pH. Both proteins participate in further rounds of iron delivery. In non-erythroid cells, iron is 
stored as ferritin and haemosiderin. (Adapted from (Andrews 2008). 
 
Mammals contain two ferritin subunits of distinct amino acid sequences, known as H 
(predominant in heart, designated heavy) and L (predominant in liver, designated light). The 
H chain ferritins are characterised by a di-Iron, ferroxidase centre, involved in the oxidation 
of Fe2+ to Fe3+, whereas the L chains are thought to be involved in the nucleation of the Iron 
core of ferritin (Crichton R 2009). Variations in the expression of the two subunits between 
tissues mean that in liver and spleen, which play important roles in iron storage, the 
population of ferritin molecules has a high L subunit content (up to 90%), whereas in human 
heart and brain, which play a more important role in iron detoxification, heteropolymers rich 
in H subunits are predominant. Apoferritin binds to free Fe2+ and stores it in the Fe3+, as the 
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Ferritin accumulates in cells of the RES, the protein aggregates are formed as haemosiderin. 
Haemosiderin is only found in conditions of iron overload, usually associated with toxic 
pathological states.  Haemosiderin is a water insoluble protein with a much higher Iron to 
protein ratio than ferritin, which is consistent with it being a lysosomal degradation product of 
ferritin  (Crichton R 2009). Ferritin is part of the acute phase response to inflammation and 
concentrations increase drastically in the presence of an infection or cancer; this is 
necessary to inhibit the infective agent's Iron uptake. The inflammatory response may cause 
ferritin to migrate from the plasma to within cells, in order to deny iron to the infective agent  
(Crichton R 2009). 
 
1.3 Iron regulation 
Iron homeostasis is controlled at both the systemic and the cell level. Over the past decade it 
has become evident that hepcidin, a 25 residue peptide hormone, with homology to the 
defensin family of antimicrobial peptides and produced predominantly by liver hepatocytes, 
plays a central role in the post-translational regulation of systemic iron balance (Krause et al. 
2000;Park et al. 2001). The iron responsive element (IRE)/ iron regulatory protein (IRP) 
system may be a key element connecting systemic and intracellular iron regulation. 
 
1.3.1 Cellular Iron metabolism 
Similar to systemic Iron homeostasis, appropriate levels of iron in the cellular LIP are 
maintained by the coordinated expression of the proteins involved in iron uptake, export, 
storage, and use. This system is controlled at multiple steps, but the post-transcriptional 
control mediated by the IRE/IRP system is central and essential because cell iron 
metabolism is co-ordinately controlled by the binding of IRP1 and/or IRP2 to the cis-
regulatory mRNA motifs IREs in various target mRNAs (Recalcati et al 2010). 
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When cellular iron levels are low, the iron responsive element bound protein (IREBP) exists 
as a 3Fe-4S iron sulfur cluster and binds to IREs located in the 5‘ and 3‘ untranslated 
regions (UTRs) of ferritin and TfR mRNA, respectively (Figure 1.5). This binding inhibits 
translation of the iron storage protein, ferritin. When cellular iron levels are low, IREBP 
containing the 3Fe-4S iron cluster also stabilizes TfR mRNA, increasing its translation into 
TfR proteins. Once generated, these proteins are embedded in the cell‘s plasma membrane 
to promote cellular Iron uptake. When cellular iron levels are high, IREBP changes to the 
alternate 4Fe-4S iron cluster; in this form, its mRNA-binding activity is repressed, and IREBP 
is released from IRE. Without the binding of IRE-BP (4Fe-4S), ferritin mRNA undergoes 
translation. TfR mRNA is rapidly degraded, decreasing translation, which results in the 
production of fewer TfR proteins. Other known genes that encode IREs in their mRNA 5‘ -
UTRs include DMT1, 5-aminolevulinic acid synthetase, hypoxia-inducible factor 2α (HIF-2α), 
and amyloid precursor protein (APP), (Recalcati et al 2010), (Finberg 2011). 
 
 
 
Figure 1.5 Iron-dependent regulation of iron regulatory protein (IRP) binding activity. 
Under conditions of iron deficiency, IRP1 and IRP2 bind to IREs, and thus repress mRNA translation 
(A) or prevent mRNA degradation (B). Increased iron levels lead to the loss of IRP affinity for IREs, 
and increase the translation of 5' IRE-containing mRNAs and the degradation of 3' IRE-containing 
mRNAs.(Adapted from (Finberg 2011). 
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1.4 Hepcidin   
Hepcidin was initially isolated from human plasma ultrafiltrate by a group investigating 
antimicrobial peptides, (Krause et al 2000) and named liver-expressed antimicrobial peptide 
(LEAP-1). Another group had also isolated this peptide from human urine and named the 
peptide hepcidin, after its hepatic origin and bacterial effect in vitro (Park et al 2001). 
 
Most early data on hepcidin expression, regulation, structure and function was obtained by in 
vitro approaches and studies using mouse models. Hepcidin was found to be significantly 
up-regulated in Iron loaded mice (Pigeon et al. 2001), while targeted disruption of the 
hepcidin mouse gene (HAMP) resulted in severe Iron overload (Viatte et al. 2005) (Nicolas 
et al. 2001). It was subsequently found that when mice over-expressed hepcidin that they 
developed severe iron deficiency anaemia (IDA) and that most died at birth (Nicolas et al. 
2002a). The development of severe Iron overload (Nicolas et al 2001) in HAMP gene knock-
out mice suggested that hepcidin was involved in Iron metabolism, whereas its key role in 
the regulation of this system was highlighted by the phenotype of hepcidin mutations in 
patients (Roetto et al. 2003). The newly discovered peptide was found to be regulated by 
inflammation, Iron stores (Pigeon et al 2001), hypoxia and anaemia (Nicolas et al 2002).  
Hepcidin exerts its function by controlling the presence of Fpn (the principal or only cell iron 
exporter) on the cell plasma membrane (Nemeth et al. 2004). Hepcidin binding induces Fpn 
internalization and degradation, which inhibits the release of Iron (mainly from enterocytes, 
macrophages, hepatocytes, and placental cells) into plasma, thus leading to the retention of 
cell Iron and decreasing the levels of circulating Iron (Andrews 2008). Inadequate hepcidin 
expression in relation to body Iron stores underlies the dysregulated duodenal iron 
absorption that characterizes most genetic Iron overload disorders.  
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1.4.1 Hepcidin synthesis and structure 
The human hepcidin gene HAMP (OMIM 606464) contains three exons located on the 
chromosome 19q13.1 encoding an 84 residue precursor protein. In vitro experiments in 
murine hepatic cell lines showed that the production and localization of pre-prohepcidin is 
assumed to be intracellular in the secretory pathway (Wallace et al. 2005), During its export 
from the cytoplasm, the full-length pre-prohepcidin undergoes enzymatic cleavage of a 20 
residue N-terminal endoplasmic reticulum (ER)-targeting signal peptide, resulting in the 
export of a 64 residue prohepcidin peptide into the ER lumen (Wallace et al. 2006). Next, the 
39 residue pro-region peptide is post-translationally removed by a furin-like proprotein 
convertase (Park et al 2001) (Valore and Ganz 2008), in the trans-Golgi network, resulting in 
the mature bioactive hepcidin 25 residue form (Figure 1.6a). Park et al identified truncated 
forms of the hepcidin peptide 22 and 20 residues in length in human urine (Park et al 2001). 
The origin of the smaller isoforms of hepcidin is unclear, although data suggests that 
calcium-independent tissue activity in pancreas extracts might lead to the systemic N-
terminal truncation of hepcidin to hepcidin-22, and that dipeptidylpeptidase 4 is involved in 
the processing of hepcidin-22 into hepcidin-20 (Schranz et al. 2009;Valore & Ganz 2008).  
 
Under physiological conditions, hepcidin-20 and hepcidin-22 are present in the urine, but are 
barely detectable in the serum (Kemna et al. 2007;Kroot et al. 2010;Park et al 2001). These 
results support the hypothesis that both the 20 and 25 residues are secretory cell products, 
whereas the 22 residue is merely a urinary degradation product of the 25 residue hepcidin 
(Ganz 2005). These smaller hepcidin isoforms occur usually only in the serum of patients 
with diseases that are associated with increased concentrations of hepcidin, such as acute 
myocardial infarction (AMI), sepsis, anemia of chronic disease (ACD), metabolic syndrome, 
and chronic kidney disease (CKD) (Kemna et al 2007;Kroot et al 2010;Peters et al. 
2009;Suzuki et al. 2009;Tessitore et al. 2010;Tomosugi et al. 2006) 
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In vivo studies in mice have demonstrated that only full-length mature hepcidin induces 
significant hypoferremia when injected intraperitoneally (Rivera et al. 2005). These findings 
are corroborated by in vitro studies that showed that the truncated 22 and 20 residue forms 
have greatly diminished or an almost complete loss of Fpn regulatory activity, respectively, 
compared with the mature hepcidin (Nemeth and Ganz 2006). 
 
Recent studies have also demonstrated hepcidin expression by cells other than hepatocytes, 
although at much lower levels. These include kidney tubule, heart, retina, monocytes, 
neutrophils, fat cells, alveolar cells, pancreatic cells, and cardiomyocardal cells (Bekri et al. 
2006;Kulaksiz et al. 2008;Merle et al. 2007;Nguyen et al. 2006;Peyssonnaux et al. 
2006)((Gnana-Prakasam et al. 2008;Isoda et al. 2010). The hepcidin produced by these 
cells is unlikely to significantly contribute to systemic circulating concentrations, but may 
exert local effects in these tissues. 
 
The solution structures of human hepcidin have been determined by nuclear magnetic 
resonance (NMR) (Hunter et al. 2002;Lauth et al. 2005). Hepcidin forms a distorted anti-
parallel beta-sheet, with four conserved disulfide bonds, three of which stabilise the anti-
parallel strands of its simple beta sheet hairpin structure (Figure 1.6b). The fourth disulphide 
links two adjacent cysteine residues in an unusual vicinal disulfide bridge found at the turn of 
the hairpin, which is probably of functional significance. Like other antimicrobial peptides, 
hepcidin has an amphiphilic structure, with hydrophobic residues disposed on the convex 
side of the structure and predominantly positively charged residues on the concave side 
(Crichton R 2009).  
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A.  
B.  
Figure 1.6  Hepcidin structure:  
A) Amino acid sequence of the human hepcidin precursor peptide. The precursor 
contains a 24 amino acid (aa) signal sequence at the N terminus (the line between  
24 and 25 aa indicates the putative signal sequence cleavage site), a 35 aa pro-
region and the C terminal 20-, 22- and 25 aa hepcidin peptides differing only by their 
N terminal truncation, as denoted by the arrows. After cleavage of the signal peptide 
from the precursor, pro-hepcidin is produced, consisting of 60 aa. The proposed 
disulphide bonds in hepcidin-25 are between the cysteines at positions 1-8, 2-7, 3-6 
and 4-5, as shown by the broken lines. (Adapted from (Kulaksiz et al. 2004). 
 
B) Molecular structure of human synthetic hepcidin-25. Distorted β-sheets shown as 
grey arrows, peptide backbone coloured grey. Disulfide bonds are coloured yellow, 
highlighting the unusual bond between adjacent cysteines. Positive residues of 
Arginine (Arg) and Lysine (Lys) are pictured in blue, the negative residue of Aspartic 
acid (Asp) in red, and the Histidine containing amino terminal Cu2+-Ni2+ (ATCUN)-
binding motif in the N-terminal region is coloured green. (Adapted from (Ganz 2006). 
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The N-terminal region of hepcidin represents a metal binding site specific for the 
coordination of Cu2+ and Ni2+ known as the ATCUN binding motif. Although the biological 
role of the metal binding motif is still unknown, its presence may be physiologically relevant, 
because has been recently demonstrated that removal of the five N terminal residues 
(DTHFP) progressively decreases the antimicrobial activity and the 20 and 22 residue 
peptides are completely inactive, both in vitro and in vivo (Melino et al. 2005). The sequence 
of hepcidin is highly conserved between vertebrate species, and notably all eight of the 
cysteine residues which form the four disulphide bonds are conserved. Whether hepcidin 
might bind copper (Melino et al 2005) or iron (Farnaud et al. 2006) remains a matter of 
controversy. The ability of hepcidin to bind iron and other divalent metals suggests there 
may be a non-hormonal role for hepcidin in iron metabolism or a conformational mechanism 
for uptake of divalent metals as part of hepcidin‘s hormonal role in regulating Fpn 
degradation. There is debate as to whether hepcidin can be considered to act as a classical 
hormone. As with a classical hormone, the hepcidin peptide is initially produced and stored 
in i biologically inactive pre- and prohormone forms. These inactive forms can then be 
converted into the mature active form in response to a particular stimulus, such as changes 
in plasma concentrations of iron. Once released by the hepatocytes in response to this 
nutrient signal, hepcidin then binds to a specific plasma membrane receptor, ferroportin. 
However a classical hormone, such as insulin growth factor-1, on binding to a specific 
receptor initiates a signal transduction which can involve a second messenger signal inside 
the cell eliciting a physiological response. Hepcidin, in contrast, induces the internalization 
and phosphorylation of ferroportin upon binding to it (thus preventing the export of iron from 
the cell) and in this respect does not resemble a hormone. 
 
1.4.2 Hepcidin interaction with ferroportin 
The molecular target of hepcidin is ferroportin (Fpn), a transmembrane protein that is the 
only known iron exporter in vertebrates. Fpn is present in all the cells and tissues that export 
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iron into plasma, including macrophages, duodenal enterocytes, hepatocytes and the 
placenta (Abboud & Haile 2000;Donovan et al 2000;McKie et al 2000). The molecular 
mechanism of hepcidin-mediated Fpn down-regulation has been studied in detail (De, I et al. 
2007). After binding of hepcidin, Fpn is phosphorylated at the plasma membrane by a 
member of the Src3 family of tyrosine kinases. This step is critical for internalisation. The site 
of phosphorylation is one of two adjacent tyrosine (Tyr) residues, Tyr 302 and Tyr 303. 
Mutation of either Tyr alone has little effect on internalisation, whereas mutation of both Tyr 
residues prevents phosphorylation and endocytosis. Subsequent to Fpn internalisation, the 
phosphate groups are removed and the protein is ubiquitinated on Lysine 253. Inability to 
ubiquinate Fpn does not prevent hepcidin dependent internalisation, but does prevent its 
degradation. Ubiquinated Fpn is trafficked through the multivesicular body (MVB) pathway 
for ultimate degradation in the late endosome/lysosome compartment.  Depletion of any of 
the members of the protein complexes involved in MVB trafficking, the Endosome Sorting 
Complex Required for Transport (ESCRT) proteins, ESCRT1, ESCRT2 and ESCRT3, by 
small interfering RNA, reduces the transfer of Fpn to the lysosome. In vivo, this has been 
demonstrated to affect Fpn at the basolateral membrane of enterocytes, blocking the 
delivery of dietary iron to the Tf in the circulation, and Fpn in macrophages recycling 
senescent erythrocytes, trapping iron within them. It remains uncertain whether hepcidin, 
itself secreted from hepatocytes, can also affect mobilisation of hepatic iron stores, notably 
from the hepatocytes themselves (De, I et al. 2009) (Crichton R 2009). 
 
1.5 Hepcidin regulation 
Three upstream regulatory pathways that control hepatocyte hepcidin production have been 
described: i) iron store-related regulation, ii) erythropoietic activity driven regulation, and iii) 
inflammation related regulation.  All of these putative pathways interact with hepatocytes to 
initiate the production of sufficient hepcidin for the maintenance of iron homeostasis (Babitt 
et al. 2006;Pak et al. 2006;Verga Falzacappa et al. 2007;Weizer-Stern et al. 2006;Wrighting 
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and Andrews 2006). Recent reports have demonstrated that the full functional effect of both 
the store regulator and erythroid regulator depends on the activity of an additional pathway 
that is controlled by the glycosylphosphatidylinositol (GPI)-linked cell associated 
haemojuvelin (HJV). HJV has been shown to maintain a mandatory regulation pathway by 
bone morphogenic protein (BMP)/ sons of mothers against decapentaplegic (SMAD) 
signalling (Babitt et al 2006), in which SMAD4 is essential (Wang et al. 2005).  
 
It now appears that most regulation of hepcidin expression occurs at the level of 
transcription. The transcription factor CCAAT/enhancer protein alpha (C/EBPα) is a potent 
activator of both the human and the mouse hepcidin promoters (Courselaud et al. 2002). 
Recent studies have demonstrated that oxidative stress represses hepcidin gene expression 
by preventing C/EBPα binding to the hepcidin promoter (Choi et al. 2007;Harrison-Findik et 
al. 2006). Two other signal transduction pathways have been shown to modulate the binding 
of transcription factors to the hepcidin promoter, as mentioned the BMPs, which are 
members of the transforming growth factor-β (TGF-β) superfamily of ligands the SMAD 
pathway and the signal transducer and activator of transcription (STAT3) pathway (Kautz et 
al. 2008). 
 
1.5.1 Hepcidin regulation by iron 
Initial studies with mouse models studies demonstrated that hepcidin mRNA expression is 
induced in response to dietary and parenteral iron loading. The physiological importance of 
the regulation of hepcidin by iron is evident from the phenotypes of several inherited 
disorders of iron balance that are characterized by hepcidin dysregulation (Pietrangelo 
2011). Hepcidin deficiency is a feature of the known recessive forms of hereditary 
hemochromatosis (HH). In contrast, a failure to appropriately down-regulate hepcidin 
production is seen in iron-refractory iron deficiency anaemia (IRIDA), an inherited disorder 
caused by loss-of-function mutations in the gene TMPRSS6 which encodes a type II 
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transmembrane protease serine-6, also known as matripase-2 (Finberg et al. 2008;Ramsay 
et al. 2008;Ramsay et al. 2009).  The fact that the genetic defects in these disorders cannot 
be compensated for to maintain systemic iron balance indicates that the encoded gene 
products play key roles in the hepcidin response to systemic iron status. 
 
Signalling by BMPs has emerged as a key pathway promoting hepcidin expression by the 
liver. There are two types of transmembrane BMP receptors involved in BMP signal 
mediation, BMPR-I and BMPR-II (Nohe et al. 2003). As with all of the TGF-β superfamily of 
cytokines, BMPs are bound by their cognate receptors (the type II receptor), which are 
constitutively active protein kinases. This ligand binding event induces the BMPR-II receptor 
to associate with and to phosphorylate BMPR-I (Figure 1.7). Phosphorylation of the type I 
receptor results in activation of its kinase activity, which results in the phosphorylation of a 
subset of ‗Receptor activated‘ SMAD4 (SMADs 1, 5 and 8) at their C terminus, which bind to 
the co-SMAD protein SMAD4 in the cytoplasm.  
 
This complex then translocates to the nucleus where it binds to specific DNA motifs and 
stimulates the transcription of a wide range of genes, including the HAMP hepcidin gene. 
BMPs can also signal through independent pathways, notably via the mitogen activated 
protein (MAP) kinase pathway. In the case of the mitogen-activated protein kinesis (MAPK) 
(p38) pathway, this may possibly be mediated by a TGF- activated kinase 1 complex 
(Tak1/Tab1) (Andriopoulos, Jr. et al. 2009;Corradini et al. 2011). Studies have also shown 
the activation of other MAP kinase dependent pathways due to BMP stimulation (Nohe et al 
2003). 
 
Liver specific inactivation of SMAD4 leads to failure to produce hepcidin and an iron 
overload phenotype similar to that observed in hepcidin knock-out mice (Wang et al. 2005). 
Treatment with BMPs increases hepcidin production (Babitt et al 2006;Truksa et al. 
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2006;Wang et al 2005), which is inhibited by expression of a dominant negative BMP 
receptor or a dominant negative regulatory SMAD protein (Babitt et al 2006).  
 
 
 
 
 
Figure 1.7 Modulation of hepcidin transcription by iron. Diferric (Holo) transferrin 
binds to transferrin receptor-1(TfR1).TfR1 leaves human haemochromatosis protein (HFE) 
free to interact with TfR2, which is stabilized on the cell surface. Interaction between HFE 
and TfR2 modulates hepcidin transcription through a mechanism not yet fully clarified. Bone 
morphogenic protein (BMP6) is produced mainly by sinusoid endothelial cells (SEC) and 
other non-parenchymal cells, and is transcriptionally activated by intracellular iron increase. 
The hepatocyte-specific BMP co-receptor haemojuvelin (HJV) binds to BMP receptors type I 
and II (BMPRI-II) in the presence of the ligand BMP6. Formation of the multiprotein complex 
on the cell surface of hepatocytes activates the phosphorylation of sons of mothers against 
decapentaplegic (SMAD) 1/5/8 and their interaction with SMAD4. The SMAD complex 
translocates to the nucleus for hepcidin activation. Conditions of hypoxia/acute iron 
deprivation increase the activity of the transmembrane serine protease TMPRSS6 (Zhang et 
al. 2011) which impairs hepcidin mRNA by cleaving membrane HJV (Adapted from 
(Camaschella and Poggiali 2011). ERK; Extracellular signal-regulated kinases, MAPK; 
Mitogen-activated protein kinases. 
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The relative potencies of different human BMPs in stimulating up-regulation of hepcidin 
transcription by murine primary hepatocytes are BMP9 > BMP4 > BMP2, and the BMP 
signalling pathway has been shown to act independently of the human haemochromatosis 
protein (HFE), transferrin receptor-2 (TfR2) and interlukin-6 (IL-6) (Truksa et al 2006). 
 
A key regulatory mechanism is the action of proteins, known as co-receptors, to promote or 
inhibit the binding of the BMR ligand to its receptor. It has been found that members of the 
repulsive guidance molecule (RGM) family (proteins known to be important in 
neurodevelopment), RGMb and RGMa, function as co-receptors which enhance BMP 
signalling (Babitt et al 2006;Corradini et al. 2009). HJV, a protein which is mutated in 
patients with severe, early onset HH, shares 50–60% amino acid identity and key structural 
features with RGMa and RGMb. It has been shown that HJV functions as a co-receptor 
which enhances BMP signalling in the hepatocyte via the classical BMP pathway (Babitt et al 
2006). HJV contains GPI anchor, suggesting that it can be present in either a soluble or a 
cell associated form (GPI-HJV). Soluble haemojuvelin (sHJV) is released by a proprotein 
convertase through cleavage at a conserved polybasic RNRR site (Lin et al. 2008). 
 
In primary human hepatocytes, cellular HJV positively regulates hepcidin mRNA expression, 
whereas recombinant sHJV suppresses hepcidin mRNA expression, suggesting that sHJV 
acts as an antagonist of GPI-HJV to down-regulate hepcidin expression (Lin et al. 2005). 
The soluble form of HJV exists in human sera at concentrations similar to those required to 
suppress hepcidin mRNA in vitro. Soluble HJV release is progressively inhibited by 
increasing concentrations of both Tf bound iron and non-Tf bound iron. It is therefore 
proposed that soluble and cell associated HJV reciprocally regulate hepcidin expression in 
response to changes in extracellular iron concentration, and that sHJV could be one of the 
mediators of hepcidin regulation by iron (Lin et al 2005). HJV binds to type I BMP receptor 
and enhances the signal produced by the binding of BMPs. It is able to enhance the 
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phosphorylation of SMAD1, 5, 8 in response to BMP stimulation, leading to enhanced 
hepcidin expression in cultured cells (Babitt et al 2006). 
 
HJV has been shown to co-immunoprecipitate with neogenin, a receptor involved in a variety 
of cellular signalling processes (Zhang et al. 2005). (Babitt et al. 2007) demonstrated that the 
administration of BMP-2 increases hepcidin expression and decreases serum iron levels in 
vivo. The authors also show that sHJV selectively inhibits BMP induction of hepcidin 
expression in vitro and that administration of sHJV decreases hepcidin expression, 
increases Fpn expression, mobilises splenic iron stores and increases serum iron levels in 
vivo. Taken together, these results support a role for modulators of the BMP signalling 
pathway in treating diseases of iron overload and the anemia of chronic disease (ACD), a 
disorder resulting from high levels of hepcidin expression. 
 
TMPRSS6 (also known as matriptase-2), appears to function as a key negative regulator of 
hepatic BMP signaling. The key role of TMPRSS6 in hepcidin suppression was revealed by 
the phenotype of a chemically induced TMPRSS6mouse mutant exhibiting iron deficiency 
anemia and increased hepatic hepcidin mRNA (Du et al. 2008). This finding facilitated the 
identification of TMPRSS6 mutations as a genetic cause of IRIDA in humans (Ramsay et al. 
2009). In vitro, TMPRSS6 has been shown to cleave HJV from the plasma membrane 
(Silvestri et al. 2008), and in accord with this result, mice with genetic loss of TMPRSS6 
show up-regulated BMP signaling that is dependent upon the presence of HJV (Finberg et 
al. 2010;Truksa et al. 2009). The cleaved form of HJV generated by TMPRSS6 is distinct 
from that generated by proprotein convertase activity (Maxson et al. 2010). Interestingly, 
TMPRSS6protein levels in rat liver increase in response to acute iron deficiency, (Zhang et 
al. 2011), and in hepatoma cells, hypoxia increases TMPRSS6 expression and concurrently 
decreases membrane-bound HJV (Lakhal et al. 2011).  
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Another molecule that may negatively regulate hepatic BMP signaling for hepcidin 
production is SMAD7, an inhibitory SMAD protein which blocks R-SMADs and Co-SMADs 
and is induced by TGF- signalling (Mleczko-Sanecka et al. 2010). SMAD7 appears to 
antagonize TGF-β signaling by acting in a negative-feedback loop. Similar to the expression 
of hepcidin and BMP-6, hepatic mRNA levels of SMAD7 increase with chronic dietary iron 
loading (Kautz et al 2008). In primary murine hepatocytes, SMAD7 expression is induced by 
BMP6, whereas SMAD7 over-expression greatly reduces hepcidin mRNA levels and 
abolishes the hepcidin response to BMP6 (Mleczko-Sanecka et al 2010). These findings 
suggest that SMAD7 may function to provide negative feedback to dampen BMP signaling 
for hepcidin production. The relative contribution of SMAD7 activity to hepcidin regulation in 
vivo has yet to be established. 
 
1.5.2 Hepcidin regulation by erythropoiesis 
 
Hepcidin production is suppressed under conditions of increased erythropoietic drive 
(Crichton R 2009). Proposed mediators of this hepcidin suppression include hypoxia and 
circulating factors secreted by erythroid precursors in the bone marrow  (Crichton R 2009). 
Hepcidin suppression is a prominent feature of congenital iron-loading anaemias that are 
characterized by ineffective erythropoiesis, such as β-thalassemia (Gardenghi et al. 
2007;Origa et al. 2007). Two products secreted by erythroid precursors that may contribute 
to the hepcidin suppression observed in iron-loading anaemias are the TGF-β superfamily 
member‘s, growth differentiation factor-15 (GDF15) and twisted gastrulation protein-1 
(TWSG1). In an in vitro model of human erythropoiesis, GDF15 and TWSG1 mRNA levels 
were up-regulated during erythroblast maturation (Tanno et al. 2007). 
 
GDF15 protein levels are elevated in the serum of individuals with β-thalassemia, refractory 
anemia with ringed sideroblasts, and congenital dyserythropoietic anemia types I and II. 
46 
 
GDF15 treatment has been shown to have some capacity to mediate hepcidin suppression 
in hepatoma cells and primary human hepatocytes, although the mechanism mediating the 
hepcidin suppression was not demonstrated (Tanno et al 2007). 
 
TWSG1 may function as an inhibitor of hepatic BMP signaling, as TWSG1 has been shown 
to inhibit the ability of BMP2 and BMP4 to induce hepcidin expression in hepatoma cells and 
primary human hepatocytes (Tanno et al. 2009).The role of GDF15 and TWSG1 in hepcidin 
suppression in vivo remains to be clarified. It also remains unclear whether either molecule 
contributes to hepcidin regulation outside of the pathological setting of ineffective 
erythropoiesis. 
 
Hepcidin expression is also modulated by hypoxia, an effect originally demonstrated in 
hepatoma cells cultured under hypoxic conditions and in mice housed in hypobaric 
chambers (Leung et al. 2005;Yoon et al. 2006). The ability of hypoxia to influence hepcidin 
expression may reflect its ability to induce EPO production by the kidney and thus promote 
erythropoietic activity. Indeed, healthy humans studied under normoxic conditions showed a 
marked reduction in their urinary hepcidin levels within 48 hours after administration of 
recombinant EPO (Robach et al. 2009). In animal models, the ability of EPO administration 
to decrease hepcidin expression is blocked by administration of cytotoxic agents that 
suppress bone marrow activity, suggesting that hepcidin suppression in response to EPO is 
dependent upon erythropoietic activity. In a cohort of healthy humans studied at sea level 
and after acute and chronic exposure to high altitude, acute hypoxia exposure caused a 
rapid and marked increase in serum erythropoietin; serum hepcidin was reduced by acute 
hypoxia exposure and showed a further decrease after several days of hypoxic exposure 
(Piperno et al. 2011). Interestingly, serum levels of hepcidin and ferritin were correlated at all 
time points in this study, suggesting that the suppression of hepcidin observed may have 
been mediated by either iron itself or by the kinetics of iron utilization in response to hypoxia. 
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Hypoxia may also exert a local effect on hepcidin production in the liver through the actions 
of hypoxia inducible factors (HIFs), heterodimeric transcription factors that promote the 
expression of genes that mediate responses to hypoxia. Under normoxic conditions, the 
regulatory α-subunit of HIF is hydroxylated by prolyl hydroxylases, which triggers its 
degradation through the ubiquitin proteosome pathway. However, under conditions of 
hypoxia or iron depletion, hydroxylation of the α-subunit is inhibited, leading to its 
stabilization, which facilitates HIF-mediated transcriptional responses  (Crichton R 2009). 
 
In one study hepatic levels of the HIF-1α isoform increased in mice fed an iron-deficient diet. 
The investigators demonstrated that HIF-1α could bind to the hepcidin promoter in mouse 
liver (Peyssonnaux et al. 2007). However, others have found no evidence for dysregulated 
systemic iron homeostasis in mice lacking HIF-1α in the liver and the ability of HIF-1α to 
directly bind the hepcidin promoter in vivo has been challenged (Volke et al. 2009). As 
described previously, it is possible that hypoxia may affect hepcidin expression locally in the 
liver through other mechanisms, such as by increasing levels of soluble HJV, (Silvestri et al. 
2008a) and/or by increasing the expression of TMPRSS6/matripase-2 (Lakhal et al 2011). 
 
1.5.3 Hepcidin regulation by inflammation 
Hepcidin elevation leads to impaired utilization of iron from macrophage stores, reduced 
absorption of dietary iron, and a resulting hypoferremic state that impairs the delivery of iron 
to maturing erythroid cells in the bone marrow. This process contributes to the ACD (also 
known as the anaemia of inflammation (AI)), an anaemia that is usually normochromic and 
normocytic and that is associated with erythropoietin (EPO) hyporesponsiveness, reduced 
proliferation of erythroid precursors and decreased RBC survival (Andrews 2004). Several 
inflammatory stimuli have been identified that induce hepcidin expression. The most clearly 
defined mechanism by which such stimuli promote hepcidin expression is via the 
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inflammatory cytokine IL-6 signalling through the STAT3 pathway (Andrews 2004;Finberg 
2011). 
 
The production of IL-6 is stimulated by lipopolysaccahrides (LPS), large molecules found in 
the outer membranes of Gram-negative bacteria that act as endotoxins and elicit a strong 
immune response in animals. From studies in humans and mice, and in cultured cells, it 
seems that IL-6 up-regulates the transcription of hepcidin (Lee et al. 2005;Nemeth et al. 
2003;Nemeth et al. 2004), as does interlukin-1 (IL-1) (Lee et al 2005). This up-regulation 
involves activation of STAT3 (Pietrangelo et al. 2007;Verga et al 2007;Wrighting & Andrews 
2006) and subsequent binding of STAT3 to a regulatory element in the hepcidin promoter 
(Verga et al 2007;Wrighting & Andrews 2006). Activation of the hepcidin gene by IL-6 
requires both the Janus kinase (JAK)-STAT and the BMP-SMAD pathways, but how the 
pathways interact is unknown (Finberg 2011). 
 
A small molecule inhibitor of BMP signalling has been identified using a novel zebra fish 
embryo screen (Yu et al. 2008). The molecule, (6-[4-(2-piperidin-1-yl-ethoxy) phenyl]-3-
pyridin-4-yl-pyrazolo [1, 5-a] pyrimidine), has been given the name dorsomorphin. In a series 
of in vitro studies it has been shown to inhibit phosphorylation of the R-SMADs, but not to 
alter MAPK-p38 phosphorylation, indicating its specificity for SMAD dependent signalling 
(Figure 1.8), most likely by affecting BMPR-1 kinase activity. In contrast, BMP sequestering 
inhibitors, such as noggin and chordin, down-regulate both pathways (Yu et al 2008).  The 
authors show that dorsomorphin blocks the expression of HAMP, the gene encoding 
hepcidin, stimulated by either BMP2 or the BMP co-receptor HJV. It also blocks the 
stimulation of HAMP expression either by iron or by the pro-inflammatory cytokine, IL-6 (Yu 
et al 2008). 
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1.5.4 Influence of other cellular regulators on systemic iron balance 
Whereas the central role of the hepcidin-Fpn axis in the regulation of systemic iron balance 
is well established, distinct mechanisms that regulate iron balance at the cellular level have 
also been identified. Recent studies have suggested that these cellular and systemic 
pathways interact to influence iron balance (Hentze et al. 2010). For example, mice 
harbouring an intestinal-specific deletion of the HIF-2α subunit have decreased serum and 
liver iron levels, even though their hepatic hepcidin expression is markedly decreased 
(Mastrogiannaki et al. 2009). HIF-2α was shown to directly bind to the promoter of DMT1, 
which encodes the principal apical transporter that imports ferrous iron into enterocytes 
(Mastrogiannaki et al 2009). Conversely, mice harbouring an intestine-specific deletion of the 
H-subunit of the iron-storage protein ferritin showed increased body iron stores even though 
their hepcidin expression in the liver was increased (Vanoaica et al. 2010). These findings 
demonstrate that under certain circumstances, hepatic regulation of hepcidin expression 
cannot fully compensate for defects in cellular iron balance in enterocytes to maintain normal 
systemic iron balance (Finberg 2011). 
 
The recent finding that hepcidin expression can be modulated at the cellular level by 
microRNA (miRNA) adds another layer of complexity to the regulation of systemic iron 
balance (Castoldi et al. 2011). MicroRNAs are a class of short non-coding RNAs that bind to 
complementary sequences on target messenger RNA transcripts to negatively regulate gene 
expression at the post-transcriptional level. In mice, injection of an antagonist of the liver-
specific miR-122 was found to induce systemic iron deficiency and to increase levels of the 
mRNAs encoding hepcidin, HFE, and HJV. In vitro studies suggest that miR-122 may bind to 
specific sites in the 3‘-untranslated region of the HIRON and HJV mRNAs (Castoldi et al 
2011). Because antagonism of miR-122 did not alter downstream markers of BMP-signaling 
responses, the mechanism by which modulation of miR-122 alters hepcidin mRNA levels 
remains uncertain (Finberg 2011). 
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1.6 Physiology of hepcidin in humans 
 
1.6.1  Hepcidin kinetics 
 
After hepcidin is secreted into the circulation by the hepatocytes and performing its 
regulatory role in cellular iron uptake and release, it is excreted from the body in the urine. 
Hepcidin clearance is assumed to occur via cellular co-degradation with Fpn at its sites of 
action, and via excretion by the kidneys. Circulating hepcidin was recently found to be bound 
to α2-macroglobulin with relatively high affinity and to albumin with relatively low affinity. On 
the basis of theoretical calculations, approximately 11% of hepcidin has been estimated to 
be freely circulating (Peslova et al. 2009). Hepcidin clearance is assumed to occur via 
cellular co-degradation with Fpn at its sites of action, and via excretion by the kidneys. 
Because of its low molecular weight, free hepcidin is likely to freely pass into the glomerular 
filtrate. In small studies in humans, the fractional excretion of hepcidin has been calculated 
to be as low as 0%–5% (Ganz et al. 2008;Swinkels and Wetzels 2008), either because it is 
reabsorbed, as with other small peptides, or because it is not freely filtered. Evidence for the 
latter explanation comes from the finding of increases of only 1- to 6-fold of hepcidin 
concentrations in patients with glomerular dysfunction (Ashby et al. 2009;Costa et al. 
2009;Ganz et al 2008;Peters et al. 2010;Tomosugi et al 2006) compared with the 20- to 30-
fold increase of serum β-2-microglobulin (β2M). The excretion of β2M is known to be almost 
completely governed by glomerular filtration. It is possible that binding to α2-macroglobulin or 
other carrier proteins prevents circulating hepcidin from being freely filtered. Alternatively, 
the otherwise expected increased circulating concentrations in patients with decreased renal 
filtration may be offset by a compensatory feedback decrease in hepatic hepcidin production. 
 
It may be possible that under certain conditions hepcidin escapes renal tubular reabsorption. 
This lack of reabsorption may play a role in several disorders of iron metabolism that are 
associated with tubular dysfunction and increased concentrations of urine hepcidin, such as 
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inflammation, iron overload, and malaria (Sumbooanonda et al 1998; Wan et al 2003). 
Possible local tubular production of hepcidin must also be taken into account in the 
interpretation of urine as reflecting serum hepcidin concentrations in such studies (Kulaksiz 
et al 2005), as well as possible defect in tubular reabsorption of hepcidin. 
 
 
1.6.2 Assessment of quantitative methods for hepcidin 
Since the discovery of hepcidin and its hypothesised role in iron homeostasis, there has 
been substantial interest in the quantification of hepcidin in biological fluids. Published 
methods have included a variety of protein and mass spectroscopic methods which have 
improved our understanding of this important hormone, although the accurate determination 
of this peptide in biological fluids is still challenging. 
 
Progress in developing a conventional immunochemical hepcidin assay has been hampered 
by difficulties in generating specific anti-hepcidin antibodies in host animals such as rabbits 
and mice. This difficulty is principally due to the small and compact structure of hepcidin, 
which leaves scarce antigenic epitopes, and the high degree of conservation of hepcidin 
among species, which complicates the elicitation of an immune response in host species. 
Furthermore interpretation of hepcidin results from the various assays maybe hampered by 
the various forms of physiological hepcidin, such as free or protein bound form and the 
presence of the hepcidin isoforms 22 and 20 residues which may well interfere with hepcidin 
quantification. 
 
In early studies a commercial, (DRG® International, Germany) serum-based enzyme 
labelled immunosorbent assay (ELISA) based upon a competitive immunoassay format 
(cELISA) was used that measures the hepcidin precursor prohepcidin, rather than the 
bioactive peptide (Kulaksiz et al 2004). However the prohepcidin concentrations did not 
correlate with urinary or serum hepcidin concentrations, and they did not correlate with 
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relevant physiological responses, suggesting that prohepcidin does not have a bioactive role 
in iron homeostasis (Brookes et al. 2005;Hadley et al. 2006;Roe et al. 2007).  
 
The first assays to measure hepcidin were a protein-based dot plot assay which was used to 
(semi)quantify hepcidin in urine (Nemeth et al 2004) and a mass spectrometry (MS) assay 
using a surface-enhanced laser desorption/ionization-time-of-flight (SELDI-TOF) method 
(Kemna et al. 2005). These assays, however, were hampered by the lack of internal 
standards and could only be used to measure hepcidin in a semi-quantitative manner and 
were initially based upon urine as the test sample, which limits the methods due to use of 
problems of using random or 24hr collections and correction for creatinine. 
 
In recent years, continued progress has been made by the introduction of appropriate 
internal standards to quantify hepcidin in serum and urine by use of updated TOF-MS assay 
(Kroot et al 2010). In addition, Ganz et al. (Ganz et al 2008) have a developed a commercial 
cELISA for human hepcidin in biological fluids. A number of other groups have also 
published hepcidin assays that can be divided into three main methodologies: (a) MS 
(Altamura et al. 2009;Anderson et al. 2010;Bansal et al. 2009;Bansal et al. 2010;Campostrini 
et al. 2010;Crockett et al. 2010;Kobold et al. 2008;Li et al. 2009;Murao et al. 2007;Murphy et 
al. 2007;Ward et al. 2008) ; (b) Immunochemical assays, comprising competitive 
radioimmunoassay (cRIA) (Busbridge et al. 2009;Grebenchtchikov et al. 2009), cELISA 
(Ganz et al 2008;Koliaraki et al. 2009;Kroot et al 2010;Schwarz et al. 2011) and a two-site 
sandwich ELISA (Butterfield et al. 2010), and (c) A ligand-binding assay (De, I et al. 2008), 
which utilises the specificity of a 19 residue peptide corresponding to the hepcidin binding 
domain on the cell surface Fpn.  
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1.6.3 Reference intervals for hepcidin 
All studies of healthy controls have revealed considerable inter-individual variation in 
hepcidin concentrations, resulting in wide reference intervals (Busbridge et al 2009;Galesloot 
et al. 2011;Ganz et al 2008;Grebenchtchikov et al 2009;Kemna et al 2007;Kroot et al. 2009). 
This suggests that reference intervals maybe limited when used for the interpretation of 
individual hepcidin concentrations. Hepcidin values should be interpreted in the context of 
other indices of iron metabolism. The wide reference intervals may be attributed in part to 
the influence of a diurnal cycle on hepcidin concentrations (Busbridge et al 2009;Ganz et al 
2008;Grebenchtchikov et al 2009;Kemna et al 2009). This circadian rhythm may be 
regulated by transcription factors such as upstream stimulatory factor and c-Myc/Max 
through E-boxes (Bayele and Srai 2009). Genes regulated through E-boxes include the 
clock genes period homolog 1 (Drosophila) (PER1), timeless homolog (Drosophila) 
(TIMELESS), and clock homolog (mouse) (CLOCK), all of which are under circadian 
rhythmic transcriptional control.  
 
To date, differences in hepcidin concentrations between genders have not been consistently 
found (Busbridge et al 2009;Ganz et al 2008;Grebenchtchikov et al 2009;Kemna et al 
2007;Kroot et al 2009;Murao et al 2007).  Hepcidin concentrations have not been 
consistently compared between races and there are few paediatric studies (Aeberli et al. 
2009;Altamura et al. 2010;Cherian et al. 2008;de et al. 2010;del Giudice et al. 2009;Rehu et 
al. 2010;Semrin et al. 2006;Tchou et al. 2009). In two published studies of hepcidin 
concentrations in pregnant women, both showed that hepcidin concentrations in anaemic 
pregnant women are lower than in non-anaemic pregnant women, but are not related to 
cord-blood or newborn hepcidin or other fetal iron parameters (Rehu et al 2010;van et al. 
2011). From the published literature it is obvious that basal hepcidin concentrations greatly 
depend on the quantitative hepcidin method used (Kroot et al. 2009). 
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1.6.4 Disorders caused by hepcidin deficiency 
1.6.4.1 Hepcidin in haemochromatosis 
Hepcidin deficiency leads to excessive Fpn function and systemic iron overload, with iron 
accumulation and toxicity in parenchymal cells of the liver and other organs. Using current 
genetic tests, the hemochromatosis genotype may be diagnosed as early as at the stage of 
genetic susceptibility to develop iron overload, before the development of any clinical 
complications (Pietrangelo 2010). Hemochromatosis is genetically heterogeneous, caused 
by at least five different genes (Table 1.3). HFE hemochromatosis is the most frequent form; 
most patients are homozygous for the HFE C282Y mutation. HFE is an atypical major 
histocompatibility complex class I–like protein ubiquitously expressed which heterodimerizes 
with β2M for cell surface localization (Camaschella and Silvestri 2011;Feder et al. 1997).  
 
HFE associates with TfR1 and participates in its endosomal cycle (Feder et al. 1998), in 
competition with diferric-Tf. In this model, when diferric-Tf increases, HFE dissociates from 
TfR1 and forms a complex with TfR2 (Gao et al. 2009). The latter complex is proposed to 
activate hepcidin transcription in response to the increased circulating diferric-Tf, but the 
molecular mechanisms remain unknown (Hentze et al 2010). This effect does not occur in 
hemochromatosis, since HFE C282Y is not expressed on the cell surface as it cannot bind 
β2M (Camaschella & Silvestri 2011). It has been shown recently in mice that HFE is 
important for a full activation of the SMAD pathway since its deficiency is associated with a 
reduced SMAD1/5/8 phosphorylation (Corradini et al 2009;Kautz et al. 2009) in the presence 
of the matching increase in BMP6 expression. 
 
Juvenile hemochromatosis is a recessive hemochromatosis due to HJV mutations. Some 
HJV mutations decrease the co receptor expression on the cell surface (Corradini et al 
2009;Silvestri et al. 2007); others abolish the interaction with BMPs (Kuns-Hashimoto et al. 
2008). Mutations of hepcidin are extremely rare (Camaschella & Silvestri 2011). They lead to 
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the virtual absence of the protein or affect the internal cysteines, and thus the peptide hairpin 
conformation. These defects cause an early-onset, severe phenotype identical to that of the 
more common HJV mutations (Camaschella and Poggiali 2009), which are also 
characterized by extremely low hepcidin levels (Papanikolaou et al. 2004).  
 
 
Table 1.2 Classification of genetic and acquired hepcidin disorders. (Adapted from 
(Camaschella & Silvestri 2011) 
 
 Gene Inheritance Mechanism Phenotype 
Genetic hepcidin deficiency 
Haemochromatosis type 1 
Haemochromatosis type 2A 
Haemochromatosis type 2B 
Haemochromatosis type 3 
 
 
HFE 
HJV 
HAMP 
TfR2 
 
AR 
AR 
AR 
AR 
 
Defective hepcidin activation 
Lack of BMP co-receptor 
Lack of hepcidin 
Defective hepcidin activation 
 
Iron overload 
Iron overload 
Iron overload 
Iron overload 
 
Genetic hepcidin resistance 
Haemochromatosis type 4B 
 
FPN 
 
AD 
 
FPN resistant to hepcidin 
function 
 
Iron overload 
Genetic defect of the hepcidin 
receptor 
Haemochromatosis type 4A 
(Ferroportin disease) 
 
 
 
FPN 
 
 
AD 
 
 
 
Loss of FPN function 
 
 
Defective iron 
recycling 
Genetic hepcidin over expression 
IRIDA 
 
TMPRSS6 
 
AR 
 
Defective hepcidin inhibition 
 
Iron-refractory 
anaemia 
Acquired hepcidin deficiency 
Iron-loading anaemias 
   
Excessive hepcidin inhibition 
 
Anaemia, iron 
overload 
Acquired hepcidin over-expression 
Hepcidin-producing adenoma 
 
Inflammation (acute, chronic) 
 
 
 
 
 
 
Inappropriate hepcidin 
expression 
IL6 induced hepcidin expression 
 
Microcytic 
anaemia 
Anaemia of 
inflammation 
(ACD) 
HFE-haemochromatosis protein; HJV-haemojuvelin; HAMP-hepcidin gene; TfR2-transferrin 
receptor 2; FPN-ferroportin; IRIDA-iron refractory iron deficient anaemia; TMPRSS6-
matripase-2 gene; AR-autosomal recessive; AD, autosomal dominant and IL6-interlukin-6 
 
TfR2-hemochromatosis is a further type of recessive disease, whose expression (early 
onset, but moderate severity) differs from both HFE-related and juvenile hemochromatosis, 
suggesting that TfR2 exerts more complex functions than that of a simple HFE partner. In 
accord with this, HFE-/- mice have less severe iron overload than Tfr2-/- mice and the 
double knockout has the most severe phenotype (Wallace et al. 2009). The recent 
identification of TfR2 as a partner of the erythropoietin receptor (EPOr) in the bone marrow 
(Forejtnikova et al. 2010) makes the interpretation of its function more complex and suggests 
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that TfR2 may represent a potential link between erythropoiesis, erythropoietin (EPO), and 
hepcidin (Camaschella & Silvestri 2011).  
 
Diseases of Fpn have dominant inheritance. Heterozygous mutations cause 
hemochromatosis type IV also called Fpn disease. The typical disorder is different from 
hemochromatosis: loss-of-function mutations, which reduce the surface expression of Fpn, 
cause macrophage iron retention and restrict iron available for erythropoiesis (Schimanski et 
al. 2005). However, few gain-of-function mutations render Fpn resistant to the hepcidin effect 
(Drakesmith et al. 2005), either because of loss of hepcidin binding or of Fpn internalization. 
In these cases, mutant Fpn remains on the macrophage surface and contributes to increase 
the available iron, causing the unique form of hepcidin-resistant hemochromatosis with high 
hepcidin levels (De, I et al 2007).  
 
1.6.5  Disorders caused by hepcidin excess  
Hepcidin over expression was first shown to cause iron deficiency anemia (IDA) in hepcidin 
transgenic mouse models (Nicolas et al. 2002). More recently, it has been demonstrated in 
two engineered animal models which are unable to inhibit hepcidin expression: the ―Mask‖ 
mouse (Du et al. 2008) and the TMPRSS6 gene knockout mouse (Folgueras et al. 2008). 
Both models lack matripase-2 function. TMPRSS6 in the Mask mouse encodes a truncated 
inactive protein devoid of the serine protease domain because of a splicing defect (Du et al 
2008). The Mask mice have observed microcytic anemia, low plasma iron, and depleted iron 
stores.  
 
Molecular defects inactivating TMPRSS6 in humans cause the inherited disorder, IRIDA 
(Table 1.1), a rare, recessive condition (Camaschella and Poggiali 2011). IRIDA is 
characterized by a moderate degree of anaemia, extreme microcytosis and hypochromia, 
low TSAT, and normal/high hepcidin levels (Camaschella & Poggiali 2011). In cases 
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followed for many years, the severity seems to decrease over time, paralleling the reduced 
iron requirements of adult life (Camaschella & Poggiali 2011;Melis et al. 2008). 
 
1.6.5 Hepcidin in acquired disorders  
1.6.5.1 Hepcidin deficiency in acquired disorders  
Hepcidin deficiency was first reported in β-thalassemia patients and then shown to be a 
feature of iron-loading anaemias. These anaemias are characterized by high degrees of 
ineffective erythropoiesis and high iron stores. However, despite iron overload, hepcidin is 
not increased. In this condition, the BMP-SMAD major activating pathway should be down-
regulated. A proposed mechanism relies on the effect of cytokines of the TGF-β family 
released by immature (murine) erythroblasts such as GDF15 and TWSG1.  
 
Extremely high levels of GDF15 in β-thalassemia may be due to the ineffective 
erythropoiesis, but it may also be released by other hypoxic cells. The levels of GDF15 that 
are able to suppress hepcidin transcription in hepatocyte cultures (Tanno et al 2007) are not 
observed in other conditions of ineffective erythropoiesis, such as congenital 
dyserythropoietic anaemia type I (Tamary et al. 2008). Searching for other potential 
candidates, the same authors proposed TWGS1, a potential ligand of BMPs released by 
immature erythroblasts in the thalassemic mouse, but its role in humans remains unproven 
(Peyssonnaux et al. 2007), or the increased EPO expression via a direct (Pinto et al. 2008) 
or more likely an indirect (Rivera et al 2005) effect. Another important player is TMPRSS6, 
which is increased, in vitro in hypoxia (Lakhal et al 2011) and might inhibit hepcidin, 
decreasing the BMP co receptor HJV on the cell surface (Silvestri et al 2008). Also, the BMP 
ligand, sHJV, which has been shown to be increased by furin cleavage in hypoxia/iron 
deficiency in cell culture (Silvestri et al 2008), might play a role as a BMP antagonist.  
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1.6.5.2  Hepcidin excess in acquired disorders  
Rare cases of hepcidin-producing, benign, hepatic adenomas have been reported in patients 
treated for inherited glycogen storage disease type 1a caused by glucose-6-phosphatase-
deficiency (Weinstein et al. 2002). All patients had microcytic anaemia, with features of iron 
deficiency, but normal ferritin levels. Anaemia reverted after surgery that removed the 
hepcidin-expressing adenoma. This rare disorder and IRIDA underline that persistently high 
hepcidin levels cause microcytosis.  
 
Hepcidin over expression occurs in ACD or AI. This is a common form of anaemia observed 
in infections/inflammatory disorders associated with overproduction of the inflammatory 
cytokines, especially IL-1b, TNF-alpha, IL-6, and gamma-IFN (Weiss 2009). The anaemia is 
mutifactorial; blunted erythropoietic response to EPO (which is decreased during 
inflammation) and reduced erythrocyte survival coexist with iron abnormalities, such as 
macrophage iron sequestration and iron-restricted erythropoiesis. Transferrin saturation 
(TSAT) is normal/low and serum ferritin normal/high. The iron abnormalities are explained by 
inappropriately high hepcidin expression enhanced by IL-6 dependent activation of the 
STAT3 pathway. Hyper production of hepcidin in inflammation also occurs in macrophages 
in response to IL-6 and toll like receptor-4 stimulation (Theurl et al. 2008). This may amplify 
iron retention through the autocrine effect of hepcidin on macrophage Fpn. In addition, 
according to recent results, hepcidin production could be beneficial to stimulate an anti-
inflammatory response (De, I et al. 2010). Because macrophages play a major role in 
recycling iron for erythropoiesis, insufficient iron release leads to anaemia. However, red 
blood cells (RBCs) usually are not microcytic, unless the process is longstanding or true iron 
deficiency coexists (Weiss 2009). ACD differs from both iron deficiency and overload, and 
can be classified as a defect of iron recycling or a condition of iron maldistribution.  
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Hepcidin has been demonstrated to be expressed in breast cancer tissue: a recent study 
based on expression arrays in breast cancer reports that the hepcidin/Fpn ratio is a potential 
novel and independent prognostic marker in large series of breast cancer patients (Pinnix et 
al. 2010), implying hepcidin production by tumour tissue. However, the specific cell type that 
produces hepcidin remains to be demonstrated and whether hepcidin might be produced by 
cancer-recruited inflammatory macrophages rather than by the cancer itself is unknown 
(Pinnix et al 2010). Iron certainly has an essential role in cancer, but whether tumour cells 
other than hematopoietic cells (Pinnix et al 2010) may produce hepcidin with an autocrine 
effect to favour cancer growth remains to be demonstrated.  
 
Renal anaemia is a common complication in progressive kidney disease where local 
destruction of kidney cells leads to reduced production of EPO, which is used to stimulate 
production of RBCs from the erythroid tissue. This is usually termed a ‗functional iron 
deficiency‘ as opposed to true IDA. Hepcidin has a low fractional excretion rate, and many 
studies have reported high concentrations of hepcidin in various stages of renal failure. 
These high concentrations would be expected to have an impact on the iron haemostasis in 
these patients, possible contributing to the anaemia seen in this condition. 
 
The introduction of erythropoietin stimulating agents (ESAs), such as EPO, has allowed 
effective treatment of anaemia in patients with chronic kidney disease (CKD). However, the 
optimal target concentration for Hb maintenance in these patients is debated, and many 
patients become ESA resistant. Hepcidin has been suggested as a possible reason for the 
observed imbalance between iron homeostasis and ESA resistance in CKD (Nicolas et al. 
2002;Swinkels & Wetzels 2008). As such, hepcidin has been described as a promising 
diagnostic marker to predict ESA responsiveness, and to guide treatment with ESA and 
intravenous iron. A number of studies subsequently examined hepcidin concentrations in 
patients with CKD. In general, these studies have reported increased hepcidin 
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concentrations in CKD patients compared with healthy controls (Ashby et al 2009;Bansal et 
al 2010;Busbridge et al 2009;Swinkels et al 2009;Ganz et al 2008;Li et al 2009;Peters et al 
2010;Tomosugi et al 2006;Viatte and Vaulont 2009;Weiss et al. 2009;Zaritsky et al. 2009). 
As these patients tend to be anaemic, even a mild hepcidin excess can be considered to be 
inappropriately high for the level of anaemia. Most studies on hepcidin in CKD patients have 
found a strong positive relationship between hepcidin and ferritin concentrations. Some of 
these studies have also demonstrated significant correlations between hepcidin and iron or 
TSAT (van der Putten et al. 2010;Weiss et al 2009).  
 
Hepcidin in CKD has also been associated with iron-restricted erythropoiesis, as reflected by 
the relation of hepcidin with lower Hb and/or reticulocyte counts (Ashby et al 2009;Valenti et 
al. 2009;Weiss et al 2009). Furthermore, CRP and IL-6 were shown to be less relevant 
predictors in the setting of renal insufficiency (Ford et al. 2010;Kuragano et al. 2010;Peters 
et al 2010;van der Putten et al 2010;Zaritsky et al 2009;Zaritsky et al. 2010). Intravenous 
iron administration did not influence hepcidin concentrations in heamodialysis (HD) patients 
that were withheld from iron and ESA therapy for 2 weeks (Weiss et al 2009), whereas it 
increased hepcidin in iron-naive CKD patients (Ashby et al 2009;Busbridge et al 2009). In 
HD patients on ESA, hepcidin did not predict which patients increase their Hb after iron 
loading (Tessitore et al 2010). As mentioned earlier, several investigators have reported a 
decrease in hepcidin concentrations following EPO administration (Ashby et al 2009;Nicolas 
et al 2002;van der Putten et al 2010;Weiss et al 2009). These findings suggest that the 
erythroid demand for iron might be a more powerful regulator of hepcidin expression than 
inflammatory- or iron-induced hepcidin synthesis. 
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1.7 Therapeutic aspects of hepcidin 
1.7.1 Hepcidin modulating agents 
Therapies targeting hepcidin may lead to improving treatment options for patients suffering 
from iron disorders. Although no specific hepcidin therapies are currently available, several 
compounds are under development as hepcidin agonists or antagonists (Nemeth 
2010;Nemeth 2010;Pietrangelo 2011). Hepcidin agonists may have a role in preventing iron 
overload due to hepcidin deficiency, such as HH, and especially β-thalassaemias and other 
iron-loading anaemias, and possibly to some acquired forms of non-hemochromatotic iron-
overload diseases (Kroot et al. 2011). Hepcidin antagonists, on the other hand, might benefit 
patients with diseases of hepcidin excess manifested as iron-restricted anaemia and 
systemic iron deficiency, such as IRIDA, ACD, CKD, anaemia related malignancies, obesity-
related iron deficiency, and cardiovascular disease (Nemeth 2010). 
 
1.7.2 Hepcidin agonists 
Preclinical studies and some clinical studies have provided proof-of-concept for synthetic 
hepcidin, small hepcidin peptides, BMP agonists, and HIFs stabilizers to prevent iron 
overload attributed to hepcidin deficiency (Kroot et al 2011).  Small hepcidin peptides have 
been shown to act as agonists in mice in vivo on the basis of their amino terminal domain 
(Gardenghi et al. 2010). Gardenghi et al. reported that transgenic hepcidin over-expression 
in β-thalassaemia intermedia mice decreased iron overload, and even ameliorated 
ineffective erythropoiesis. Hepcidin concentrations can also be induced by targeting the BMP 
pathway. BMP2 administration in mice was found to increase liver hepcidin expression and 
reduce serum iron concentrations in vivo (Babitt et al 2007). Supraphysiological doses of 
exogenous BMP6 for 10 days were reported to improve hepcidin deficiency, reduce serum 
iron, and redistribute tissue iron to appropriate storage sites (RE macrophages, spleen) in a 
mouse model for HFE- hemochromatosis (Corradini et al. 2010). HIF antagonists are used in 
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cancer to inhibit tumour angiogenesis (Yoon et al 2006). Blocking HIF could also be used to 
increase hepcidin concentrations in iron-overload diseases (Kroot et al 2011). 
 
1.7.3 Hepcidin antagonists 
Preclinical and clinical studies have also demonstrated that hepcidin functional antagonists 
such as hepcidin monoclonal antibodies, BMP antagonists, cytokine receptor antibodies, and 
HIF stabilizers can decrease hepcidin expression and reverse iron abnormalities (Babitt et al 
2007;Fatih et al. 2010;Hashizume et al. 2010;Kawabata et al. 2007;Poli et al. 2011;Sasu et 
al. 2010;Song et al. 2010;Yu et al 2008). In a proof-of-principle study, (Sasu et al 2010) 
neutralized hepcidin using a monoclonal antibody in the Brucella abortus mouse model of AI 
and found it to restore responsiveness to EPO (Xiao et al. 2010). The results of this study 
suggest that administration of anti-hepcidin therapies alone or in combination with ESAs may 
improve patients‘ erythropoietic response and allow the use of lower EPO doses to avoid the 
potential detrimental effects of high EPO concentrations (Kroot et al 2011).  
 
Several components can interfere with the BMP/ SMAD pathway. Administration of 
dorsomorphin, a small inhibitor of BMP signaling, prevented hepcidin induction by iron in 
mice (Yu et al 2008). GDF15 and TWSG1 are both BMP antagonists produced by 
erythroblasts which may have some therapeutic potential (Babitt et al 2007). Soluble HJV, 
which also acts as an antagonist of BMP signaling, decreases basal hepcidin expression in 
mice, mobilizes RE-system (splenic) iron stores, increases liver iron content and 
concurrently increases serum concentrations (Babitt et al 2007). Heparin and heparin 
derivatives have also recently been shown to inhibit hepcidin expression in vitro and in vivo 
by interfering with BMP signaling (Poli et al 2011). An immunosuppressive drug 
(Tocilizumab, which is a humanised monoclonal antibody directed against the IL-6 receptor) 
was shown to suppress IL-6 induced hepcidin production in Castleman disease (a rare 
disorder with systematic inflammation and aneamia) (Ding et al. 2009;Ding and Jones 2006). 
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Inhibitors of the key initiators of the cellular hypoxic response, such as prolyl hydroxylases, 
prevent inactivation and degradation of HIF and as such may be effective hepcidin 
suppressors and restore natural iron regulation in aneamia (Braliou et al. 2008). 
 
1.8 Summary 
Whilst our understanding of the way in which iron metabolism and homeostasis is regulated 
has increased in the last decade, the impact on the therapy of disorders of iron overload and 
iron deficiency remains modest. Numerous studies have contributed insights into the 
regulation of hepcidin and its functional properties. The continuing progress in the methods 
available for quantifying hepcidin and its isoforms in biological fluids has helped to establish 
the role of hepcidin in a variety of clinical conditions affecting iron regulation. However, it is 
unclear whether these methods or the routine measurement of hepcidin will be useful in the 
diagnosis or monitoring of these conditions remains in a clinical context.  The potential of 
exploiting hepcidin analogues with agonistic or antagonistic activity towards Fpn 
internalisation and degradation could potentially revolutionise the treatment of both 
hereditary and secondary iron overload syndromes and of ACD and AI, and remains an 
exciting prospect. 
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1.9 Hypothesis 
Hepcidin is a bioactive peptide with an important role in the regulation of iron metabolism. 
 
1.9.1 Aims 
1. To develop high affinity monoclonal and polyclonal antibodies to bioactive human hepcidin. 
2. To develop a robust and well validated immunoassay to human hepcidin.  
3. To determine a reference interval for hepcidin concentrations in human plasma and to 
compare the levels measured with urinary hepcidin concentrations and plasma prohepcidin 
concentrations from a healthy control population.  
4. To investigate hepcidin levels in various disease populations in which hepcidin 
concentrations would be expected to be altered.  
5. To investigate the existence of a hepcidin diurnal variation in healthy controls. 
6. To investigate the response of hepcidin to an acute iron load in healthy controls. 
7. To investigate the response of hepcidin to intravenous iron therapy in anaemic patients. 
8. To investigate the distribution of hepcidin and prohepcidin immunoreactivity in human 
plasma. 
9. To determine levels of hepcidin in renal comprised patients with mild to moderate chronic 
kidney disease (CKD) and in clinical stable CKD patients requiring haemodialysis (HCKD). 
10. To investigate the hepcidin response to intravenous iron in anaemic renal patients and 
determine whether diurnal variation is still preserved in CKD patients 
11. To further characterise the response of hepcidin to EPO therapy in CKD patients. 
12. To investigate the temporal association between plasma hepcidin and other iron indices in 
healthy humans after EPO administration and venesection. 
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Chapter 2 
Preparation of Antibodies 
and Development of 
Hepcidin Immunoassay 
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2.0 Introduction to immunoassays 
2.1 Principles of immunoassay 
First described by Solomon Berson and Rosalyn Yalow in the USA in 1960 (Berson et al. 
1964), radioimmunoassay (RIA) and other immunoassays have become the foremost 
method in the endocrine laboratory for the measurement of hormones (Gosling 1990). Ekins 
in the UK described the general analytical system based on any antigen (Ag) binding agent 
called ‗saturation analyses. Although the name was not widely adopted, his work on the 
theory of immunoassay practice based on the law of mass action was instrumental in guiding 
the general development and refinement of immunoassay methodology (Ekins 1969). The 
unique utility of the technique is based on the inherent specificity and avidity of the binding of 
an antibody (Ab) to its Ag. In the clinical laboratory, the major advantages of immunoassay 
methods are the ability to develop sensitive assays for a wide range of hormones, and the 
suitability of these methods to the processing of large numbers of clinical samples in a short 
time interval, aided by the development of automated instrumentation.  
An immunoassay is essentially the quantitative measurement of a substance using its 
reaction with an Ab (immunoreagent) (Edwards R 1985). Immunoassays usually use 
external labels (e.g. radioisotopes, fluorescent agents, and reagents that change colour in 
response to enzymatic action) to monitor the Ag: Ab binding reaction. Immunoassays are 
classified as either limited reagent, competitive immunoassays (which include RIA) or 
excess reagent, non-competitive immunoassays (which include immunometric assays). 
At the beginning of the reaction, the Ab reacts specifically with elements of the Ag (analyte) 
structure to form a complex (Ag: Ab), at a rate governed by the association rate constant, Ka 
(equation (1)). The reaction is reversible; as the reaction proceeds the complex will also 
dissociate at the rate governed by the dissociation rate constant, Kd (equation (1)). 
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After a defined time, the reaction will reach equilibrium and at this point the net association 
Ka will be balanced by the net dissociation Kd (equation (1)). The equilibrium constant, Keq, 
is equal to the ratio Ka/Kd (formula (2)). 
                         Ka 
(1) Ab + Ag →  Ab:Ag  
                              ← 
                         Kd 
 
      (2)           Keq = Ka = [Ab][Ag]   
                                Kd    [Ab:Ag] 
 
The affinity of the Ag for its Ab is a measure of strength of the binding between Ab and Ag 
which forms the complex (Edwards R 1985). The affinity will affect the detection limit, the 
incubation time and influence the choice of separation method in the assay. 
 
2.1.1.1  Limited reagent assays (competitive)  
The classical example of limited reagent assay is radioimmunoassay (RIA). A diagrammatic 
representation of this assay is shown in Figure 2.1.1. The sample containing the analyte to 
be measured is incubated with a limited amount of specific Ab and a small, constant amount 
of radiolabelled analyte. During incubation, the labelled and unlabelled Ag compete for the 
limited number of Ab binding sites, with the result that at equilibrium the more Ag that is 
present in the sample, the less labelled Ag there is bound to the Ab. After separation of the 
Ab bound and free fractions, the radioactivity in the bound fractions are usually quantified. 
The more radioactivity (labelled Ag) present (i.e. bound to the Ab), the lower the analyte 
concentration in the sample. By incubating the known amounts of unlabelled Ag (standard 
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Ag) with the same quantities of Ab and labelled Ag, a standard curve can be produced and 
the concentration of the analyte in the unknown samples determined by interpolation 
(Edwards R 1985). 
 
 
Figure 2.1.1 Components of a competitive radioimmunoassay (RIA). A) Schematic diagram 
showing the steps involved in a competitive immunoassay in which labelled antigen competes with 
endogenous antigen for binding sites on the antibody, with the incubation step followed by separation 
of antibody bound antigen from free antigen. B) Concentration of endogenous antigen is determined 
by a plot of the relationship between proportion of antigen in the bound fraction and concentration of 
antigen which is indirectly proportional. 
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2.1.1.2  Excess reagent assays (non-competitive) 
This technique was first described by Miles and Hales in 1968 (Miles and Hales 1968), but it 
was not widely used until monoclonal Abs (Mab) became available in the late 1970‘s and 
early 1980‘s. A good example of an excess reagent method is the two site immunometric 
assay (IMA). A diagrammatic representation of this assay can be seen in Figure 2.1.2. Two 
analyte specific Abs are used in relative excess with respect to Ag concentration, one 
labelled with an isotopic or enzyme label, and the other linked to a solid-phase support. Two 
incubations and a wash step are used to facilitate the assay. In the first incubation the 
sample containing the analyte is incubated with the labelled Mab (specific to one antigenic 
determinant on the Ag surface). After a defined incubation time solid-phase Ab is added. The 
alternate Ab binds to a separate specific epitope on the Ag to form a solid-phase Ab-Ag-
labelled Ab complex or sandwich. Washing separates the solid phase complex from the 
unreacted Ab. Depending on type of label used and detection signal; the unknown analyte 
concentration can be calculated from the calibration curve formed using defined analyte 
standards (Edwards R 1985;Price and Newman 1997). The Ab, not the analyte is labelled, 
and thus the calibration curves are exponential, since as the concentration of analyte 
increases then more binding occurs and more label signal is employed. The excess reagent 
immunometric assays can offer greater precision, lower detection limits, shorter incubation 
times and potentially enhanced specificity, compared to the traditional competitive 
immunoassay. 
Development of a two-site immunometric assay for hepcidin requires the use of antibodies in 
excess and may be constructed from either a pair of Mabs recognising spatially separated 
hepcidin peptide epitopes, or a combination of a single Mab (usually labeled) and a 
polyclonal antibody (Pc Ab) attached to a solid phase matrix, particle, bead or plastic 
surface. The first stage in developing an immunometric two-site assay is therefore the 
production of Mabs specific to hepcidin. 
70 
 
 
Figure 2.1.2 Components of a two-site immunometric assay. A) Schematic diagram showing 
the steps involved in a two-site immunometric assay in which endogenous antigen is bound by two 
antibodies (usually monoclonal) that recognize distinct epitopes on the antigen resulting in a 
‘sandwich’ formation. The assay is then incubated followed by a separation step to remove free 
antibody from bound.  B) Concentration of unknowns is determined by plotting the relationship 
between proportional bound labelled Ab and concentration of antigen which is directly proportional. 
 
2.1.1 Adaptive humoral immune response to the immunogen 
Production of anti-peptide Abs exploits the ability of an animal to defend itself from infection. 
The first line of defence is from macrophages (also known as antigen presenting cells 
(APCs)) that engulf and degrade foreign particles (i.e. antigenic proteins). Fragments of the 
Ag are presented on the cell surface of the APC, and here they bind to major 
histocompatibility complex (MHC) class II protein (a cell-surface glycoprotein) (Figure 2.1.3 
A). 
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Next, a helper T-cell binds to the APC (Figure 2.1.3 B). This interaction is mediated by 
binding of the Ag fragment-class II protein complexes on the APC with T-cell receptors on 
the surface of the helper T-cell. The T-cell receptor specifically recognizes both the Ag 
fragment and the class II protein. This binding ensures that helper T-cells do not respond to 
free Ag or to unoccupied class II proteins.  
The helper T-cell can now bind to the growth factor interleukin-1 (IL-1) (which is non-
specifically produced by APC). This combined stimulation of Ag binding and IL-1 induces the 
helper T-cell to secrete another growth factor, interleukin-2 (IL-2), and to synthesize IL-2 
receptors, which results in the proliferation of that class of T-cell by autocrine stimulation.  
Simultaneously, B-cells engulf and degrade the Ag in a manner similar to the APCs. Unlike 
the APCs, the uptake of Ag by B cells is specific to that particular epitope. The B-cells then 
present the Ag fragments in manner similar to the APCs (Figure 2.1.3 C).  
The next step, which is key to generating a strong response, is the specific binding of the 
helper T-cell via its receptor to the B-cell‘s MHC II peptide receptor. For a compound to 
induce an Ab response, it must have an epitope that can bind to the surface Ab on the Virgin 
B cell, and on degradation must generate a fragment that can bind simultaneously to both 
the class II protein and the T-cell receptor. Binding causes the B-cell to synthesize a cell-
surface receptor for a B-cell growth factor interleukin-4 (IL-4). The activated helper T-cell 
synthesizes IL-4. After binding IL-4, the B-cells start to synthesize the receptor for a B-cell 
differentiation factor, interleukin-5 (IL-5). IL-5 is also produced by the activated helper T-
cells. Binding of IL-5 in conjugation with other signals induces differentiation of the dividing B 
cells into plasma cells and memory cells (Figure 2.1.3 D) (Harlow and Lane 1988;Price & 
Newman 1997;Weir and Stewart 1997). 
The plasma cells are responsible for the secretion of large amounts of Ab‘s, and live for 
approximately 3-4 days. The memory cells do not secrete Ab‘s, but are long lived cells that 
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retain the cell-surface Ab as their specific Ag receptor. These cells remain in circulation and 
are primed to respond to subsequent exposure to the Ag. The Ab‘s produced during a 
primary response are predominately of the immunoglobulin M class (IgM). If the animal is 
subsequently challenged with the same immunogen, the memory B-cells mount a quicker, 
more potent and persistent response. The cellular and molecular events of the secondary 
response are similar to the primary response. However, the Ab‘s produced are now 
predominately of the immunoglobulin G class (IgG), and bind to the Ag with a higher affinity 
than those produced in the primary response.  This secondary response is critical to the 
obtaining of large amounts of usable Ab‘s, and is why primary immunizations are followed by 
boosts in Ab generation protocols. Failure to activate any the cells involved in secondary 
response results in no response to an immunization. If the Ag is too small to be detected by 
the APCs, or the Ag fragments presented by the APCs are not recognized by a helper T-cell, 
no immune response is generated. Small peptides are often conjugated to larger carrier 
proteins to ensure that the molecule is large enough to react with the immune system and to 
provide epitopes that can be recognized by the helper T-cells (Harlow & Lane 1988;Price & 
Newman 1997). 
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Figure 2.1.3 The immune response to immunogens. (A) Antigen processing and presentation. 
The antigen is engulfed by APC with partial degradation and exposure on cell surface with MHC 
Class II complex (B), Helper T-Cells bind to APC’s leading to proliferation and differentiation of T-
Cells, mediated by binding of IL-1with IL-2 required as polypeptide growth factor (C) B Cell processing 
of antigen. Specific uptake of antigen via antibody on cell surface to bind antigen with expression of 
antigen-Class II protein on B Cell surface. (D) Contact between B Cells and helper T Cells is a major 
factor in regulation of antibody production, which leads to B Cell division and antibody production, 
mediated by IL-4 and IL-6 leading to differentiation of B Cells into Plasma and Memory Cells. 
(Adapted from (Harlow & Lane 1988;Weir & Stewart 1997). APC; antigen processing cell, IL-1; 
interleukin 1, IL-2; interleukin-2, IL-4; interleukin-4 and IL-5; interleukin-5. 
 
A 
B 
C 
D 
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2.1.2 Antibodies 
The critical component of an immunoassay is an Ab. Antibodies play a crucial role in the 
immune system, which defends the body against toxins that enter the bloodstream and 
counters the threat of disease from invading microbes and viruses. Antibodies are 
glycoproteins belonging to the immunoglobulin (Ig) supergene family. There are five classes 
of Ig in higher mammals: IgG, IgM, IgA, IgD and IgE, which differ on the basis of the number 
of Y-like units, amino acid composition and carbohydrate content. In addition there is some 
heterogeneity within class, especially IgG, giving rise to four subclasses in humans (IgG1, 
IgG2, IgG3, IgG4) and four subclasses in mice (IgG1, IgG2a, IgG2b, IgG3), although these 
subclasses are not identical between species (Harlow & Lane 1988;Price & Newman 1997). 
Structurally, Ab‘s are composed of one or more copies of a characteristic unit that can be 
visualized as forming a flexible Y shape. Each Y contains four polypeptide chains, two 
identical heavy (H) polypeptide chains paired with two identical light (L) chains. The four 
chains are held together by disulfide bridges and noncovalent bonds, giving a total molecular 
mass of approximately 150KDa.  
The IgG antibody consists of a single Y unit (Figure 2.1.4), and constitutes the most 
abundant antibody in serum. IgG molecules have three protein domains. Two of the domains 
are identical and form the arms of the Y. Each arm contains an Ag binding site and is known 
as a Fab fragment, making IgG molecules bivalent. The third domain forms the base of the Y 
and is termed the Fc fragment, for the fragment that crystallizes. The region between the 
Fab and Fc fragments is called the hinge. This segment allows for lateral and rotational 
movement of the two Ag binding domains. Portions of the amino-terminal amino acids of the 
heavy and light chains contribute to the structure and specificity of the antigen binding site 
and are called variable (V) regions. The remaining domains in each chain are invariant and 
are called constant (C) regions (Harlow & Lane 1988;Price & Newman 1997). 
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2.1.2.1  Polyclonal and monoclonal antibodies 
The term monoclonal indicates that the Ab is of a single type, that is, it will bind to an 
antigenic determinant, the epitope region. A polyclonal antibody (Pc Ab) is a heterogeneous 
mixture of different antibodies raised against an immunogen to which the Abs produced are 
reactive to a number of different epitopes on the immunogen molecule. A monoclonal 
antibody (Mab) is an Ab produced artificially from a single cell or single clone and therefore 
consists of a homogenous type of immunoglobulin that is reactive to a single epitope. 
An advantage of using a Mab over a Pc Ab in immunoassays is that it is theoretically 
possible to produce unlimited amounts of Ab at a consistent and predefined specificity 
(homogenous reagent). This is because they are synthesised by a population of identical 
cells (a clone) with each population descended from a single hybridoma cell. Polyclonal 
antibodies, in contrast, are products of many different populations of antibody producing 
cells, and hence they differ in their precise specificity and avidity for the Ag (Figure 2.1.5). 
Monoclonal Abs therefore has the potential to be more sensitive and specific than Pc Abs. In 
addition, these specific Mabs may be produced from impure or mixed immunogens, unlike 
Pc Abs for which highly purified immunogens are required (Edwards R 1985;Harlow & Lane 
1988). 
The production of Mabs is a time consuming procedure that involves many stages. A large 
amount of work is needed to screen all the clones usually generated, of which only a few 
secrete the appropriate Mabs. Tissue culture techniques and immunoassay skills are 
required to reduce the risk of contamination and to increase the success rate of the 
hybridisation procedure (Edwards R 1985;Harlow & Lane 1988). 
 
76 
 
 
 
Figure 2.1.4 Structure of immunoglobulin G (IgG). The bivalent IgG molecules have three 
protein domains. The two domains that carry the antigen binding sites are known as the Fb 
fragments, and the protein domain involved in immune regulation is the Fc fragment. The two heavy-
chain and two light-chain polypeptides are both identical in nature, with one light-chain associating 
with amino-terminal region of one heavy-chain to form an antigen binding domain. The carboxyl-
terminal regions of the heavy-chains fold together to produce the Fc domain. The four polypeptide 
chains are held together by disulfide bridges and noncovalent bonds. (Adapted from (Harlow & Lane 
1988;Price & Newman 1997). 
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Figure 2.1.5 Schematic overview of polyclonal antibody production. Based upon a rabbit 
immunisation, with antigen recognition by B Cells, cloning of plasma cells in vivo, with subsequent 
secretion of heterogeneous polyclonal antibodies, which can then be harvested by bleeding the 
animal. 
 
2.1.2.2  Monoclonal antibody production 
Kohler and Milstein developed the techniques to produce Mab in 1975 and were awarded 
the Nobel Prize in physiology and medicine for this work in 1984 (Kohler and Milstein 1975). 
The technique had a major impact on the development of two site immunometric methods. 
The classical disadvantage of having to maintain large volumes of antisera and the problems 
inherent in radiolabelling polyclonal antisera have been to a large extent circumvented as 
Mab technology enables the production of gram quantities of purified Ab of defined 
specificity. 
In retrospect, the principle underlying the successful production of Mabs is deceptively 
simple and is outlined in Figure 2.1.6. Lymphocytes from immunized animals will not 
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themselves grow in vitro, but by fusion with myeloma cell lines they can be immortalized. 
The resulting hybrid myeloma (hybridoma) cells retain the useful properties of both cell types 
involved in the fusion. Thus, they not only grow indefinitely as tumour cells like the myeloma, 
but also continue to secrete the Ab characteristic of the lymphocyte. The key to this success 
was the careful choice of fusion partners, these being not only from the same species 
(originally from the Balb/c mouse (Potter 1972)), but also of the same basic cell type. As an 
important refinement the myeloma cells were engineered to specifically lack the enzyme 
hypoxanthine guanine phosphoribosyltransferase (HGPRT) (Littlefield 1964). Thus, after cell 
fusion, hybrids but not parental cells survive to grow in selective medium called HAT which 
contains hypoxanthine, aminopterin and thymidine supplements. There are two pathways for 
possible nucleotide synthesis in normal cells the de novo pathway, which is inhibited by 
aminopterin, and the salvage pathway for which hypoxanthine and thymidine precursors are 
required providing there is a functional HGPRT enzyme system. Therefore incubation in HAT 
will allow survival of the positive HGRP hybridomas but not the negative HGPRT myelomas. 
After a few days of incubation in the HAT, the culture will contain only hybridomas. This is 
important as the efficiency of fusion is low (of the order of 1 in 10,000 cells) and 
consequently hybrids are initially vastly outnumbered by myeloma cells.  
After a positive tissue culture supernatant has been identified, the next step is to clone the 
Ab-producing cell. The original positive well will often contain more than one clone of 
hybridoma cells. If all the hybridoma cells that occurred after a fusion were expanded 
together, then a mixture of Ab would be released similar to those found in the serum of the 
whole animal. Similarly, many hybrid cells have an unstable assortment of chromosomes 
and fail to produce the detected Ab on extended culture. Both of these problems may lead to 
the desired cells being outgrown by cells that are not producing the Ab of interest. However, 
single-cell cloning ensures that cells that produce the one Ab of interest are truly monoclonal 
and that the secretion of this Ab can be stably maintained. 
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Isolating a stable clone of hybridoma cells that secretes the desired Ab is the most time-
consuming step in the production of hybridomas. It is a major problem stabilising the first few 
cells to grow, since cells do not like to grow in isolation. To overcome this, ‗feeder‘ cells or 
conditioned media containing growth factors are used. Feeder cells (e.g. thymocytes, 
macrophages, or splenocytes) are short lived in culture but provide the growth support 
required. The cloning is normally repeated two or more times to ensure monoclonality. Due 
to the stability of frozen cell lines and stability of growth in appropriate culture medium, the 
supply of Ab is considered permanent (Goding 1996;Harlow & Lane 1988). 
 
 
Figure 2.1.6 Production of monoclonal antibodies. Outline of steps involved in the production of 
monoclonal antibodies from initial immunization through fusion of B-Cells with immortal myeloma 
cells, cloning of specific secreting cells and finally propagation and storage of selected cells.  
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2.2 Hypothesis 
Improved quantification methods for hepcidin will allow an evaluation of its clinical diagnostic 
role in human diseases associated with disordered iron physiology. 
 
2.3 Aims 
In order to investigate the role of hepcidin in human physiology I aim to: 
1. To develop high affinity monoclonal (mouse) and polyclonal (rabbit and/or sheep) 
antibodies to bioactive human hepcidin. 
2. To develop a robust and well validated immunoassay to human hepcidin.  
3. To determine a reference interval for hepcidin concentrations in human plasma and to 
compare the levels measured with urinary hepcidin concentrations and plasma 
prohepcidin concentrations from a healthy control population.  
4. To investigate the distribution of hepcidin and prohepcidin immunoreactivity in human 
plasma. 
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2.4 Methods  
Unless otherwise stated all reagents and consumables were purchased from Sigma-Aldrich, 
UK. 
2.4.1 Conjugation of hepcidin to a carrier protein 
Low molecular weight peptides (<6KDa) are only weakly immunogenic. To generate Abs 
efficiently, they require coupling to a large immunogenic protein molecule known as a 
‗carrier‘ before being injected into the host animal. This carrier protein facilitates the 
production of Abs in several ways. The peptide-carrier complex is sufficiently large enough 
to be recognised and engulfed by the Ag presenting cells of the immune system. The carrier 
protein also contains T-Cell helper epitope sequences that stimulate the proliferation of 
helper T-Cells. In addition, because the carrier proteins are foreign to the host animal, they 
further enhance the immune system response (Edwards R 1985;Harlow & Lane 1988). 
Synthetic hepcidin (Bachem, UK) was conjugated to keyhole limpet hemocyanin (mcKLH) 
using 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDAC). EDAC condenses carboxyl 
and primary amine groups to form amide bonds. These bonds are extremely rigid and cause 
considerable steric hindrance as the peptide is tightly bound and unable to rotate, is rather 
non-specific and able to couple to the peptide at different sites giving rise to a variety of 
antibody responses (Edwards 1999). Peptide conjugation was carried out using an Imject 
Immunogen EDAC kit with mcKLH (Thermo Fisher Scientific Inc, Rockford, USA), according 
to  the manufacturers guidelines. Briefly; 200µl ultrapure water was added to one vial 
mcKLH (10mg/mL). Hepcidin (1mg) peptide was then dissolved in 0.5ml 20% acenonitrile 
solution. This peptide solution was then added to mcKLH solution. One vial EDAC was then 
dissolved in 1ml ultrapure water, and 50µl added to the mcKLH-peptide solution. Solution 
was incubated at room temperature for 2 hours and then dialysed against 0.1M Phosphate 
Buffered Saline pH 7.4 (PBS) in a 10K mwco Slide-A-Lyzer dialysis membrane. 
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2.4.2.1 Production of a rabbit polyclonal antibody to hepcidin 
Two female rabbits were each immunised at Diagnostic Scotland, UK using the hepcidin 
EDAC conjugate. A preimmune bleed was removed from each animal prior to immunisation. 
A primary subcutaneous injection (0.5ml immunogen comprising 0.25ml of conjugated 
peptide and 0.25ml of adjuvant - Titermax ™) was given followed by a boost injection (0.5ml 
immunogen) 28 days later. If the animal remained healthy, boost injections were given every 
28 days until the target hepcidin Ab titre was reached, (>30% binding of antibody to I125 
hepcidin). Unfortunately one of the immunised rabbits died before primary bleed was due, so 
only one rabbit immunisation schedule (R2708) was completed.  
The immune serum from each of the rabbit monthly bleeds was tested for Ab titre by titration 
of the primary antisera diluted in assay buffer (0.01M PBS, 0.5% Bovine Serum Albumin 
(BSA) and 0.01% sodium azide). The affinity of the Ab for hepcidin was determined with a 
displacement assay, where the antisera of a positive bleed was diluted in assay buffer 
compared to the antisera diluted in a known amount of hepcidin (10ng/ml hepcidin in assay 
buffer). A screening assay was developed using an I125 hepcidin radioisotope label. 
 
2.4.2.2 Production of a sheep polyclonal antibody to hepcidin 
One female sheep was immunised at Diagnostic Scotland, UK using the hepcidin EDAC 
conjugate prepared as previously discussed in Section 2.4.1. A preimmune bleed was 
removed from the animal prior to immunisation. A primary subcutaneous injection (1.0ml 
immunogen comprising 0.5ml of conjugated peptide and 0.5ml of adjuvant - Titermax ™) 
was given followed by a boost injection (1.0ml immunogen) 28 days later. As the animal 
remained healthy, boost injections were given every 28 days until the target hepcidin Ab titre 
was reached, (>30% binding of antibody to I125 hepcidin).  
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The immune serum from the monthly sheep bleeds was tested for Ab titre by titration of the 
primary antisera diluted in assay buffer (0.01M PBS, 0.5% Bovine Serum Albumin (BSA) and 
0.01% sodium azide). A screening assay was developed using an I125 hepcidin radioisotope 
label. 
 
2.4.3 Isotopic labelling of hepcidin 
The basic method for introducing radioiodine into a molecule is by oxidation of sodium 
125Iodide to form reactive 125Iodine. Synthetic hepcidin (Tyr) peptide, (commercial synthesis 
by Bachem, UK), was iodinated with Sodium (Na)-I125 (Perkin-Elmer, UK) using the 
Chloramine-T reaction (GREENWOOD et al. 1963). Sodium 125I is oxidised by Chloramine-T 
in the presence of the protein to be labelled, with the subsequent incorporation of 125Iodine 
into the tyrosine residues of the protein. Incorporation into histidine residues can also occur, 
but with less efficiency. Excess Chloramine-T is reduced by the addition of the reducing 
agent sodium metabisulphate, and the free iodine is reduced to iodide (Edwards R 1985). 
Briefly; Hepcidin-(Tyr) 10µg/10µl of diluted with 40µl of 0.5M Phosphate buffer (pH 7.4), and 
1mCi Na I125 (Perkin Elmer LAS, UK) (approx 10µl) added and the resulting solution mixed. 
Then 25µl of Chloramine-T (10mg/ml solution, 0.25M Phosphate Buffer, pH 7.4) was added 
and incubated for 15secs before the reaction was stopped by the addition of 100µl of sodium 
metabisulphate (10mg/ml solution.0.25M Phosphate Buffer, pH 7.4).  
The iodinated hepcidin-(Tyr) was purified using reverse-phase high pressure liquid 
chromatography (RP-HPLC) (Jasco, UK), (Supleco Column LC-C18 4.6 x 250mm) with a 
gradient of 5-35% acetonitrile (ACN):dH20 with 0.1% trifluoroacetic acid (TFA) over 60mins. 
A flow rate of 1ml/min was used. RP-HPLC separation is based on the hydrophobicity of the 
peptide. The column contains silica substituted with octadecyl (C18), which retains the 
peptides by Van der Waals interactions. The peptides are eluted by increasing the 
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concentration of non-polar solvent, acetonitrile (ACN). The specific activity of the iodinated 
peptide was calculated from the percentage incorporation of radioiodine into the peptide 
(formulae 1 to 3) (GREENWOOD, Hunter, & GLOVER 1963). The iodinated peptide peak 
was stored at 4oC and diluted in assay buffer until required. 
 
1) % Iodination yield = Counts in [125I] iodine peak (cps) x 100 
Original Counts 
 
2) Radioactivity incorporated into protein (uCi) = % Iodination yield x 1000 
             100 
 
3) Specific Activity (uCi/μg) = Radioactive incorporation 
                                                                  Amount of protein 
  
 
2.4.4.1 Screening rabbit bleeds for antibody response 
Rabbit bleeds were serially diluted (1:20 to 1:10240) with assay buffer then assayed as 
described below, using the I125 hepcidin label, to determine immune response to 
immunogen, and to determine the appropriate titre of primary antisera for the development of 
the RIA.  
Briefly assay format as follows; Label assay tubes, Totals, non-specific binding (NSB), Pre-
immune bleed sample (PI), and appropriate tubes for rabbit bleed dilutions, (samples in 
duplicate). Test sample (100μL) was incubated with 125I hepcidin-(Tyr) (apx 
10,000cpm/100μL) overnight at 40C. Secondary antibody precipitating reagent (Sheep-anti 
Rabbit antibody (Scipac, UK) in 6% Polyethylene glycol 6000 (PEG) was added to the assay 
and incubated at 40C for 1 hour. The assay was then separated by centrifugation with 0.1% 
Triton at 1500g for 40mins (GF720 RMS UK Ltd.). The supernatant (free fraction) was 
discarded and the bound fraction (pellet) counted for 125I radioactivity by gamma-counter 
(1261 Wallac Gamma Counter, Perkin Elmer LAS, UK) for 1min.  The percentage binding in 
relation to the total counts added was calculated using RiaCalc Software (Wallac). The 
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percentage antibody binding (%B0) of 125I hepcidin-(Tyr) at each dilution of hepcidin anti-
rabbit antibody was calculated and plotted to form an antibody dilution curve. (Calculate 
%B0 from counts per minute (CPM) (sample CPM-NSB CPM / Total CPM x 100), plot %B0 
against antibody dilution.) 
 
2.4.4.2 Screening sheep bleed for antibody response 
Sheep bleeds were serially diluted (1:20 to 1:40960) with assay buffer then assayed as 
previously described in Section 2.4.4, using the I125 hepcidin label, to determine immune 
response to immunogen, and to determine the appropriate titre of primary antisera for the 
development of the RIA. The secondary antibody precipitating reagent used in this 
experiment was a Donkey anti-sheep antibody (Scipac, UK) in 6% PEG 6000. 
 
2.4.5 Antibody displacement assay 
Hepcidin Ab avidity was assessed by an Ab displacement assay. Two sets of Ab dilutions 
from positively screened sera were prepared.  One set of Ab dilutions was incubated with 
assay buffer, whilst the other set of Ab dilutions was incubated with a known concentration of 
the synthetic hepcidin (10ng/mL in assay buffer). Assay format briefly as previously 
described in section 2.2.4. A displacement curve of Ab dilution against % binding was plotted 
for both the buffer assay and the standard assay, and the relative displacement (% 
inhibition) was calculated, see below; 
   % inhibition = B0 – B0 x 100 
             B0 
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2.4.6 Production of mouse monoclonal antibodies to hepcidin 
Development of a two-site immunometric assay requires the use of Ab in excess and can be 
developed from either a pair of Mabs recognising spatially separated hepcidin peptide 
epitopes, or a combination of a single Mab (usually labelled) and a Pc Ab attached to a solid-
phase matrix, particle, bead or plastic surface. 
The immunogen was produced as previously discussed in Section 2.2.1. Five Balb/c mice, 
six to eight weeks old, (reared and housed according to established Diagnostic, Scotland 
procedures), were each given a primary immunisation (100μg/L immunogen comprising 
50μg/L of conjugated peptide and 50μg/L of adjuvant - Titermax ™). Booster immunisations 
consisted of 100μg/L immunogen per mouse. The first boost was given 14 days after 
primary injection and followed by a boost every 28 days to a maximum of four boost 
injections. Serum hepcidin Ab titre was arbitrarily acknowledged as sufficient for 
hybridisation, (i.e. mouse had sufficient number of hepcidin producing lymphocytes to be 
fused with myeloma cells to produce viable hybrid cells), when the percentage binding of 
antibody to I125 hepcidin was >30%. 
Mice were bled from their central tail vein 14 days after each boost injection. The blood (apx 
20-50μL) was collected into eppendorfs centrifugal vials (Eppendorf, UK). The test bleed 
was assessed for anti-hepcidin titre using the previously described methods in sections 2.2.4 
and 2.2.5, except the initial starting dilution for the mouse sera was 1:50 (10uL of sera + 
490μL assay buffer). 
 
2.4.6.1  Myeloma cell lines 
Mouse myeloma cell lines Sp2/0-Ag14 (European Collection of Cell Cultures) were 
maintained in myeloma cell culture medium (RPMI-1640, containing N-2-
hydroxyethylpiperazine-N‘-2-ethane sulfonic acid (HEPES) 20mM and L-Glutamine 200mM 
w/o NaHCO3) 10% fetal bovine serum (FBS), Penicillin/Streptomycin (100,000U/L, 
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100mg/mL respectively) and Amphotericin B (2.5mg/L). The medium was stored at 4oC and 
warmed to 37oC in an incubator prior to use. The concentration of cells and their viability was 
assessed using a conventional Neubauer haemocytometer (sigma) and trypan blue dye 
exclusion. The myeloma cells were maintained in logarithmic growth (minimum and 
maximum densities of 2.0 x 105 and 1.5 x 106 cells/ml; with doubling time of 16-24hrs) prior 
to hybridisation. 
 
2.4.6.2  Preparation for hybridisation 
Five days prior to hybridisation the selected hyper-immune mouse was given a final 
intraperitoneal (i.p) boost injection of the conjugated hepcidin (50µg/200µl) without adjuvant. 
Myeloma cell numbers were gradually expanded at log growth in T75 flasks, to ensure fifty 
million live cells with a cell viability of greater than 90% were available for the fusion protocol. 
Hybridisation media (127ml / fusion) was prepared as previously described for myeloma cell 
culture media with the exception of an increased FBS concentration (20% (v/v)) and the 
addition of HAT (i.e. 4ml, 50 x concentrate/100ml media) (MP Biomedicals). Final 
concentrations used were Hypoxanthine 27.22mg/L, Aminopterin 0.35mg/L and Thymidine 
7.752mg/L. The hybridisation medium was stored at 4oC and warmed to 37oC prior to use. In 
the absence of a macrophage feeder layer, Hybridoma Enhancing Supplement (HES) was 
added to the medium to give a final concentration of 10% (v/v). 
 
2.4.6.3  Preparation of spleen lymphocytes  
The immunised Balb/c mice selected for hybridisation were sacrificed by CO2 asphyxiation, 
and pinned to the dissection board. The spleen was transferred to a pre-weighed universal 
container containing RPMI-1640 (5ml). The weight of the spleen was calculated by 
differential weighing, to provide a useful guide to the immunised status of the mouse and 
also the number of lymphocytes likely to be recovered. The procedure was conducted by 
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Diagnostics Scotland and the spleen placed in warm RPMI-1640 media (10% FCS) and 
couriered overnight to Charing Cross laboratories. 
 
The spleen and medium were transferred to a sterile Petri dish inside a sterile laminar flow 
cabinet. Using two scalpel blades, the lymphocytes were teased out of the spleen. The 
spleen cell suspension was transferred to a fresh universal container and allowed to stand 
until the larger pieces of spleen tissue had settled. The cell suspension was transferred to a 
further universal and centrifuged at 950rpm for 10min at room temperature (R.T). The 
supernatant was discarded and the pellet gently re-suspended in RPMI-1640 (5ml). 
Lympholyte-M (5ml) (Lonza, UK) was pipetted into a centrifuge tube (15ml). The spleen 
suspension (5ml) was carefully layered onto the Lympholyte-M surface and centrifuged at 
670g for 20 min (GF720 RMS UK Ltd.) at R.T.  After centrifugation there was a well defined 
lymphocyte layer at the interface between a layer of medium above the lymphocytes, and a 
layer of Lympholyte-M below the lymphocytes. The majority of red blood cells and dead cells 
will form a cell pellet. The majority of the upper layer was removed and discarded and the 
lymphocyte layer carefully transferred to a universal container. RPMI-1640 (15ml) was 
added and the mixture recentrifuged at 670g for 10 min (GF720 RMS UK Ltd.) at R.T. The 
RPMI-1640 was discarded. The centrifugal wash was repeated and the recovered 
lymphocytes were resuspended in RPMI-1640 (5ml).  
 
2.4.6.4  Hybridisation protocol 
Aliquots of spleen (5ml) and myeloma cells (5ml) were mixed and centrifuged at 950rpm for 
10mins at R.T. As much of the supernatant as possible was removed to avoid subsequent 
dilution of the 50% PEG 1500 (Hybri-Max Pre-made solution). The mixed cell pellet was 
disaggregated by agitating the container and placed in a water bath at 37oC. The PEG 
solution (800µl) was added dropwise over 60 seconds with continuous stirring, which was 
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continued for a further 90 seconds. Pre-warmed RPMI-1640 media (10ml) was added very 
slowly over 5mins with agitation. The hybridisation mixture was centrifuged at 670g for 
10mins (GF720 RMS UK Ltd.) at R.T., washed in RPMI-1640 and resuspended in pre-
warmed hybridoma cell medium (60ml). The hybridisation products were aliquoted 
(100µl/well) into five sterile 96-well plates with additional media containing HES (100µl/per 
well). Plates were sealed with plate sealing tape, lids attached and incubated at 37oC for 10-
14 days. Plates were examined microscopically at intervals for the presence of growing 
hybrids. When good cell growth was observed, (defined as 10-15% occupation of the well) 
then the supernatants were screened for Ab production. 
 
2.4.7 Antibody characterisation of the polyclonal hepcidin antibody 
To establish the binding activity of the rabbit anti-hepcidin Ab for endogenous human 
hepcidin, an immunocytochemistry (ICC), experiment was performed on paraffin wax-
embedded sections of healthy human liver, (liver tissue was kindly supplied by the 
histopathology department, Hammersmith Hospital), and healthy human duodenal tissue, 
(duodenal tissue was harvested from patients undergoing routine Endoscopic retrograde 
cholangiopancreatography (ERCP) for gall stone removal). All biopsy patients (n=2) had 
normal chemistry profile. The study was approved by the local research ethics committee of 
Ealing Hospital Trust. Healthy tissue samples were fixed in 4% (w/v) paraformaldehyde for 
18 hours at 40C, then embedded in paraffin, and cut into 5μm thin sections. All tissue 
samples were kindly prepared for ICC by the Histopathology department, Hammersmith 
Hospital. Normal rabbit serum was used as a negative control. The specificity of the hepcidin 
Ab was confirmed by western blot (WB) analysis of the precipitated endogenous protein from 
human plasma and diluted synthetic hepcidin, (Bachem, UK) as a positive control sample. 
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Both of these studies required the rabbit polyclonal hepcidin Ab to be purified to limit non-
specific binding. 
 
2.4.7.1  Affinity chromatography of hepcidin antibody 
Affinity chromatography occupies a unique place in separation technology, being the only 
technique which enables purification of almost any biomolecule on the basis of its biological 
function or individual chemical structure. The widespread adoption of this technique reflects 
its success in achieving rapid separations which are time consuming, difficult or even 
impossible using other techniques. Affinity chromatography is a type of adsorption 
chromatography in which the molecule to be purified is specifically and reversibly adsorbed 
by a complementary binding substance (ligand) immobilised on an insoluble support 
(matrix). Purification is often of the order of several thousand fold and recoveries of active 
material are generally very high. 
 
HiTrap protein G HP columns are packed with Protein G SepharoseTM High Performance, 
(GE Healthcare, UK). The protein A is immobilised to 6% highly cross-linked spherical 
agarose (Sepharose High Performance) using the N-hydroxysuccinimide activation method, 
which gives high capacity and performance. Protein A is a bacterial protein from 
Staphylococcus aureus which binds specifically to the Fc region of polyclonal and 
monoclonal IgG-type Abs. In the immobilised form, as derivatives of Sepharose, they are 
extremely useful, high capacity adsorbents for purification and isolation of monoclonal and 
polyclonal IgG from sera. HiTrap Protein A uses recombinant protein A, which is produced in 
E.coli and contains two IgG binding regions. The albumin region of native protein A has been 
genetically deleted, thereby avoiding undesirable cross-reactions with albumin.  
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A successful separation requires that the biospecific ligand (protein A) is covalently attached 
to a chromatographic bed material, the matrix (Sepharose). There is a strong affinity 
between protein A and IgG at pH 7.0. When the sera containing the Ab to be purified, is 
pumped onto the column with binding buffer (pH 7.0) the immobilised protein A specifically 
binds IgG from the sera. Unbound material is washed through the column without binding. 
The buffer is changed to a lower pH elution buffer (pH 2.7), the IgG is then desorbed in an 
active form from the protein A and eluted (Amersham Pharmacia Biotech 1995).  
 
HiTrap Protein A columns (GE Healthcare) were used for antibody purification of polyclonal 
antibody from the rabbit antisera. A packed guard column G-25 Sephadex (1 x 5cm) and a 
pre-packed Protein A column were connected in series and equilibrated with starting buffer 
(0.02M sodium phosphate, pH 7) to achieve a stable ultraviolet-light (UV) baseline (UViCord 
SII, 280nm (GE Healthcare)). Briefly; 10mls of undiluted rabbit antiserum was centrifuged, to 
remove particulate debris. Supernatant was then removed and 10mls of starting buffer was 
added to give a final volume of 20mls. Diluted antiserum was then pumped onto the column 
(flow rate 1ml/min), followed by starting buffer until the unbound protein was washed from 
the column, as indicated by re-zeroing of the UV trace on chart recorder. Column buffer was 
then changed to elution buffer (0.1M glycine, pH 2.7) and the IgG released was collected, as 
indicated by an increase in absorbance on the UV trace. Aliquots containing IgG were 
dialysed against sodium bicarbonate (0.01M, pH 8) overnight and protein concentration was 
estimated by Bradford Dye method (Biorad, UK). Samples were then concentrated to 
1mg/mL by ultracentrifugation, (Urisep® maxi centrifugal concentrators; Jouan GR422 
centrifuge at 800g for 20mins) and stored at -20oc. 
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2.4.7.2  Western blot analysis of hepcidin antibody 
Immunoblotting is an accurate technique for detecting a single protein of interest in a 
complex mixture and determining its molecular weight. Immunoblotting can measure relative 
amounts of the protein present in different samples and it is an invaluable tool for testing the 
specificity of Abs. Proteins in the sample are separated according to MW by electrophoresis. 
The separated proteins are subsequently transferred from the electrophoresis gel to a thin, 
rigid support membrane by an electroblotting method and then detected by their Ab binding 
(Harlow & Lane 1988;Polak and Van Noorden 1997). 
Briefly; 10mls of normal human plasma was centrifuged and filtered through a 0.2µm filter 
(Millipore, UK). After addition of the redox agent Dithiothreitol (DTT), plasma was then again 
filtered through a 30KDa filter (Millipore, UK) and the filtrate precipitated using 25% 
tricholoroacetic acid (TCA). The precipitated proteins were resuspended in loading buffer 
and subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) on 
a 4-16% NuPAGE Novex Bis/Tris gel (Invitrogen, UK). Western blot was performed using an 
X-Cell II blot module (Invitrogen, UK) and a 0.1mm pore size nitrocellulose membrane. Non-
specific sites were blocked with 5% BSA in 0.1M PBS and the membrane probed with 
purified rabbit anti-hepcidin antibody (1/2000 dilution in blocking buffer). Incubation was with 
secondary anti-rabbit antibody conjugated with horse-radish peroxidase (HRP). Specific 
signals were detected with 3, 3‘, 5, 5‘ tetremethyl benzidine liquid substrate (TMB). Synthetic 
hepcidin, (Bachem, UK), was diluted in assay buffer to a final concentration of 50ng/mL; this 
was used as a positive control in the WB study. 
 
2.4.7.3  Immunocytochemistry using hepcidin antibody 
ICC is the use of labelled Abs as specific reagents for localisation of tissue constituents 
(antigens) in situ, and has become an indispensable investigative technique in histo- and 
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cytopathology and many branches of biomedical science. Its versatility allows it to be used 
on whole cells or on tissue sections from frozen or fixed or embedded samples, and at both 
light and electron microscopic levels. ICC can be combined with other localisation methods 
such as histological staining and in situ hybridisation of nucleic acids. The requirements are 
a specific Ab to the Ag in question, suitable preservation of the Ag and a revelation method 
sensitive enough to depict low quantities of Ag (Polak & Van Noorden 1997). 
Briefly; Liver and duodenal tissue sections (5µm) were deparaffinised (x2) in xylene for 5min 
and rehydrated in descending grades of ethanol, (100%, 95% and 70%) for 2min each. 
Antigen retrieval was accomplished by immersing and heating slides in 10mmol/L citrate 
buffer. Slides were then incubated with blocking solution, (3% FBS, 1% BSA, 0.05% Tween 
in tris-buffered saline) for 30mins, followed by a 4oC overnight incubation with purified rabbit 
anti-hepcidin antibody (1/800 dilution). Sections were then incubated for 1hr with secondary 
anti-rabbit conjugated with HRP. The reaction was then visualized by the addition of 3, 3‘-
diaminobenzidine (DAB) substrate for 5min, and the reaction was stopped by washing with 
laboratory grade water. Sections were counterstained with haematoxylin for 1min. Slides 
were then dehydrated in 70%, 95% and 100% ethanol for 2 min each, cleared in xylene for 
5min and then mounted in a mixture of distyrene, a plasticizer, and xylene (DPX) as a 
synthetic resin mounting media. 
 
2.4.8 Hepcidin competitive RIA Protocol 
This is a general description of the immunoassay protocol for hepcidin to follow in setting up 
an assay of unknown samples by constructing a standard curve. The standard curve covers 
the analytical range 1.25 – 160 ng/mL. Briefly; Tubes were labelled for Totals, NSB, B0 and 
appropriate tubes for standards (1-8), low and high internal quality controls (IQC) and 
unknowns (duplicate).  Prepare dilution tubes for the standard curve (1-7): A) Assay buffer 
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(500µl) was added to 500µl of 160ng/mL hepcidin standard (Std 7). B) Add 500µl assay 
buffer + 500µl Std 7 (Std 6) etc. C) Add 100µl 160ng/ml (Std 8) to relevant tubes. Add 100µl 
of standard dilutions to relevant tubes, 100µl of QC to relevant tubes, and 100µl sample to 
unknowns. Add 300µl buffer to NSB and 200µl buffer to B0 tubes and 100ul buffer to each 
standard, QC tube and unknown sample tube. Add 100ul Ab to all tubes except Totals and 
NSB, add 100µl I125 label to all tubes. Vortex, then incubate overnight 40C. Add 500µl 
precipitating reagent (Sheep-anti Rabbit (SAR) 1:160, Normal Rabbit serum (NRS) 1:800 
and 6% PEG in assay buffer), to all tubes except Totals. Vortex and incubate 40C for apx 40 
– 60 mins. Add 1ml 0.1% Triton and centrifuge (Jouan GR422) 1040g for 40mins. Decant 
supernatant and count pellet in gamma-counter for 1min counts. Calculate unknowns with 
appropriate computer package e.g. RiaCalc, (Perkin Elmer LAS, UK).  
 
2.4.8.1 Hepcidin immunoassay validation 
Assay validation was carried out by a series of experiments to confirm the selectivity of the 
assay, sensitivity of the assay, a measure of imprecision, inaccuracy (%recovery), assay 
linearity, assay specificity (% cross-reactivity), hepcidin stability during sample storage and a 
method comparison against a published mass-spectroscopic method for human hepcidin. 
Validation experiments were based upon Clinical & Laboratory Standard Institute guidelines, 
(CLSI, EP10-A3). The studies using patient samples were approved by the local NHS 
Research Ethics Committee (06/Q0406/134) and all participants gave informed consent 
according to the principles of the Declaration of Helsinki. 
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2.4.8.2  Assay selectivity 
Human plasma samples (n=3) from iron deficient patients (ferritin <10µg/L) were pooled and 
diluted 1/10 with assay buffer. Calibration curves using the diluted patient sera and assay 
buffer were then assayed in parallel. Both curves were assayed three times over three 
different days.  
 
2.4.8.3  Limit of detection (analytical sensitivity) 
This experiment was designed to determine the minimum detectable measurable 
concentration of hepcidin in patient samples. (B0 is the maximum binding in competitive 
immunoassays in the absence of antigen – only labelled peptide is bound and therefore 
maximum detection for the assay is obtained). Twenty replicates of the B0 were processed 
according to the RIA protocol. This experiment was repeated three times in three separate 
assays.  
 
2.4.8.4  Imprecision 
The variation within and between assays (intra- and inter-assay respectively) was measured 
using two samples of known hepcidin concentration: one low concentration sample (5ng/ml) 
and one high concentration sample (50ng/ml). The samples were produced by spiking 
depleted pooled human plasma (Scipac, UK) with a known amount of synthetic hepcidin. 
The samples were then assayed according to the hepcidin assay protocol and precision 
reported as; 
i. Intra-assay precision = % Coefficient of variation (CV) calculated from mean 
of ten results from a single assay. 
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ii. Inter-assay precision = %CV calculated from mean value of twenty-five 
results across five assays. 
 
2.4.8.5  Recovery (inaccuracy) 
To assess the % recovery, three patient samples of known hepcidin concentration were 
spiked with 5, 10 and 50 ng/ml concentrations of synthetic hepcidin. Each sample was 
assayed to produce three results, and the assay repeated six times. The inaccuracy is 
reported as % recovery: 
Assayed Result (ng/mL)   x 100 = % Recovery 
                                   Theoretical Result (ng/mL) 
 
 
2.4.8.6  Linearity 
In order to show identity exists between the endogenous hepcidin present in the sample and 
the synthetic hepcidin used to calibrate the assay, a dilution test was carried out using two 
human plasma samples. Both samples had high hepcidin values and were diluted with assay 
buffer (0.05M PBS, pH 7.4 (0.5% BSA)).  
 
2.4.8.7  Cross-reactivity (analytical specificity) 
Analytical specificity was assessed by measuring cross-reactivity with proteins that share 
some structural homology with hepcidin. The following proteins were used: Hepcidin, 
Hepcidin-20*, Human Insulin, Human Glucagon 1, Human Angiotensinogen 1, Human β-
Defensins 1 – 4, Human α-Defensin 1, Plecstasin and Protegrin-1  
*(All proteins were obtained from Bachem UK, except hepcidin-20 which was purchased 
from Peptide Institute, Japan).  
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Cross reactivity was expressed as a percentage: 
Cross Reactivity (%) = Assayed conc. (ng/mL)  x 100 
             Actual conc. (ng/mL) 
 
Before conducting an interference experiment, the performance characteristics of the 
analytical methods must be defined such that; 
 Method comparison studies confirm that no significant proportional bias exists. 
 Precision (within-run) is acceptable. 
 Stable operation of the method is confirmed by appropriate quality control 
procedures. (Westgard QC Charts). 
 
2.4.8.8  Sample stability 
Aliquots of patient samples (n=5) were kept in long term storage (4 weeks) at 4oC, or placed 
through multiple freeze-thaw cycles (x 3), and then assayed for hepcidin. 
 
2.4.8.9  Method comparison 
To verify the comparability of the method, a direct comparison of the competitive hepcidin 
RIA method against a published SELDI-TOF-MS hepcidin method (Ward, Roberts, 
Stonelake, Goon, Zampronio, Martin, Johnson, Iqbal, & Tselepis 2008) was conducted. 
Patient samples covering the analytical reportable range for the RIA hepcidin method were 
selected. Calculations were performed which provide information about the Deming and 
classical regression and include estimate of 95% confidence interval (CI) for the slope and 
intercept. Criteria of acceptance of comparability of results are defined as; 
 Slope (0.9-1.10). 
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 Y intercepts 0 (or closes enough to zero to be clinically insignificant). 
 Correlation Coefficient (R) ≥0.975. 
A Bland-Altman plot was also constructed.  A Bland-Altman plot examines the relationship 
between the differences and the magnitude of measurements between comparable 
methods, allowing visual overview of; 
 Average discrepancy between methods (mean bias). 
 Identification of trends in the data and whether the difference between methods tends 
to get larger (or smaller) as the average increases i.e. proportional bias. 
 The consistency of the variability across the plot and whether the scatter of data 
around the mean bias gets larger as the average gets higher. 
If the differences within the 95% CI are not clinically important, then the two comparable 
methods can be used interchangeably (Bland and Altman 1986). 
For the comparison study, healthy human plasma samples were supplied by Prof K Srai, 
University College, London, (n=99). A brief format of the SELDI-TOF-MS method is 
described; An initial 1:5 dilution of human sera in 8M Urea is made, 1% 3-[(3-
Cholamidopropyl) dimethylammonio]-1-propanesulfonate (CHAPS) in binding buffer (0.5M 
NaCl, 0.1M sodium phosphate, pH 7.0). A further 1:10 dilution was then made in binding 
buffer. The sample (100 µl) was then applied to the Cu2+ IMAC30 proteinchip arrays (Biorad, 
UK).  Thirty minutes was allowed for binding, and the proteinchip arrays were then washed 
with binding buffer, rinsed with water, and dried. Two 1µl volumes of 50% saturated sinapinic 
acid in 50% ACN / 0.5% TFA were added. Spectra were then collected over m/z 0 – 20,000 
focussed at m/z 2800 using a laser power of 165 (Ciphered, Biosystems Inc., Fremont, CA, 
USA). Following mass calibration, total ion current normalisation and baseline subtraction, 
the hepcidin peaks were manually picked and intensities (peak heights) extracted using the 
Biomarker Wizard Software Tool (Ciphered, Biosystems Inc., Fremont, CA, USA).  
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2.4.9 International comparative study of hepcidin assays 
A variety of hepcidin research methods are currently being used. Assays are being 
developed using various mass spectrometry (MS) platforms including surface enhanced 
laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS), matrix 
assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) and 
liquid chromatography tandem-MS techniques (LC-MS/MS). Some of these methods use an 
internal standard of either hepcidin-25 analogs or bioactive hepcidin-25 synthesized with 
stable isotopes (Castagna et al. 2010). Recently, a number of immunochemical (IC) assays 
for hepcidin have also been developed, including a competitive radioimmunoassay (RIA), 
(Busbridge et al 2009), described earlier in this chapter, and enzyme-linked immunosorbent 
assays (ELISA) (Ganz et al 2008;Koliaraki et al 2009), (see Table 2.1.1, for list of methods 
included in the first Round-Robin study).  As this these assays are primarily research tools 
and as yet no proven clinical utility for hepcidin has been published, no reference method or 
reference internal standard for hepcidin has been developed. Therefore, to increase 
comparability of hepcidin data across clinical studies, an international round-robin study was 
proposed and co-ordinated by Prof D Swinkels, Radboud University Nijmegen Medical 
Center (Kroot et al 2009). 
Met 
A prospective repeated measurement design with 12 replicates was used to assess 
concordance in urine and plasma hepcidin analysis. The study was coordinated by the 
Department of Clinical Chemistry of the Radboud University Nijmegen Medical Centre. All 
laboratories invited to participate performed 12 replicates that consisted of triplicate assays 
of each sample on four consecutive days. The only information provided about the samples 
was the urinary creatinine levels. Eight urine samples with a range of hepcidin 
concentrations were collected from healthy subjects (samples1-5) and patients (samples 6-
8), with informed consent according to the declaration of Helsinki. Synthetic hepcidin 
(Peptide Institute Inc., Osaka, Japan), was added to a final concentration of 13.1 nmol/mmol 
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creatinine to a urine sample that by SELDI-TOF was found to have a hepcidin concentration 
below the lower limit of detection of 0.5 nmol/L (or 1.4 ng/mL) (sample 5). The seven plasma 
pools were composed from hospitalised patient samples, (samples 9-15). All samples were 
centrifuged for 10 min at 2600 g, and immediately stored in aliquots at –80°C.  
Samples were shipped on dry ice to all participants, and measured within four weeks of 
receipt. All samples underwent only one freeze-thaw cycle before analysis to minimize 
changes such as the formation of hepcidin aggregates and breakdown products that may 
differently affect the various methods. 
The round robin study was designed to compare hepcidin levels as well as the reproducibility 
of the various methods used for serum and urine. For an estimate of assay reproducibility 
total variance for each method was calculated; (calculate variation that exists between 
samples and between measurements of the same sample relative to the total variation): 
(i) Between-sample variance 
(ii) Analytical variance 
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Table 2.1.1 Hepcidin methods compared in the first international round robin. List of all 
hepcidin methods, both spectroscopic and protein methods, with associated details of primary 
extraction technique if required and the type of internal standardardisation. 
M 
Method Hepcidin 
Extraction 
 
Standard Urine Plasma 
(I)  SELDI-TOF MS Normal Phase None X X 
(II) SELDI-TOF MS 
Weak cation 
exchange 
Internal synthetic hepcidin-24 X X 
(III) MALDI-TOF MS* Reversed Phase External Synthetic hepcidin-25 X  
(IV) LC-MS/MS 
Weak cation 
exchange 
Internal [15N,13C2]Gly-12,20-
hepcidin 
X X 
(V) Competitive ELISA None External Synthetic hepcidin-25 X X 
(VI) Competitive RIA** None External Synthetic hepcidin-25 X X 
(VII) LC-MS/MS* None Internal synthetic hepcidin-25 X  
(VIII) Competitive ELISA None 
External Recombinant hepcidin-
25(HIS) 
X X 
 
X indicates participation in hepcidin round robin for urine and/or plasma. * These methods are not 
standardised for urine hepcidin measurements. **indicates Imperial College hepcidin RIA method 
 
 
 
2.4.9.1  Samples for establishing preliminary reference intervals 
The Clinical & Laboratory Standards Institute (CLSI, USA), working group recommend 
establishing a reference interval based upon a minimum of 120 samples from qualified 
reference individuals for analysis by non-parametric means (Clinical and Laboratory 
Standards Institute 2010). For defining reference intervals for the hepcidin RIA, a total of 
sixty-four sample controls were recruited for the healthy control group (HC). Healthy men 
and non-pregnant women aged between 18-55y were recruited for the HC group. Exclusion 
criteria included subjects on nutritional supplements containing iron, underlying 
malabsorption disease or previously diagnosed medical problems known to affect iron 
homeostasis. 
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Blood (3-4mL) was taken by venepuncture into one serum separator tube (SST) and one 
lithium heparin tube. Both samples were centrifuged for 5 min at 2000 rpm and the 
serum/plasma frozen at –20°C. Twenty-two of the HC also donated a random matched urine 
sample; 10-20mls of urine was collected into a specimen container centrifuged for 5 min at 
670g (GF720 RMS UK Ltd) and supernatant frozen at –20°C. All control samples were 
standardised on a 10am collection. 
 
Routine chemistry profile, ferritin, Fe, unsaturated iron-binding capacity (UIBC) and C-
Reactive Protein (CRP) were measured using standard methods on the Abbott Architect 
ic8000 system, (Abbott Diagnostics, Ireland). Total iron binding capacity (TIBC) is a 
calculated test; serum iron + UIBC. Transferrin saturation (TSAT) is calculated from; serum 
iron / TIBC x 100. Full blood counts were kindly processed by Haematology department, 
using the Sysmex system, (Sysmex, USA), Hammersmith Hospital Trust. EPO and 
Prohepcidin were measured using commercial ELISA methods, (R & D Systems, UK and 
DRG Diagnostics, Germany). Briefly; the test is a solid-phase enzyme-linked immunosorbent 
assay (ELISA), based upon the principle of competitive binding. The test sample was 
incubated in microtitre wells coated with a polyclonal antibody, directed against an antigenic 
site on the prohepcidin. The prohepcidin-biotin conjugate was added and competed with the 
endogenous prohepcidin in the test sample. The amount of bound biotin conjugate was 
inversely proportional to the concentration of prohepcidin. After the substrate solution was 
added, the intensity of the colour developed was inversely proportional to the concentration 
of prohepcidin. 
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2.4.9.2  Statistical analysis 
Study sample size required for an alpha at 0.05 and a power of 80% was calculated 15 
cases per group, (anticipated difference 13.7ng/mL and the anticipated standard deviation 
(SD) 16.3ng/mL); to test the null hypothesis that any difference observed between the 
healthy control samples and diseased groups is significantly different. Variables that are 
normally distributed are expressed as mean, and those variables that are not normally 
distributed are expressed as median with range as indicated. Normality was assessed using 
the Shapiro-Wilk test and skewed data was log transformed before statistical analysis. 
Quantitative variables were compared using unpaired t-test. Pearsons rank correlation was 
used for calculating correlation between the various variables; Spearman rank correlation 
was used for data that was not normally distributed. Deming Regression and Bland-Altman 
analysis were used for the method comparison data. A value of p <0.05 was considered 
significant. All statistical analyses were carried out using the statistical package GraphPad 
Prism version 5.00 for Windows, (GraphPad Software, San Diego California USA, 
www.graphpad.com).  
 
For the round robin study, a linear mixed model was used to estimate the variance 
components of each method separately. The dependant variable was hepcidin outcome, and 
the independent random variables were: sample (plasma seven levels, urine eight levels), 
days (four levels) and repeated measurement (three levels). The SD (a measure of absolute 
error), the % coefficient variation (%CV) (a measure of the relative error), and the 
percentage variance relative to the total variance of each random variable was calculated for 
each method separately, (Kroot et al 2009). 
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2.5 Results 
2.5.1 Isotopic labelling of hepcidin-(Tyr) 
Radioiodinated hepcidin-(Tyr) was purified using a RP-HPLC column. Two radioactive peaks 
were obtained in the elution profiles: the first small peak corresponded to the elution of free 
iodine and the high radioactivity second peak corresponded to the elution of radioiodinated 
hepcidin. A 50% incorporation of radioiodine into hepcidin was used as an arbitrary measure 
of tracer viability. Approximately 25% incorporation into the selected peak yielded hepcidin 
I125 with a specific activity of 20.2µCi/µg (Figure 2.1.7). The iodinated label was tested using 
diluted antisera to give a maximal B0 of approximately 40%. 
 
 
Figure 2.1.7 RP-HPLC elution profile of synthetic hepcidin-(Tyr) following iodination using 
the Chloramine-T method. The small first peak represents free iodine, and the subsequent major 
peak represents hepcidin-(Tyr), (45% radioisotope incorporation). Fractions collected 1ml/min over a 
5-45% ACN: H20 gradient. Cps; Counts per second Na I
125
. 
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2.5.2.1 Screening rabbit bleeds for antibody response 
There was a rapid response in the one of the rabbits to immunisation with hepcidin 
conjugated to mcKLH via EDAC. Ab titres were detected after the primary boost. The rabbit 
immune response is shown in Figure 2.1.8. A pre-immune bleed and three more bleeds on a 
monthly basis were collected and 100-150mls of antiserum prepared after terminal 
exsanguinations.   
 
 
Figure 2.1.8 Hepcidin rabbit antibody dilution curve. Rabbit antibody dilutions in assay buffer 
(0.05M PBS) of immune bleeds 1-3 over dilution range 1:20-1:10240, using I
125
 hepcidin (Tyr) as test 
reagent to screen for positive antibody titre. Bleed 1 shows no binding whereas bleeds 2 and 3 
demonstrate maximal antibody binding at a 1:160 dilution. 
 
 
 
106 
 
2.5.2.2 Rabbit antibody displacement assay 
An Ab displacement experiment was carried out using the positive immune bleed from 
previous dilution curve, (rabbit bleed 2). An Ab dilution was performed in assay buffer. Two 
assays were then set-up, one in presence of assay buffer and the other assay in presence of 
hepcidin (10ng/mL (diluted in assay buffer)). Displacement analysis with hepcidin at 
10ng/mL shows optimal performance at a final dilution of 1:160. At this point % bound was 
55% and maximum relative displacement was 91% (Figure 2.1.9).   
 
Figure 2.1.9 Hepcidin rabbit antibody displacement curves. Rabbit bleed 2 diluted antisera in 
presence of assay buffer and a known concentration of hepcidin (10ng/mL), demonstrates maximal 
antibody binding at a 1:160 dilution with >90% inhibition of antibody binding in presence of synthetic 
hepcidin. 
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2.5.3.1 Screening sheep bleeds for antibody response 
There was a immune response in the sheep to immunisation with hepcidin conjugated to 
mcKLH via EDAC. Ab titres were detected after the primary boost. The sheep immune 
response is shown in Figure 2.1.9.1. A pre-immune bleed and three more bleeds on a 
monthly basis were collected and 500-1000mls of antiserum were prepared after terminal 
exsanguinations.   
 
Figure 2.1.9.1 Hepcidin sheep antibody dilution curve. Sheep antibody dilutions in assay buffer 
(0.05M PBS) of immune bleeds 1-4 over dilution range 1:20-1:40960, using I
125
 hepcidin (Tyr) as test 
reagent to screen for positive antibody titre. Bleed 1 shows ≤5% binding whereas bleeds 3 and 4 both 
demonstrate maximal antibody binding of 24% at a 1:2560 dilution. 
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2.5.3.2 Sheep antibody displacement assay 
An Ab displacement experiment was carried out using the positive immune bleed from 
previous dilution curve, (sheep bleed 4). An Ab dilution was performed in assay buffer. Two 
assays were then set-up, one in presence of assay buffer and the other assay in presence of 
hepcidin (10ng/mL (diluted in assay buffer)). Displacement analysis with hepcidin at 
10ng/mL showed poor affinity of the antigen for the antibody at a dilution of 1:2560. At this 
point % bound was 24% and maximum relative displacement was 25% (Figure 2.1.9.2).   
 
 
Figure 2.1.9.2 Hepcidin sheep antibody displacement curves. Sheep bleed 4 diluted antisera in 
presence of assay buffer and a known concentration of hepcidin (10ng/mL), demonstrates maximal 
antibody binding (24%) at a 1:2560 dilution but only 25% inhibition of antibody binding in presence of 
synthetic hepcidin. 
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2.5.4 Screening mouse bleeds for antibody response 
Five Balb/c mice were immunised with the hepcidin conjugate. There was a significant 
immune response in four mice (>10% binding) generated following three boosts. One of the 
mice reached the criteria for hybridisation (>35% binding) after the third boost and the 
remaining four mice showed (≤25% binding) (Figure 2.2.1). Unfortunately due to culture 
problems post hybridisation with the myeloma cell line, no hybridoma growth was observed 
post 7 days, so the production of Mab to hepcidin was terminated and all efforts 
concentrated on establishing the Pc Ab for immunoassay development. 
 
 
Figure 2.2.1 Hepcidin mouse antibody dilution curve. Mouse antibody dilutions (0.05M PBS) of 
immune bleeds from five immunised mice, after three immunisations. Antisera diluted over range 
1:50-1:102400, using I
125
 hepcidin (Tyr) as test reagent to screen for positive antibody titre. Mouse 4 
demonstrates maximal antibody binding of 45% at a 1:50 dilution. 
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2.5.5 Western blotting experiment 
The specificity of the Ab for endogenous human hepcidin was confirmed by WB analysis of 
the precipitated proteins, where a single band <6 KDa was detected (Figure 2.2.2). 
 
 
 
 
Figure 2.2.2 Western blot analysis of serum proteins. Using purified rabbit anti-hepcidin 
antibody to demonstrate the presence of a protein band at <6 KDa, corresponding to human hepcidin-
25 (2789Da), in the positive control sample containing synthetic hepcidin and the human plasma 
sample. 
 
 
 
2.5.6 Immunocytochemistry analysis of human tissue  
To establish the binding activity of the rabbit anti-hepcidin Ab for native endogenous 
hepcidin, ICC was performed on paraffin wax embedded healthy human liver and duodenal 
tissue sections. The Ab showed strong cytoplasmic staining in hepatocytes from the positive 
control liver tissue section, but no staining was observed in the duodenal tissue sections 
(Figure 2.2.3). 
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Figure 2.2.3 Specificity of rabbit anti-hepcidin antibody, against endogenous hepcidin. 
Representative ICC staining of healthy, A) human liver; strong cytoplasmic staining of the hepatocytes 
(indicated by arrows) and B) duodenal tissue; no staining was observed in the mucosal lining, (HRP-
DAB staining, original magnification x40 magnification). Normal rabbit serum was used as a negative 
control on the duodenal tissue sections, data not shown 
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2.5.7  Assay validation of hepcidin radioimmunoassay 
2.5.7.1  Assay selectivity 
The curves observed in Figure 2.2.4 correlate well and show no significant difference and no 
observable matrix effect between hepcidin calibrator in assay buffer and hepcidin calibrator 
in human plasma. 
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Figure  2.2.4 Hepcidin calibration data. Graph represents three calibration curves over three 
different days, (mean data with standard error of the mean (SEM) plotted). Red line represents curve 
in serum-free assay buffer, blue line represents hepcidin standards diluted (1:10) in pooled human 
plasma from selected iron-deficient patients (ferritin <15 μg/L and iron <10 μmol/L) (n=3).  
 
2.5.7.2  Limit of detection (analytical sensitivity) 
The minimum detection limit of the hepcidin RIA was calculated from the mean+3SD of 20 
replicates of the B0 repeated in three separate assays. The minimum detection limit of the 
assay was found to be 0.6ng/mL.  
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2.5.7.3  Imprecision 
The hepcidin RIA demonstrated acceptable levels of imprecision (CV <10%), Table 2.1.2, 
over the selected analytical range, for a manual based assay (Clinical and Laboratory 
Standards Institute 2004). 
 
Table 2.1.2 Imprecision studies for the hepcidin RIA. Results show that the hepcidin assay 
has acceptable imprecision limits for a manual based assay 
 
 Intra-assay Inter-assay 
Sample Low (5ng/mL) High (50ng/mL) Low (5ng/mL) High (50ng/mL) 
N 10 10 25 25 
Mean (ng/mL) 4.74 52.8 4.68 52.5 
SD 0.3 3.1 0.4 3.5 
CV (%) 7.2 5.8 7.6 6.7 
N; number of tests, SD; standard deviation and CV; coefficient of variation 
 
2.5.7.4  Recovery Study (inaccuracy) 
Recovery levels in the hepcidin RIA demonstrated acceptable levels of inaccuracy, (between 
80-110% (Clinical and Laboratory Standards Institute 2004) in distinguishing between 
exogenous and endogenous concentrations of hepcidin (Table 2.1.3). 
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2.5.7.5  Linearity Study 
Results from the linearity experiment, Table 2.1.4, demonstrate that the hepcidin RIA is 
linear up to hepcidin concentrations of 200ng/mL. 
 
Table 2.1.3 Assay recovery (%) results for the hepcidin RIA. Measure of inaccuracy of the 
hepcidin assay, acceptable levels of recovery between 80-110%. 
 
Added hepcidin 
(1:1 in plasma samples) 
5ng/mL 10ng/mL 50ng/mL 
Theoretical (ng/mL) 2.54 5.7 28.1 
Assayed hepcidin 
(ng/mL) 
2.6 6.1 29 
% Recovery 98 94 97 
 
 
Table  2.1.4  Linearity results for the hepcidin RIA. Two patient samples run neat and as a 
series of dilutions in assay buffer demonstrate hepcidin assay is linear over analytical range. 
 
Dilution Factor Undiluted 1:2 1:4 1:8 1:16 
Assayed Hepcidin 
(ng/mL) 
2101 
 
1902 
1071 
 
1012 
49.31 
 
43.72 
25.11 
 
23.22 
12.11 
 
10.32 
Expected Hepcidin 
(ng/mL) 
 
 
 
1051 
 
952 
52.51 
 
47.52 
26.21 
 
23.72 
13.11 
 
11.82 
% Recovery 
 
 1021 
 
1062 
941 
 
922 
961 
 
982 
921 
 
872 
*sample 
1
 and sample 
2 
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2.5.7.6  Cross-reactivity study (analytical specificity) 
Cross-reactivity studies with similar structured peptides and proteins demonstrated that the 
hepcidin antibody cross-reacts with the 25 residue synthetic hepcidin used for immunizations 
and as an internal standard, but also cross-reacts with synthetic hepcidin-20 to a lesser 
degree (10%). There is no cross-reactivity observed with other known proteins that share 
some sequence homology with hepcidin (Table 2.1.5). 
 
Table 2.1.5 Cross-reactivity experiment.  Cross-reactivity (%) of similar structured peptides and 
proteins assayed using the hepcidin RIA. 
 
Cross-reactant % Cross-reactivity 
Hepcidin-25 (200ng/mL) 100 
*Hepcidin-20 (200ng/mL) 10 
Glucagon I (200ng/mL) <0.1 
Angiotensinogen I (200ng/mL) <0.1 
ß-Defensin 1 (47aa) (100ng/mL) <0.1 
ß-Defensin 2 (100ng/mL) <0.1 
ß-Defensin 3 (100ng/mL) <0.1 
ß-Defensin 4 (100ng/mL) <0.1 
Plectasin (200ng/mL) <0.1 
Progretin-1 (200ng/mL) <0.1 
 
All cross-reacting peptides purchased from Bachem Ltd, UK, except *Hepcidin-20 which was 
purchased from Peptide Institute, Japan. 
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2.5.7.7  Method comparison 
Patient demographics for the method comparison study are described in Table 2.1.6. Both 
methods demonstrated significant correlation with ferritin levels (Figure 2.2.5 A and B). 
Deming regression data demonstrated a linear relationship between the two methods, 
(Slope; 0.83±0.025, Y intercept -1.94±0.9), (Figure 2.2.6 A), and also significant correlation 
between the methods, (R 0.96, p <0.0001). This significant comparability between methods 
was also observed with the Bland-Altman analysis with the majority of results between the 
95% CI levels (Figure 2.2.6 B).  However, significant variation was observed in results at 
hepcidin concentrations ≤5ng/mL. 
 
Table 2.1.6 Demographic and biochemical parameters. Patient samples used for hepcidin 
method comparison. 
Parameter Result 
N 99 
Iron (µmol/L) 
(Male: 9-29) 
(Female: 7-27) 
16.2 (5.8-35)+ 
Ferritin (µg/L) 
(Male: 20-300) 
(Female (16-50y): 10-120) 
Female (>50y): 20-300) 
86 (8-1039)+ 
TSAT % 
(16-55) 
27 (±10.9)* 
Hepcidin MS (ng/mL) 27.6 (2.4-99.1)+ 
Hepcidin RIA (ng/mL) 21.2 (2.3-90)+ 
+
 median (Range), * mean (±SD) 
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Figure 2.2.5 Correlation data for hepcidin methods with ferritin levels in sample group 
(n=99). A) Hepcidin MS levels correlate with ferritin levels, (Spearman R 0.67, p <0.0001*) and B) 
Hepcidin RIA levels correlate with ferritin levels, (Spearman R 0.69, p <0.0001*). (p <0.05* considered 
significant). 
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Figure 2.2.6 Method comparison data for the two hepcidin methods (samples n=99); A) 
Deming Regression (Slope; 0.83±0.025, Y intercept 0; -1.94±0.9 and r
2
 0.92) and B) Bland-Altman (% 
Difference between methods vs. average of methods, solid line represents mean Bias (29.8%), dotted 
lines represents 95% confidence-interval levels (-18.88% to 78.57%). 
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2.5.8 International comparative study of hepcidin assays 
The mean hepcidin levels for all the samples differed significantly between all the methods 
(Appendix I, Table 1.1). Figures 2.2.7 and 2.2.8 represent; a) mean sample result for each 
method with a line representing the sample mean for all the methods and b) difference 
between each method and the sample mean for all methods, respectively for the urine and 
plasma sample results. The results in particular for method V, which represents the ELISA 
competitive based method, were particularly high compared to the other methods, exhibiting 
a proportional bias when compared against the overall group mean for the urine and plasma 
samples. For this round robin study, only native urine and plasma samples were used, 
except for one sample i.e. urine sample number five, which contained synthetic hepcidin, 
added to a final concentration of 13.1nmol/mmol creatinine. The mean results for the 
methods II (SELDI-TOF-MS), IV (LC-MS-MS) and VI (RIA), for this ‗spiked‘ urine sample 
were closer to the theoretical concentration than the other methods (Kroot et al 2009) 
 
Most of the methods show similar analytical and between-sample variation (Appendix I, 
Table 1.2). However, the between-sample CV is significantly lower for the plasma samples 
than compared to the urine samples, (p 0.0009). This probably reflects differences in 
hepcidin metabolism e.g. hepcidin excretory pathways. The MS methods IV and VII 
demonstrate a lower contribution of the analytical variance to the total variance compared to 
the other MS methods. Method V (C-ELISA) shows higher between-sample CV (137.6%) 
and analytical CV (24.1%) for the urine samples and a between-sample CV (85.8%) and 
analytical CV (20.9%), compared to the other IC methods. 
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Figure 2.2.7 Urine sample results for first Round Robin study for hepcidin methods. A)  
Sample mean result for each method with a mean for all methods (continuous line). B) Difference 
between each method and sample mean for all methods. 
121 
 
H
e
p
c
id
in
 (
n
m
o
l/
L
) 
L
o
g
0.1
1
10
100
1000
9 10 11 12 13 14 15
Plasma Samples
Method I
Method II
Method III
Method IV
Method V
Method VI
Method VII
Method VIII
Method sample meanA.
D
if
fe
re
n
c
e
 b
e
tw
e
e
n
 M
e
th
o
d
s
 a
n
d
 M
e
th
o
d
 g
ro
u
p
 m
e
a
n
-300
-200
-100
0
100
Plasma Samples
Method I
Method II
Method III
Method IV
Method V
Method VI
Method VII
Method VIII
9 10 11 12 13 14 15
B.
Figure 2.2.8 Plasma sample results for first Round Robin study for hepcidin methods. A) 
Mean sample result for each method with a sample mean for all methods, (continuous line). B) 
Difference between each method and sample mean for all methods. 
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2.5.8.1  Samples for defining reference interval for hepcidin 
Healthy control samples (HC) (n=64) were assayed using the validated hepcidin RIA and the 
commercial Prohepcidin ELISA, (Table 2.1.7). A significant difference (p <0.0001) was 
observed between male and female hepcidin results (n=34, median age: 34 years, mean 
male: 42 ng/mL, ± 20.7ng/mL and n=30, mean age: 31.2 years, median female: 8.5 ng/mL, 
range: 2.1–37 ng/mL), and between male and female Ferritin (p <0.001) and TSAT (p 
0.0092) results. No significant difference (p 0.68) was observed between male and female 
prohepcidin results (n=34, median age: 34 years, median male: 71 ng/mL, range: 39–
282ng/mL and n=30, mean age: 31.2 years, median female: 63 ng/mL, range: 52–129 
ng/mL) (Figure 2.2.9). Pearson rank correlations in the complete HC group revealed a 
significant correlation between ferritin and hepcidin, there were also significant correlations 
between plasma hepcidin and urinary hepcidin (corrected for urinary creatinine), iron, TSAT, 
Hb, creatinine and EPO, (Table 2.1.8).  There was no significant correlation between 
prohepcidin and hepcidin (R -0.19, p 0.47) or between prohepcidin and ferritin in the HC 
group, (R -0.06, p 0.7) or with other iron indices, Hb, creatinine or EPO. The prohepcidin 
ELISA method was not validated for urine measurements.  
 
 
 
 
 
 
 
 
 
 
 
 
 
123 
 
Table 2.1.7  Demographic and biochemical parameters of patient samples for defining 
hepcidin normal reference intervals.  
 
Parameter 
(Reference Range) 
Men 
 
Women 
 
 
P 
N 34 30  
Age (years) 30 (25-54)
+
 31.2 (±5.7)* 0.69 
Albumin (g/L) 
(35-50) 
46 (±2.6)* 42 (±3.2)* 0.69 
Creatinine(mmol/L) 
(Male: 60-125) 
(Female: 55-110) 
78 (65-109)
+
 61.1 (49.1-84)
+
 <0.0001
#1
 
eGFR (mls/min/1.73m
2
) 
(>59) 
111 (±18.2)* 108 (±17.2)* 0.0049
#
 
hsCRP (mg/L) 
(0-5) 
0.9 (0.2-6.6)
+
 2 (0.2-6.1)
+
 0.68
1
 
EPO
 
(mIU/mL) 8 (±3.1)* 9.5 (4.4-33)
+
 <0.0001
#1
 
Hb
 
(g/dL) 15.4 (±0.8)* 12.6 (±1.0)* <0.0001
#
 
Iron (µmol/L) 
(Male: 9-29) 
(Female: 7-27) 
15.5 (±4.1)* 13.2 (±6.4)* 0.0463
#
 
Ferritin (µg/L) 
(Male: 20-300) 
(Female (16-50y): 10-120) 
(Female (>50y): 20-300) 
68 (10.6-235)
+
 30 (±17.8)* <0.0001
#1
 
TSAT (%) 
(16-55) 
27.2 (±7.9)* 20.7 (±9.8)* 0.0092
#
 
Prohepcidin
 
(ng/mL) 71 (39-282)
+
 63 (52-129)
+
 0.68
1
 
Hepcidin
 
(ng/mL) 42 (±16)* 8.5 (2.1-37)
+
 <0.0001
#1
 
Urine Hepcidin (ng/mL) 72 (±57)* 10.9 (3.2-79)
+
 0.001
#1
 
 
+
median (Range), *mean (±SD). *Student unpaired t-test, p <0.05 considered significant, 
1
Log 
transformed data. TSAT; transferrin saturation, eGFR; estimated glomerular filtration rate, hsCRP; 
high sensitive C-reactive protein, EPO; erythropoietin, Hb; haemoglobin. 
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Table 2.1.8 Hepcidin correlation with measured parameters in the complete healthy control 
(HC) group. (Pearson R, p <0.05* considered significant). 
 
Parameter R p 
Ferritin 0.57 <0.0001*1 
Iron 0.3 0.03* 
TSAT  0.49 0.0008* 
Hb 0.7 <0.0001* 
Creatinine 0.51 0.0019*1 
eGFR 0.16 0.412 
Prohepcidin -0.19 0.471 
Urine Hepcidin 0.57 0.0061*1 
hsCRP 0.4 0.1461 
EPO -0.64 <0.0001*1 
 
1
Log transformed data .TSAT; transferrin saturation, Hb; haemoglobin, eGFR; estimated glomerular 
filtration rate, hsCRP; high sensitive C-reactive protein, EPO; erythropoietin. 
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Figure 2.2.9 Gender differences in A) Prohepcidin and hepcidin and B) Ferritin and 
transferrin saturation (TSAT).(Box and Whisker plot [2.5–97.5 percentile]). Student unpaired t-test, 
p <0.05 considered significant, ns). 
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2.6 Discussion 
The primary aim of the experiments described in this chapter was to produce high affinity 
antibodies to the human bioactive hepcidin peptide, using a combination of polyclonal and 
monoclonal antibodies to hepcidin, and then to use these antibodies to develop either a 
basic radioimmunoassay or a sandwich based immunoassay. Initially, I have developed and 
established a novel radioisotopic assay for hepcidin measurement in human sera and 
plasma, based on a synthetic hepcidin peptide and a rabbit anti-hepcidin Pc Ab.  Following 
the development of this RIA, capable of measuring hepcidin in human serum and plasma 
samples at a range of 1.25–160 ng/mL with good imprecision, linearity, recovery and 
specificity, I was able to measure levels of hepcidin in a HC population to define a primary 
reference interval (2.1-58 ng/mL (5% Percentile 2.7ng/mL and 95% Percentile 54ng/mL)).  
All the animal species chosen for the immunisation schedules with the conjugated hepcidin 
peptide demonstrated a good immune response, especially with the rabbits and mice, (>30% 
B0). Although the sheep antibody titre was positive, the antibody affinity was low (<25%) as 
reflected by the lack of % inhibition in the antibody displacement experiment. Due to 
problems with production of the hepcidin Mab at the tissue culture cloning stage due to 
mycoplasma contamination, it was decided to concentrate on characterising the hepcidin 
RIA based on the rabbit polyclonal antibody. 
The initial conjugation method using EDC is a non-specific technique but is a rapid and 
efficient reaction, although it is not possible to predict where conjugation will occur on the 
peptide. An alternative technique would have been to use the sulfhydryl conjugation method, 
(Sulfo-SMCC, Sigma-Aldrich, UK), a much more specific reaction that utilises a malemide 
group to react with primary amines on cysteine residues. The final conjugate is then purified 
to remove and recover unconjugated peptide. The degree of conjugation can also be 
measured with this technique. However due to the presence of multiple cysteine residues 
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within the hepcidin peptide it would be difficult to predict on which cysteine residue the 
conjugation would occur, and might result in the epitope region on the peptide being 
masked. The use of KLH as a carrier protein has been well described (Edwards 1999). 
Alternatives such as BSA are available, but anti-BSA antibodies can be generated during the 
immunisation and may subsequently be a problem if BSA is also used as a blocking agent in 
the immunoassay buffer.  Electrolyte concentrations in reagent buffers must be carefully 
chosen as salts can inhibit antibody binding. I used a phosphate buffered saline (0.01M), at 
a physiological pH7.4, using BSA as a blocker of non-specific binding.  
The use of a second antibody precipitation reagent as a technique for separating antibody 
bound antigen from non-bound antigen has been well documented (Edwards 1999) and has 
a number of advantages over traditional charcoal absorption methods.  The divalent nature 
of the anti-IgG allows formation of a lattice of cross-linking between the primary and 
secondary antibody, and these cross-linked molecules are then precipitated in the presence 
of PEG 6000 and separation achieved by centrifugation and decantation.  I used a 
standardised overnight incubation period (of approximately 16hrs) to allow the formation of 
the antigen-antibody complex to reach equilibrium. The use of a sequential assay, where 
addition of unlabeled antigen precedes the addition of labelled antigen could increase the 
sensitivity and possible reduce the incubation for the hepcidin assay.  
A direct method comparison against a published SELDI-TOF-MS method for hepcidin 
demonstrated adequate comparability between the methods, although the absolute hepcidin 
values measured varied. The Bland-Altman plot does demonstrate high variability at low 
levels between the methods, which is probably due to a combination of differences in 
quantification of the internal standards used, pre-treatment steps in the MS method, and 
detection limits for the assays. As clinically relevant levels of hepcidin have yet to be 
rigorously defined, due to the lack of a defined reference method and an international 
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reference standard, the use of current hepcidin methods remain principally as research 
tools. 
The first round-robin international organised by Prof DW Swinkels demonstrated the 
significant differences between the physical and protein methods for measuring hepcidin, 
which can lead to some difficulty in interpreting published data from groups utilising these 
different quantitative methods. These differences between hepcidin methods are may be due 
to; 
(i) The use of different material for calibration solutions, with levels assigned based 
upon different techniques. 
(ii) Hepcidin aggregation of the ‗spiked‘ or patient samples. 
(i) Binding of hepcidin to α-2-macroglobulin or albumin, (Peslova G et al 2009). 
(iii) Presence of hepcidin isoforms -22 and -20. 
A recent study suggested that more 90% of circulating hepcidin may be bound to α-2-
macroglobulin, and that hepcidin shows some affinity for albumin as well. This raises the 
question of whether total or free hepcidin methods will more accurately determine active 
hepcidin levels (Peslova et al 2009). However, this was a single study and no subsequent 
studies have been published to corroborate these initial results. Amongst the MS methods 
there was a degree of difference observed in the analytical variation that was probably 
related to the use difference in internal standards used, as this would tend to decrease the 
analytical variation with these methods. 
The significant high between-sample CV and high analytical CV for the IC method (cELISA) 
compared to both the IC and MS methods was striking. A possible explanation is the 
differences in calibration material, but with this particular method there is a lack of published 
evidence concerning the avidity of the antibody used for endogenous hepcidin (Ganz et al 
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2008), such as western blotting or immunohistochemical experiments. Looking at the 
significantly higher responses with this method, it may suggest cross-reactivity with hepcidin 
isoforms and with the prohormone, prohepcidin. This has also been discussed as another 
significant difference between the IC and MS methods, as the more selective MS methods 
are able to differentiate between bioactive hepcidin-25 and its two isoforms hepcidin-20 and 
hepcidin-22. The significance of this is unclear, as the overall contribution of these isoforms 
to total hepcidin is very low as they represent degradation products. Importantly, the 
contribution of analytical variation to total variance in all the methods is low, which suggests 
that all the methods in the study are able to discriminate between altered hepcidin levels in 
different pathological conditions. 
There was debate as to how this study was organised and statistically evaluated when the 
round-robin protocol was under review. It was suggested by several of the included groups 
that using study samples that included a more heterogeneous mix of sample types, and 
which contained levels of endogenous and synthetic hepcidin assigned theoretical values, 
would have more clearly determined how accurately the various methods recognise 
endogenous and synthetic hepcidin. 
We can conclude from this study that hepcidin estimates vary considerably between all 
methods, but that analytical variance is generally low and similar for all methods. Further 
harmonisation has been suggested by the Swinkels group to include possibility of; (Kroot et 
al 2009b) 
(i) Introduction of internal standards for all MS based methods 
(ii) A general consensus on level assignment and level adjustment of calibrator material 
(iii) Use of a calibrator that has a similar matrix to patient sera 
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(iv) Regular testing of shared samples and/or calibrators that are commutable and have 
been value assigned for quality control use. 
The implementation of these measures depends upon the clinical diagnostic utility of 
hepcidin measurements, which still needs to be established.  
The hepcidin concentrations observed in healthy control human plasma were highly 
heterogeneous. The significant variation in plasma hepcidin concentrations found in the HC 
group may therefore reflect the true biological variability of hepcidin as a sensitive regulator 
of iron homeostasis in humans. Using the optimised hepcidin RIA, it was also possible to 
demonstrate a significant gender difference, although the higher hepcidin levels seen in 
males are probably secondary to gender variation in iron demand and ferritin stores as 
reflected in the lower ferritin and TSAT levels in females observed in this and in other studies 
(Ganz et al 2008;Kemna et al. 2008).  
Hepcidin and serum ferritin respond similarly to inflammation and changes in iron stores, and 
this is reflected in the significant correlation between hepcidin with ferritin, seen in the HC 
group. This similar correlation has been reported in other studies (Ganz et al 2008;Kemna et 
al. 2005;Tanno et al. 2007) and further emphasises the key role of hepcidin in iron 
homeostasis. 
In our HC group, the urine contained a median of 44.8ng hepcidin/mg Creatinine, thus 47% 
of hepcidin maybe being retained in the kidney either because it is not freely filtered through 
the glomerular membrane or because it is reabsorbed and degraded in the proximal tubules, 
as seen with other small peptides (Carone et al. 1982). Although I observed good 
correlations between urinary hepcidin, normalised for creatinine, and plasma hepcidin in the 
HC group, urinary hepcidin concentrations probably will not accurately reflect plasma 
concentrations of hepcidin due to decrease of eGFR with age and renal disease. 
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The results of an immunoassay that reportedly detected human prohepcidin do not reflect 
the expected physiological or pathological changes in mature bioactive hepcidin 
concentrations seen with other hepcidin assays, (Kemna et al 2008;Kulaksiz et al 2004;Roe 
et al 2007). As observed in these previous studies, no significant correlation with prohepcidin 
or any iron status markers in the HC group was seen. This further emphasises the 
importance of specifically measuring bioactive hepcidin to study iron metabolism. 
Most recent studies of hepcidin quantification have used a variety of MS techniques to 
determine hepcidin concentration. Although these are sensitive techniques, they do require 
specialized and expensive equipment, a degree of sample pre-treatment and the use of 
appropriate internal reference standards. Urine, which has been used in some previous 
studies, also presents a number of analytical difficulties as a sample matrix (e.g., use of 
random or timed collections, correction for creatinine, and time-consuming extraction 
procedures to purify and concentrate the urine sample). The development of this RIA and 
subsequent patient results suggest my assay can effectively quantify hepcidin in human 
plasma.  
In conclusion, I have developed of an RIA assay capable of measuring hepcidin in human 
serum and plasma samples at a range of 1.25–160 ng/mL with low imprecision, linearity, 
recovery and specificity. This immunoassay makes it possible to simplify the measurement 
of mature hepcidin in serum or plasma samples, eliminating time-consuming pre-analytical 
procedures.  
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Chapter 3 
Hepcidin Regulation in 
Human Physiology 
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3.0 Introduction 
3.1 Hepcidin and human disease 
Several physiological and pathological processes regulate the synthesis of hepcidin. 
Pathological conditions in which there is an increased requirement for iron, such as those 
associated with increases in erythropoietic activity, will elicit an increase in hepcidin 
synthesis. These conditions include iron deficiency, hypoxia and anaemia (Hentze et al. 
2010). A decrease in hepcidin results in the release of stored iron from enterocytes and 
macrophages with a subsequent increase in dietary iron absorption. The functional signalling 
routes by which i) iron status, ii) erythropoietic activity, iii) hypoxia, and iv) inflammation 
affect hepcidin expression have received much attention in the literature, and studies 
suggest they involve a number of highly interconnected regulatory pathways (Hentze et al 
2010;Kroot et al 2011). I measured hepcidin in number of disease conditions where hepcidin 
levels would expect to be altered such as iron deficiency anaemia (IDA), ulcerative colitisis 
(UC), human haemochromatosis protein (HFE)-haemochromatosis (HFE-H), stable chronic 
kidney failure not requiring dialysis (CKD) and stable chronic kidney failure patients on 
haemodialysis (HCKD) to investigate its role and to shed light on these regulatory pathways.  
 
3.1.1 Iron deficient anaemia 
The World Health Organisation (WHO) defines anaemia as a condition in which the number 
of RBCs or their oxygen-carrying capacity is insufficient to meet physiologic needs. These 
needs can vary by age, sex, altitude, smoking, and pregnancy status. ID is thought to be the 
most common cause of anaemia globally, either due to negative iron balance through blood 
loss (commonly gastrointestinal or menstrual), or to inadequate intake which may be 
nutritional or related to poor GI absorption, although other conditions, such as folate, vitamin 
B12 and vitamin A deficiencies, chronic inflammation, parasitic infections, and inherited 
disorders can all cause anaemia. In its severe form, it is associated with fatigue, weakness, 
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dizziness and drowsiness. WHO defines anaemia as a Hb concentration of <12g/dL in 
women and <13g/dL in men (World Health Organisation (WHO) 2008) (Table 3.1). 
 
Table 3.1 WHO haemoglobin threshold levels used to define anaemia in the general 
population (World Health Organisation (WHO) 2008). 
 
Age or gender group Hb threshold (g/dL) 
Children (6 months to 5 yrs) 11.0 
Children (5 to 12 yrs) 11.5 
Children (12 to 15yrs) 12.0 
Women, non-pregnant (>15yrs) 12.0 
Women, pregnant 11.0 
Men (>15 yrs) 13.0 
 
 
Studies in elderly patients (aged over 65 years) show that the ACD predominates; 
accounting for 34% to 44% of causes (Guyatt et al. 1990;Joosten et al. 1992;Patterson et al. 
1991). Worldwide, the most important cause of IDA is parasitic infection, in which intestinal 
bleeding caused by the worms can lead to undetected blood loss in the stool. In adults of 
post-menopausal age (>50yrs), the most common cause of IDA is chronic GI bleeding from 
non-parasitic causes, such as gastric or duodenal ulcers or a GI malignancy (World Health 
Organisation (WHO) 2008). In the developed world, where intestinal worm parasite burden is 
less than in many undeveloped countries, about 20% of all women of childbearing age have 
IDA, compared with only 3% of adult men (World Health Organisation (WHO) 2008). 
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Recent studies have, described a familial syndrome characterized by IDA which does not 
respond to oral iron and responds only partly to parenteral iron (Barker and Schofield 
2008;Finberg et al 2008). This condition IRIDA is an autosomal recessive disease 
characterized by anaemia (see Chapter 1; Section 1.5.1). 
 
3.1.2 Ulcerative Colitis 
Anaemia is the most common systemic complication of inflammatory bowel disease (IBD), 
affecting about one-third of IBD patients, (Gasche et al. 2004). IBD describes a group of 
intestinal disorders involving non-specific chronic inflammatory disease and sharing a variety 
of symptoms including chronic or recurrent diarrhoea, abdominal pain, fever, thrombocytosis 
and anaemia. There are two main types of IBD: Crohn‘s disease (CD), which can affect any 
part of the GI tract, and ulcerative colitis (UC), which is associated with disease of the large 
intestine. Intestinal inflammation is a major manifestation associated with IBD, which is often 
found in patients with chronic inflammatory diseases of other tissues, including sclerosing 
cholangitis and ankylosing spondylitis. One of the common markers of inflammation is 
anaemia, and haematological changes such as anaemia and thrombocytosis are among the 
symptoms of these diseases.  
 
The chronic blood loss through intestinal ulceration is thought to be the underlying cause of 
the anaemia in IBD, though it can also be exacerbated by reduced intestinal iron uptake due 
to the chronic inflammatory state associated with these conditions. IDA and ACD are 
frequently combined in such cases. As blood is lost, iron stores are depleted and a negative 
iron balance results in IDA. IBD also results in the up-regulation of various inflammatory 
cytokines, including Tumour Necrosis Factor-α (TNF-α), Interferon (INF-γ) and interlukin-6 
(IL-6), and the activation of inflammatory cells, including macrophages and T-cells, which 
cause tissue damage. These inflammatory responses affect erythropoiesis and iron 
metabolism. Circulating IL-6 levels have been demonstrated to up-regulate expression of 
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hepcidin mRNA, resulting in increased circulating hepcidin concentrations that can cause the 
changes in iron metabolism in ACD by blocking the release of iron from macrophages, 
thereby reducing the iron available to the bone marrow. 
 
3.1.3 Primary iron overload, hereditary haemochromatosis 
Hereditary haemochromatosis (HH) is a family of genetic disorders of iron over-load, caused 
by a failure to prevent excess dietary iron entering the circulation. The long term 
consequences of this iron overload include diabetes, arthritis and cirrhosis of the liver 
(Pietrangelo 2004). In most forms of HH, hepcidin circulates at inappropriately low levels, 
resulting in levels of the iron export protein Fpn in excess of physiological requirements. This 
unrestricted activity of Fpn allows iron to be transferred to the circulation from the duodenum 
and from macrophages, thereby increasing TSAT and serum ferritin levels (Pietrangelo 
2006a;Pietrangelo 2006b).  
 
HH is characterised by: 1) hereditary origin (which is usually autosomal recessive) 
(Pietrangelo 2006a); 2) early and progressive increase in TSAT from approximately 30% to 
complete saturation over 45%, with the appearance of highly toxic non-transferrin bound iron 
(NTBI) (Brissot 2002); 3) progressive parenchymal iron deposits causing severe tissue 
damage to endocrine glands, heart and liver; and 4) unimpaired erythropoiesis and a good 
response to therapeutic phlebotomy (Brissot and de 2006). 
 
Haemochromatosis disorders presenting with a common pathological phenotype currently 
include HFE C282Y homozygosity and rare disorders due to mutations in TfR2, HAMP, HJV 
and Fpn mutations (see Chapter 1;Section 1.6.1, ;Table 1.1) (Pietrangelo 2007). The most 
common form of HH is HFE-H, corresponding to the classical human leucocyte antigen 
(HLA) linked haemochromatosis, which is transmitted as an autosomal recessive trait and 
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which represents more than 90% of hereditary iron overload syndromes (Pietrangelo 
2009;Pietrangelo 2010b). 
 
The gene mutated in HFE-HH encodes a 348 residue type I transmembrane glycoprotein, 
HFE, which is homologous to class I major histocompatibility complex (MHC) molecules and 
associates with the class I light chain β2M (Pietrangelo 2006b). Most HFE-HH patients are 
homozygous for the C282Y mutation, in which the single base change, 845 G to A results in 
a cysteine being substituted for a tyrosine, disrupting a disulphide bond found in the 
unmutated molecule and thus preventing association with β2M and the stabilization, 
transport and expression of HFE on the cell surface and on endosome membranes, where it 
interacts with TfR1 (Camaschella 2005;Pietrangelo 2006) 
 
HFE-HH population-based correlation studies have highlighted the high prevalence of this 
genotype, particularly in the European population (≥90%), but the exact trigger that makes 
some patients with this genotype accumulate iron is still unknown (Beutler 
2006;Camaschella & Poggiali 2011). Although the biochemical expressitivity is high, the 
clinical penetrance is low; only 1% for the full blown disease (Beutler et al. 2003), 11% for 
liver cirrhosis (Ayonrinde et al. 2008), and between 10%-50% for fatigue and arthralgias 
(Brissot et al. 2008).  
 
Diagnosis is based upon assessment of ferritin levels in suspected individuals, although 
hyperferritinaemia is also found in a range of non-iron overload conditions such as 
inflammation, chronic alcohol abuse and insulin resistance (Pietrangelo 2011), which limits 
its specificity. TSAT is also used in initial diagnosis, but an elevated TSAT can also result 
from excess iron release from damaged cells (hepatitis, haemolysis) or hepatocellular 
insufficiency leading to decreased Tf synthesis (Deugnier et al. 2008), and so it also lacks 
specificity. Following the discovery and confirmation of elevated TSAT, the next stage is for 
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HFE genetic testing. If the C282Y mutation is detected, then venesection therapy should be 
started to remove excess iron (Deugnier et al 2008). Assessing liver iron excess in these 
patients can be done using magnetic resonance imaging (MRI) or by traditional liver biopsy 
to determine iron content (Pietrangelo 2011). Therapeutic phlebotomy, where one unit (400-
500 ml) of blood (containing approximately 200-250 mg of iron) is removed weekly until 
serum ferritin is ≤30 µg/L and TSAT ≤30%, is currently the most economical and effective 
treatment for haemochromatosis (Pietrangelo 2006). Haemochromatosis could in the near 
future be treated by pharmacological agents in the form of hepcidin agonists/antagonists to 
treat the hepcidin deficiency characteristic of these conditions. 
 
3.1.3 Kidney disease 
Chronic Kidney Disease (CKD) describes reduced kidney function or kidneys that are 
damaged or abnormal (Levy et al. 2007). The condition is progressive and often irreversible. 
A range of underlying diseases can cause CKD but they all produce a similar range of 
symptoms and have similar treatment strategies. CKD has become a global public health 
problem, and is associated with increased risk of a wide range of co-morbidities, including 
complete kidney failure and cardiovascular disease, and with increased all-cause mortality 
(Weiner et al. 2004).  
 
CKD is often categorised by degree of excretory kidney function into five stages, where 
stage 1 represents normal kidney function and stage 5 indicates progression to the greatest 
extent of kidney disease (US National Kidney Foundation 2002) (Table 3.2). At stage 5, 
which is known as Established or End Stage Renal Failure (ERF/ESRF), renal replacement 
therapy (RRT) is often required for long-term survival.  
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Table 3.2 Stages of Chronic Kidney Disease (CKD).  Kidney damage is defined as 
pathological abnormalities or markers of damage, including abnormalities in blood or urine tests or 
imaging studies, (adapted from(US National Kidney Foundation 2002). 
 
Stage GFR 
(ml/min/1.73m2) 
Description 
1 > 90 Normal or increased eGFR*, with other evidence of kidney 
damage 
2 60–89 Slight decrease in eGFR, with other evidence of kidney 
damage 
3a 45–59 
Moderate decrease in eGFR, with or without other 
evidence of kidney damage 
3b 30–44 
4 15–29 Severe decrease in eGFR, with or without other evidence 
of kidney damage 
5 < 15 ( or dialysis) Established renal failure 
Diagnosis of CKD should be on the basis of evidence kidney damage or eGFR <60 ml/min/1.73m
2
 for ≥ 
3 months. 
*eGFR; estimated glomerular filtration rate 
 
 
Iron balance is significantly altered in kidney disease and is required for production of EPO 
to effectively stimulate RBC production (Macdougall 1992;Macdougall 1998). The presence 
of a functional IDA is almost universal in patients on dialysis or with moderate estimated 
glomerular filtration rate (eGFR <30mL/min) to severe (eGFR <15mL/min) CKD. The 
symptoms of anaemia can present well before the ureamia, and can occur in some patients 
with only mild reduction in eGFR (<60mL/min).   
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There is conflicting data in the literature concerning whether iron absorption is increased or 
decreased in patients on haemodialysis (HD) (Nissenson and Strobos 1999). However, iron 
demand is significantly increased in dialysis patients, with estimated iron losses of 1000-
3000 mg/year from blood loss on HD and phlebotomy. In addition, RBC lifespan is reduced 
in renal disease, requiring more rapid RBC turnover to maintain given Hb concentration. The 
use of recombinant human erythropoietin (rHuEpo) accelerates this RBC differentiation and 
production, resulting in a ―functional iron deficiency‖ state (Macdougall 1992).  This occurs 
when increased RBC iron requirements exceed the available supply of iron, even in the 
presence of adequate stores of iron (in form of ferritin). 
 
N-terminal cleavage of hepcidin produces the biologically less active forms, hepcidin-22 and 
hepcidin-20 (Nemeth & Ganz 2006;Rivera et al 2005). Together with hepcidin, these 
peptides are excreted in the urine, (Park et al 2001;Rivera et al 2005).  Recent work has 
suggested that hepcidin, like β2M, is freely filtered and reabsorbed in the proximal tubule, 
(Swinkels & Wetzels 2008). In this context, it has been suggested that the functional iron 
deficit which accompanies renal disease may be attributable to increased circulating levels 
of hepcidin due to impaired urinary excretion (Ganz 2007).  
  
Hepcidin expression is also induced by inflammatory stimuli such as IL-6 (Nemeth et al 
2004). As the erythropoietic demand for iron is large in relation to the quantity normally 
available in the plasma, (Rivera et al 2005) (Hentze et al 2010), it is believed that excess 
hepcidin in inflammatory states may reduce the iron recycling which is necessary for 
erythropoiesis. This leads to ACD, characterized by reduced erythropoiesis and reduced 
serum iron despite apparently normal stores, (De et al 2007;Ganz 2006). These features are 
similar to the EPO resistance observed in renal patients (Locatelli et al. 2006;Madore et al. 
1997). Increased hepcidin may therefore cause, and act as a marker of, EPO resistance. A 
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better understanding of abnormal iron homeostasis in renal disease may permit therapeutic 
improvements to increase EPO responsiveness. 
 
3.1.4 Diurnal variation of hepcidin  
The diurnal variation of iron is well documented, although the published studies offer 
conflicting conclusions concerning the pattern of variation, as some studies describe lower 
values in the afternoon (Kuhn et al. 1967;LAURELL 1953;Sinniah et al. 1969), while others 
report increased values in the afternoon (Dale et al. 2002). A recurrent finding in studies 
including blood samplings at more than two different time points is that the peak value for 
iron is in the late morning, between 10 and 12am (Malhotra et al. 2004). Ferritin is thought to 
lack circadian variation (Dale et al 2002). The possible effect of biological variation in 
hepcidin concentrations due to a circadian rhythm has been reported (Kemna et al 2007). 
Hepcidin correlates inversely with daily variations in serum iron concentrations, in accord 
with previous reports that  TfR1 and TfR2 on the outer hepatocyte membrane act as sensors 
of circulating iron and Tf, thereby linking low serum iron with increased hepcidin synthesis 
(Frazer and Anderson 2003;Ganz and Nemeth 2006). This circadian variation may, however, 
be secondary to the influence of dietary iron intake during the day (Ganz & Nemeth 
2006;Ganz and Nemeth 2006). 
 
3.1.5 Effect of iron administration on hepcidin concentrations  
Iron replacement therapy (IRT) is common practice for ID patients whether the ID is absolute 
or minimal stores of iron, or functional ID where there is inadequate release of iron to 
support erythropoiesis, despite the presence of adequate iron stores. The IRT can be 
administered as a dietary supplement, usually as a ferrous sulfate tablet. In the absence of 
any underlying gastric pathology, iron absorption will normally occur through the enterocytes 
of the GI tract, although certain foods (e.g. tannins, ascorbic acid) and drugs (e.g. Calcium 
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Acetate, Lanthanum Carbonate, and Aluminium-containing antacids) can interfere with this 
process.  
 
Intravenous iron therapy (IV-Fe) is usually used clinically in cases of severe anaemia and is 
used routinely in treatment of the functional iron deficiency seen in the renal anaemia 
associated with CKD. Iron Dextran, Iron Sucrose or Ferric Gluconate can all be used for 
these IV infusions. The ineffectiveness of oral iron supplements in patients on HD probably 
results from problems with iron incorporation into RBCs. A small study in 14 patients on HD 
compared the kinetics of 59Fe counts following administration of radiolabeled iron, either IV 
as iron dextran or orally as iron sulfate (Magana et al. 1984). Following oral iron 
supplementation, absorption was normal, but the time required to reach maximal RBC 
incorporation was prolonged to 33 days (Magana et al 1984).  In contrast, the time to 
maximal RBC incorporation for IV-Fe dextran was 8.6 days (and thus within the normal time 
frame of 4-10 days) (Magana et al 1984). Although IV-Fe seems to be better utilized than 
orally administered iron, these IV iron products can lead to acute adverse reactions such as 
anaphylactic shock (Altman and Petersen 1988). 
 
Several studies have investigated the relationship between iron absorption and hepcidin 
concentrations. In healthy human volunteers, hepcidin in urine and serum generally 
increased upon oral iron dosing, although non-responders have been reported (Ganz et al 
2008;Lin et al. 2007;Nemeth et al 2004;Roe et al. 2009;Young et al. 2009;Zimmermann et al. 
2009). Some studies report a weak, but significant, negative correlation between serum 
hepcidin concentrations and iron absorption (Roe et al 2009;Young et al 2009;Zimmermann 
et al 2009). These results suggest that quantification of hepcidin concentrations could predict 
the therapeutic effect of oral iron administration, and the hepcidin response to oral iron may 
prove a useful test to evaluate iron absorption in iron deficiency. 
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3.1.6  Immunoreactive distribution of hepcidin in human plasma 
Hepcidin circulates in plasma as the bioactive 25 residue form, but 20 and 22 residue 
isoforms of hepcidin also exist. These isoforms are found at much lower concentrations and 
have much lower activity than the bioactive 25 residue hepcidin (Nemeth et al. 2006), The 
isoforms are present in low levels as degradation products as part of the normal metabolic 
process, but are quantifiable in certain pathological conditions such as CKD (Swinkels et al. 
2008). Immunoassays based upon polyclonal antibodies generated against the synthetic 
hepcidin may not be able to discriminate between these isoforms, and so would in effect 
measure total hepcidin.  
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3.2 Hypothesis 
Hepcidin the central iron regulator is physiologically altered in human pathological conditions 
 
3.3 Aims 
To investigate: 
1. Hepcidin levels in various disease populations in which hepcidin concentrations would be 
expected to be altered.  
 
2. The existence of a hepcidin diurnal variation in healthy controls. 
 
3. The response of hepcidin to an acute iron load in healthy controls. 
 
4. The response of hepcidin to intravenous iron therapy in anaemic patients. 
 
5. The immunoreactivity of hepcidin in human plasma 
 
 
 
 
 
 
 
 
 
 
 
145 
 
3.4 Methods 
3.4.1 Patient samples 
To establish whether or not the hepcidin RIA could detect physiologically and 
pathophysiologically relevant changes in circulating hepcidin levels, samples from patients 
predicted to have low and high hepcidin levels were compared with healthy controls.  All the 
studies using patient samples were approved by the local NHS Research Ethics Committee 
(06/Q0406/134) and all participants gave informed consent according to the principles of the 
Declaration of Helsinki. No clinical data was available for the selected disease group 
patients. 
Sixty-four sample controls were recruited for the healthy control group (HC) as previously 
described in Section 2.4.9.1. Blood (3-4mL) was taken by venepuncture into one serum 
separator tube (SST) and one lithium heparin tube. Both samples were centrifuged for 5 min 
at 670g (GF720 RMS UK, Ltd.) and the serum/plasma frozen at –20°C. All control samples 
were collected at approximately 10am. 
Patient plasma samples for the UC; n=40 and IDA; n=15 groups were collected over a six-
month period through the out-patient clinic of the Gastroenterology Department, Ealing 
Hospital, London. Plasma samples (Lithium Heparin) were transported directly to Clinical 
Biochemistry Laboratory, Charing Cross NHS Hospital Trust centrifuged for 5 min at 670g 
(GF720 RMS UK, Ltd.) and plasma frozen at –20°C. In the UC group, the condition was 
diagnosed on clinical features supported by endoscopy, histological and/or radiological 
findings. None of the patients in this group were on immune modulators or anti-TNF-α 
therapy. The anaemia seen in the UC and IDA group was defined as Hb <12 g/dL in females 
and <13 g/dL in males, (World Health Organisation (WHO) 2008). IDA was considered to be 
present if ferritin <15 μg/L and iron (Fe) <10 μmol/L.  
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Pre-treatment patients for the HFE-H; n=6 group were recruited (two female: four male) from 
outpatient clinics at St Mary‘s Hospital NHS Trust and Ealing Hospital NHS Trust, London, 
UK, between August 2008 and March 2010. HFE-HH Blood samples (Lithium Heparin) were 
transported directly to Clinical Biochemistry Laboratory, Charing Cross NHS Hospital Trust, 
centrifuged for 5 min at 670g (GF720 RMS UK, Ltd.), and the plasma separated and frozen 
at –20°C.  Confirmation of the clinical diagnosis of HFE-H patients homozygous for the gene 
mutation C282Y/C282Y was based on genetic analysis (North West Thames Regional 
Genetics Centre). TSAT>45% and a liver biopsy confirming tissue iron overload were all 
positive criteria data for inclusion in the study. All included patients had previously been 
successfully treated with phlebotomy and had achieved a stable serum ferritin (30-150g/L). 
Patients with acute or chronic inflammatory disorders such as IBD or rheumatoid arthritis, 
hepatitis B, hepatitis C or HIV infection, cirrhosis of liver, excess alcohol ingestion and 
phlebotomy less than 6 weeks before participation in research, were excluded from the 
study. None of the Participants were on herbal medication, supplemental vitamins, proton 
pump inhibitors or H2 blockers; (pharmaceutical histamine H2-receptor antagonists are used 
in the treatment of gastric and duodenal ulcers because they reduce gastric acid output as a 
result of histamine H2-receptor blockade; they are also used to relieve symptoms of gastro-
oesophageal reflux, (Eriksson et al 1996)). 
 
The UC, IDA and HFE-H patients were the groups predicted to have low hepcidin. 
Prohepcidin was also measured in the HC, UC and IDA groups to investigate the 
relationship with ferritin levels in these populations. 
 
The renal patients were recruited from a regional center and were of mainly Caucasian and 
South Asian ethnicity. The CKD; n=44 and HCKD; n=94 were recruited from the West 
London Renal Service, Hammersmith Hospital NHS Trust. Plasma samples were collected 
over a three-month period and frozen at –20°C. The CKD group had varying degrees of 
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renal impairment (eGFR 13–98 mL/min/1.73m2), and none were receiving rHuEPO or IV-Fe 
therapy, and had not yet begun regular dialysis, whereas those patients in the HCKD group 
were all treated with rHuEPO and IV-Fe intended to maintain Hb >11 g/dL and ferritin >400 
ng/mL. The HCKD patients were dialyzed for 4 h using 2.1m2 low-flux acetate membranes 
with a minimum ultrafiltrate volume of 2 litres, delivering a dialysis dose (spKt/V) of over 1.5 
in all patients. This group was predicted to have high hepcidin.  
 
3.4.2 Diurnal variation of hepcidin in healthy controls 
As Fe and EPO levels show a diurnal variation in healthy individuals (Pasqualetti and Casale 
1996), we measured hepcidin levels in eight male healthy controls (HC) consuming their 
usual diet over a 24hr period. Blood samples were collected as previously described above 
in Section 3.2.1. Samples were taken over a 24hr period at 08.00am, noon, 16:00pm and 
08.00am the following day.  
 
3.4.3 Hepcidin response to acute iron load in healthy controls 
To investigate the response of hepcidin to an acute iron load, we measured hepcidin levels 
in five healthy (male) controls in a 24hr time-course study before and after the administration 
of oral iron. All HC participants were admitted to the hepatology outpatient clinical, St Marys 
Hospital NHS Trust, after an overnight fast. A 14-French venous cannula was placed in the 
anticubital fossa and fasting blood drawn in the morning between 08:00am and 09:00am for 
routine haematological, biochemical and iron parameters, including hepcidin. All HC 
participants were required to ingest 65mg of oral iron (ferrous sulphate 200mg tablet) 
supplied by the Pharmacy Department, Ealing Hospital NHS Trust, followed by a 
standardized meal to prevent any influence from dietary factors. A 200mg tablet of ferrous 
sulphate contains 65 mg (20%) of elemental iron. The therapeutic oral iron dose for iron 
deficiency aneamia is 100-200mg daily (3–6 mg/kg/day). This is usually given as dried 
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ferrous sulphate three times daily; for mild iron deficiency or for prophylaxis, a does of 
ferrous sulphate 200mg once or twice daily may be effective. Toxic effects begin to occur at 
doses above 10–20 mg/kg of elemental iron. Ingestions of more than 50 mg/kg of elemental 
iron are associated with severe toxicity, (British National Formulary 2008). Serial blood 
samples were obtained at 1, 2, 3, 4 and 24hr after ingestion of tablet, to measure 
serum iron indices and hepcidin. Samples were collected, serum separated and 
stored at – 20oC until analysis. 
 
3.4.4 Hepcidin response to iron therapy in an anaemic patient 
To confirm that hepcidin responds to Fe status, blood samples were taken from a CD patient 
admitted to Hammersmith Hospital NHS Trust with severe anaemia (pre-treatment iron 
3.8μmol/L, ferritin 2.3μg/L and Hb 6.2g/dL) requiring routine IV-Fe therapy. When patients 
are undergoing IV-Fe for the first time, the procedure is conducted in a controlled area under 
close clinical supervision, due to the possibility of anaphylactic shock (Altman & Petersen 
1988). Serial blood samples were collected before and after administration of Venofer™, (Fe 
complex 200mg (IV) infusion for 10mins). The CD patient was recruited from the 
Gastroenterology Department, Ealing Hospital Trust. 
 
3.4.5 Immunoreactive hepcidin distribution in human plasma  
Reserve-phase high-pressure liquid chromatography (RP-HPLC) was used in conjunction 
with the Hepcidin RIA and the DRG Prohepcidin ELISA to determine the chromatographic 
profile of hepcidin- and prohepcidin-immunoreactivity in human plasma samples.  
Patient plasma samples were first purified using Sep-pak cartridges (Waters, UK). Sep-pak 
cartridges are pre-packed disposable solid-phase extraction devices for sample preparation. 
149 
 
They contain C18 chromatographic packing (a silica-based bonded phase with strong 
hydrophobicity), which absorbs analytes from aqueous solutions; the principle is similar to 
RP-HPLC columns. Large interfering plasma proteins e.g. fibrin are removed from the 
plasma by loading the sample onto the device and selectively eluting the desired compounds 
using different solvents. 
Five plasma samples from the healthy control (HC) group (pre-extracted mean hepcidin 
25ng/mL and mean prohepcidin 62ng/mL) were pooled, acidified with 0.01M HCL and 
centrifuged for 5 mins at 670g (GF720 Centrifuge, RMS UK Ltd). The supernatant, (1ml), 
was then applied to a C18 Sep-Pak cartridge (Waters, UK.). The column was then washed 
with 0.01M HCL and sample eluted with 30% (vol/vol) 2-propanol / 30% (vol/vol) methanol in 
0.01M HCL. Eluted fractions were placed in a centrifugal concentrator for evaporation of 
solvent, (Eppendorf Concentrator Plus, UK). They were then reconstituted in 250µl assay 
buffer, (0.01M PBS, 0.5% BSA, 0.05% TFA) before use. Reconstituted samples were 
injected onto a Supleco Discovery BIO Wide Pore C18 HPLC Column (Sigma-Aldrich, UK). 
Samples were run using a 15-45% ACN: H20 gradient for 75mins at a flow rate of 1ml/min 
and fractions collected every minute (HPLC PU980, Jasco, UK). Eluted fractions were 
placed in a centrifugal concentrator (Concentrator Plus, Eppendorf, UK), for evaporation of 
solvent and reconstituted in 250µl assay buffer (w/o TFA) before use. The same protocol 
was used for pooled plasma samples from chronic renal failure (CKD) patients. Synthetic 
human hepcidin, (Bachem, UK), was used as an internal standard. Synthetic hepcidin 
(50ng/mL) was added to double charcoal stripped pooled human sera (Scipac, UK); charcoal 
stripped serum is used when a suitable serum matrix for calibrator and quality control 
material is required. The sera is filtered through charcoal to remove non-polar material so 
that the resulting reagent has low to undetectable levels of proteins and hormones, and may 
then be used as a blank reagent. This internal standard was then extracted and injected onto 
the HPLC column as described above to determine the elution profile. All the eluted fractions 
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were assayed using the hepcidin RIA and the prohepcidin ELISA to determine 
immunoreactive fragments of hepcidin and prohepcidin. Due to expense of the prohepcidin 
ELISA, only the ‗spiked‘ stripped sera and HC extracted sera samples were assayed with 
this method. 
 
3.4.6 Biochemical assays 
Routine chemistry profile, ferritin, iron, unsaturated iron-binding capacity (UIBC) and C-
Reactive Protein (CRP) were measured using standard methods on the Abbott Architect 
ic8000 system, (Abbott Diagnostics, Ireland). Total iron binding capacity (TIBC) is a 
calculated test; serum iron + UIBC. TSAT (%) is calculated from; serum iron / TIBC x 100. 
Full blood counts were kindly processed by Haematology department, using the Sysmex 
system, (Sysmex, USA), Hammersmith Hospital Trust. EPO and Prohepcidin were 
measured using commercial ELISA methods, (R & D Systems, UK and DRG Diagnostics, 
Germany). Hepcidin was measured using the validated immunoassay as previously 
described in Chapter 2; Section 2.5.7 (Busbridge et al 2009). 
 
3.4.7 Statistical analysis 
Study sample size required for an alpha at 0.05 and a power of 80% was calculated 15 
cases per group (anticipated difference 13.7ng/mL and the anticipated standard deviation 
16.3ng/mL) to test the null hypothesis that any difference observed between the sample 
groups is significantly different. Variables that are normally distributed are expressed as 
mean, and those variables that are not normally distributed are expressed as median with 
range as indicated. Normality was assessed using the Shapiro-Wilk test and skewed data 
was log transformed before statistical analysis. Quantitative variables were compared using 
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unpaired t-test, one-way ANOVA with Dunnetts multiple comparison test and two-way 
ANOVA repeated measurements for test of difference; Pearsons rank correlation was used 
for calculating correlation between the various variables. A value of p <0.05 was considered 
significant. All statistical analyses were carried out using the statistical package GraphPad 
Prism version 5.00 for Windows, (GraphPad Software, San Diego California USA, 
www.graphpad.com).  
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3.5 Results 
3.5.1 Patient results 
Patient samples were assayed using the validated hepcidin RIA and commercial Prohepcidin 
ELISA, (Table 3.3). As discussed previously (Section 2.5.7), there was a significant 
correlation with hepcidin and ferritin (R 0.57, p <0.0001), but no correlation between 
prohepcidin and ferritin (R -0.9, p 0.47), in the HC group. This correlation with ferritin was 
also observed in some of the disease groups (UC: R 0.5, p <0.05, IDA: R 0.7, p <0.05 and 
CKD: R 0.84, p <0.05). In the HFE-H and HCKD groups, no significant relationship between 
hepcidin and ferritin was observed. Interestingly, in the HFE-H group, hepcidin levels were 
inappropriately normal and the lack of correlation with ferritin is likely due to the low number 
of subjects (n=6). In the HCKD group, the lack of correlation with ferritin is most probably 
due to the treatment with IV-Fe in these patients. There was a significant difference 
observed between the HC group and all the disease groups (p <0.0001) except the HFE-H 
group (p 0.59) (Figure 3.1). There was no relationship between ages with either hepcidin or 
prohepcidin in any of the patient groups studied. There was a significant difference observed 
in prohepcidin levels between the HC group and the UC, IDA groups (p <0.0001) (Figure 
3.2), but no correlation between prohepcidin and ferritin in these groups (UC group, R 0.05, 
p 0.82 and IDA group, R -0.04, p 0.81). Due to cost constraints and sample volumes, 
prohepcidin was not measured in the HFE-H, CKD or HCKD groups.  
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Table 3.3 Demographic and biochemical patient parameters for the healthy control group 
and the disease groups. 
 
Parameter 
(Reference intervals) 
 
HC 
 
 
 
 
 
UC IDA HFE-H CKD HCKD 
n (men/women) 64 (34/30) 40 (26/14) 15 (N/A) 6 (4/2) 44 (N/A) 94 (62/32) 
Age (years) 31 (22-54)
+
 45 (20-88)
+ 
(N/A) 
53.8 (40-
67)
+ 45 (23-84)
+
 64 (39-83)
+
 
Creatinine
 
(mmol/L) 
(Male 60-125) 
(Female 55-110) 
72 (±12.4)* (N/A) (N/A) (N/A) 
153 (58-
702)
 +
 
669 (±171)* 
hsCRP (mg/L) 
(0-5) 
1.1 (0.2-6.6)
+
 (N/A) (N/A) (N/A) 5 (5-88)
 +
 7 (5-75)
 +
 
EPO
 
(mIU/mL) 
(5-25)
# 
9 (3.7-33)
+
 (N/A) (N/A) (N/A) 
13.6 (4.2-
33)
 +
 
(N/A) 
Hb
  
(g/dL) 
(Male 13.8-17.2) 
(Female 12.1-15.1) 
14.4 (±1.6)* 
12.2 (6.5-
15.8)
+ 
8.1 (6.1-
11)
+ (N/A) 
12.4 
(±1.5)* 
12.4 (9.2-
14.2)
 +
 
Iron (µmol/L) 
(Male 9-29) 
(Female 7-27) 
14.6 (±5.3)* 6 (1-39)
+ 
5.3 (1-25)
+ 
28 (20-39)
+ 
12 (5-31)
 +
 
9.5 (3-27.6)
 
+
 
Ferritin (µg/L) 
(Male 20-300) 
(Female (16-50y) 10-120) 
(Female (>50y) 20-300 
43 (4.2-235)
+1
 28 (1-317)
+1 9 (2.7-
15)
+1 51 (39-67)
+1 82 (4.5-
646)
 +1
 
521 (79-
1470)
 +1
 
TSAT
 
(%) 
(16-55) 
24 (±9.2)* 
14.3 (1.6-
47.1)
+ 
7.1 (2.2-
29)
+ 52 (37-74)
+ 18.6 (7.1-
62)
 +
 
23.6 (9.1-
75)
 +
 
Prohepcidin
 
(ng/mL) 70 (39-282)
+1
 
142 (24-
293)
+1 
142 (71-
287)
+1 (N/A) (N/A) (N/A) 
Hepcidin
 
(ng/mL) 28 (2.1-58)
+1
 
4.5 (2.8-
54)
+1 4.5 (±2.6)*
 16.9 
(±12.7)*
 
26 (0.8-
130)
 +1
 
58.5 (16-
436)
+1
 
Urine Hepcidin
 
(ng/mL) 
25 (3.2-172)
+
 (N/A) (N/A) (N/A) (N/A) (N/A) 
 
*mean (±SD),
 +
median (Range). 
1
Log transformed data. N/A (No data available). hsCRP; high 
sensitivity C-reactive protein, EPO; erythropoietin,(
#
when haematocrit is normal), Hb; haemoglobin, 
TSAT; transferrin saturation. 
 
 
 
154 
 
 
 
 
HC UC IDA HFE-H CKD HCKD
0.1
1
10
100
1000
*
*
*
*
Patient sample groups
H
e
p
c
id
in
 (
n
g
/m
L
) 
L
o
g
expected low hepcidin expected high hepcidin
 
Figure 3.1 Plasma hepcidin concentrations in patients with iron disorders: (Box and 
Whisker plot [2.5–97.5 percentile] with outliers). Groups include healthy controls (HC, n=47), 
ulcerative colitis (UC, n=40), iron-deficiency anaemia (IDA, n=15) HFE-haemochromatosis (HFE-H, 
n=6), chronic kidney disease, not requiring dialysis (CKD, n=45) and chronic kidney disease, stable 
haemodialysis patients (HCKD, n=94). All disease groups differed significantly from HC except the 
HFE-H group (*p <0.0001, one-way ANOVA, Dunnetts multiple comparison test p <0.05 for all groups 
compared to HC). 
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Figure 3.2 Plasma prohepcidin concentrations in patients with iron disorders: (Box and 
Whisker plot [2.5–97.5 percentile] with outliers). Groups include healthy controls (HC, n=47), 
ulcerative colitis (UC, n=40) and iron-deficiency anaemia (IDA, n=15). All disease groups differed 
significantly from HC (*p <0.0001, one-way ANOVA, Dunnetts multiple comparison test p <0.05 for all 
groups compared to HC). 
 
 
3.5.2 Diurnal variation of hepcidin in normal individuals 
Plasma hepcidin was measured in eight individuals over a 24 hour period at 08:00am, 
12:00noon, 16:00pm and 08:00am (Figure 3.3). All individuals ate their normal diet. Hepcidin 
levels rose during the day, reaching a peak in the afternoon with a subsequent fall overnight. 
There was a significant difference in the hepcidin concentration between 08.00 am samples 
and other time points (p <0.0001). Two individuals with ferritin levels <50µg/L had 
suppressed hepcidin levels at 08:00am, and also failed to show an afternoon peak. The 
profile was also repeated in two individuals who fasted between 22:00pm the night before 
and 17:00pm the day of the measurements with no significant difference observed in 
hepcidin levels between the time-points. Hepcidin was correlated with 08:00am ferritin (R  
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0.49) and 08:00am iron (R 0.58) and negatively correlated with change in iron during the 
course of the day (R 0.71). To confirm the finding that plasma hepcidin varies diurnally it was 
measured in a further twenty additional normal individuals at 09:00am and 17:00pm, and a 
significant rise was observed (Figure 3.4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 Diurnal changes in plasma hepcidin and iron concentrations in healthy 
volunteers (n=8). Collected at four time points over a 24-h period, showing the diurnal variation of 
hepcidin and iron. A/C) Box and whisker plot (2.5–97.5 percentile). B/D) Mean result from each time 
point plotted with SEM error bars. Two-way ANOVA repeated measures (*p <0.0001 for 08:00am 
sample versus other time points). 
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Figure 3.4 Rise in plasma hepcidin and with corresponding fall in iron levels in healthy 
controls (n=15) between 08:00am and 16:00pm. ((mean+/-SEM 15.4+/-3.2 to 28.6+/-5, p 0.003 for 
hepcidin levels and mean+/-SEM 21.9+/-1.9 to 15.9+/-1.3, p 0.01 , paired t-test, *p <0.05 indicates 
significance). 
 
3.5.3 Hepcidin response to an acute iron load in healthy controls 
Simulating a conventional iron replacement regime, at 08:00am on the test day, over-night 
fasted human male volunteers (n=5) (Table 3.4) ingested 65mg iron as a ferrous sulfate 
tablet. TSAT and hepcidin were measured before and at 1,2,3,4 and 24hrs after ingestion. 
Expected variations in iron absorption resulted in differential increases in TSAT and hepcidin 
at 2hrs in all subjects, indicating that the iron load was adequately absorbed, and this 
continued up to 4hrs post iron load before subsequent decline. Serum ferritin did not show 
any pattern in the HC group in response to oral iron ingestion with time. Figure 3.5 shows 
the time course response of hepcidin and TSAT to oral iron.  
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Table 3.4 Demographic and basal biochemical data for the iron load study (n=5) 
Parameter 
(Reference interval) 
HC 
 
 
 
 Age (years) 28 (±4)* 
Iron (µmol/L) 
(Male 9-29) 
(Female 7-27) 
14.6 (12.7-16.8)
+
 
Ferritin (µg/L) 
(Male 20-300) 
(Female (16-50y) 10-120) 
(Female (>50y) 20-300) 
 
51.2 (34.7-75.5)
+
 
TSAT
+
 (%) 
(16-55) 
25.3 (21.5-29.8)
+
 
Hepcidin(ng/mL) 32.9 (24.8-43.7)
+
 
*mean (±SD), 
+
 median (Range), TSAT; transferrin saturation. 
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Figure 3.5 Hepcidin response to dietary 
iron is proportional to the increase in 
transferrin saturation (TSAT). Five healthy 
controls (male) A, B, C, D and E subjects 
ingested 65 mg of iron (as ferrous sulfate) and 
their plasma hepcidin concentrations and 
TSAT were assayed at 0, 1, 2, 3, 4, and 24 
hours after ingestion. Each graph depicts the 
response of a single subject. Plasma hepcidin 
is shown as blue circles; TSAT is shown as 
dashed line.  
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3.5.4 Hepcidin response to iron therapy in anaemic patients 
Hepcidin levels in a Crohn‘s patient (n=1) receiving IV-Fe (Venofer™, (Fe complex 200mg (IV) 
infusion for 10mins) for treatment of severe anaemia increased from a pre-treatment basal 
level of 2.8ng/mL to a 24hr post-treatment level of 10.3ng/mL (Figure 3.6). There was no 
observed difference (Figure 3.7) in prohepcidin levels in the Crohn‘s patient, pre-treatment 
basal level 140ng/mL to 24hr post-treatment of 168ng/mL level. Ferritin levels increased 
from basal level of 2.3µg/L to 105µg/L. 
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Figure 3.6 Hepcidin response to IV iron in an anaemic Crohn’s Patient. Increase between 
basal (2.8ng/mL) and 24hr (10.3ng/mL) sample with hepcidin and ferritin levels. (Venofer™, (Fe 
complex 200mg (IV) infusion for 10mins). Ferritin levels increased from basal (2.3µg/L) to 24hr 
(105µg/L). 
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Figure 3.7 Prohepcidin response to IV iron an aneamic Crohn’s Patient. No observed 
difference between basal (140ng/mL) and 24hr (168ng/mL) sample with prohepcidin. (Venofer™, (Fe 
complex 200mg (IV) infusion for 10mins). Ferritin levels increased from basal (2.3µg/L) to 24hr 
(105µg/L). 
 
 
3.5.5 Chromatographic profile of hepcidin immunoreactivity in human plasma 
The hepcidin RIA and prohepcidin ELISA were performed on extracted pooled plasma from 
HC and HCKD patients, which after preliminary C18 Sep-Pak extraction were subsequently 
separated by RP-HPLC (Figures 3.8 and 3.9). Although a small additional peak was 
detected in HCKD plasma, over 90% of the hepcidin immunoreactivity measured 
corresponded chromatographically to hepcidin. An internal standard of synthetic hepcidin 
(50ng/mL) was used in both elution profiles. 
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Figure 3.8 Elution profiles for extracted pooled human healthy control (HC). Elution profiles 
for endogenous prohepcidin and hepcidin from pooled HC and a synthetic hepcidin ‘spiked’ stripped 
sera sample. Eluted post-extraction and HPLC purified samples assayed using the Hepcidin RIA and 
DRG Prohepcidin ELISA methods. 
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Figure 3.9 Elution profiles of plasma hepcidin immunoreactity from pooled chronic kidney 
disease (CKD) patient samples. Elution profiles for endogenous hepcidin from pooled CKD and 
synthetic hepcidin ‘spiked’ stripped sera samples. Eluted post-extraction and HPLC purified samples 
assayed using the Hepcidin RIA. The first peak on the CKD elution profile may represent the isoform 
hepcidin-20. 
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3.6 Discussion 
I have determined that the novel hepcidin RIA established and validated in the studies 
described in chapter 2 is able to detect changes in hepcidin between healthy controls and 
various disease groups. I have detected a diurnal variation in hepcidin levels, and have 
observed an increase in hepcidin in response to an oral iron load, and to IV-Fe therapy, in 
healthy controls and a severely anaemic hospitalized patient, respectively. 
The hepcidin levels in the UC and IDA and groups were inappropriately low compared to the 
HC group, as would be expected from the physiology of hepcidin regulation in anaemia-
related conditions, where loss of, or deficiency of, iron leads to a down regulation in 
expression of hepcidin. Similar results have been reported for IDA patients (Ganz et al 
2008;Kemna et al 2007;Koliaraki et al 2009), but this was the first study to report low 
hepcidin levels in a UC patient population with IDA (Busbridge et al 2009).  
The IDA patients were selected on the basis of measured biochemical parameters. 
Confirmation of absolute iron deficiency is by the Perls Stain test, which is an 
immunohistochemical Prussian blue staining for iron in reticuloendothelial (RE) cells from 
bone-marrow aspirate samples (Tanaka et al 1969).  This is an invasive and time-consuming 
test only used in patients for whom the biochemical diagnosis has been difficult to interpret. 
Examples include patients presenting with a mixed anaemia where an underlying chronic 
disease may be responsible for the anaemia. Other less invasive tests that can be used to 
aid diagnosis of iron deficiency are the reticulocyte production index (RPI), (Chang et al 
1997), and the zinc protoporphyrin test (ZPP), (Labbe et al 1999). The RPI is used to assess 
whether the bone marrow is producing an appropriate response to an anaemic state, as 
reticulocyte production should increase in response to any loss of red blood cells due to 
either a nutritional deficiency (i.e. iron, folate or Vitamin B12) or insufficient erythropoietin 
stimulus. The ZPP test may also be used to assess iron deficiency. ZPP is a compound 
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found in red blood cells when heme production is inhibited by lead and/or by lack of iron. 
Instead of incorporating a ferrous ion, to form heme, protoporphyrin IX, the immediate 
precursor of heme, incorporates a zinc ion, forming ZPP, (Labbe et al 1999). The fluorescent 
properties of ZPP in intact red cells allow the ZPP/heme molar ratio to be measured quickly, 
at low cost, and in a small sample volume (Crowell et al 2006). It would be interesting to 
investigate the potential of using these tests in association with traditional iron parameters 
and hepcidin to distinguish iron deficiency from anaemia of chronic disease.  In the UC 
patient group it would have been beneficial to have the clinical data and levels of 
inflammatory markers e.g. hsCRP and IL-6 to ascertain the severity of the colitis on sampling 
to determine whether the hepcidin concentrations correlated with the degree of anaemia or 
the inflammatory response in this disease. It would also be intresting to recruit patients with 
iron-loading anaemias such as the alpha and beta-thalassaemias and to observe basal 
hepcidin concentrations in these patients and the changes in those patients undergoing 
transfusional therapy. 
The hepcidin levels in the pre-treated HFE-H patients were inappropriately normal in these 
patients with the adult form of HH, suggesting that this condition is not due to a deficiency of 
hepcidin but rather to defective hepcidin signalling. This inappropriately normal hepcidin has 
also been reported in pre-treated HH patients in similar studies (Ganz et al 2008;Kemna et al 
2007). Thus for this small group of patients the data was in accord with that from other 
groups, but for future studies it would be interesting to measure hepcidin concentrations in 
the other inherited causes of HH mutations i.e. HJV, HAMP, TfR2 and Fpn (although these 
mutations are rare and patient recruitment would require careful consideration). For the 
HFE-H patients recruited it would have been interesting to measure serial hepcidin 
concentrations pre/post-phlebotomy and a time-point remote from their phlebotomy, (3-4 
weeks) to observe possible changes in hepcidin, and also to have measured hepcidin in 
members of the patient‘s family who were not yet symptomatic, to ascertain the possibility of 
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hepcidin as a screening tool for HFE-H. Currently there is no consensus whether to screen 
with genotyping for HFE mutations, followed by phenotyping with traditional tests such as 
transferrin saturation and ferritin, which lack specificity and sensitivity, or to perform 
phenotyping first, followed by genotyping (McLaren and Gordon 2009). 
Hepcidin concentrations were abnormally increased in the CKD and HCKD groups without 
associated inflammatory disorders. This was probably due to retention of hepcidin secondary 
to renal impairment, and provides a possible mechanism for the impaired iron absorption 
observed in renal disease (Macdougall and Cooper 2005). The elevated hepcidin seen in 
CKD has been previously reported (Ganz et al 2008;Kemna et al 2008), but this was the first 
study to report elevated hepcidin in CKD patients on haemodialysis (Ashby et al 
2009;Busbridge et al 2009). Subsequent studies have also confirmed these findings (Bansal 
et al 2010;Peters et al 2009;Peters et al 2010). The significant correlation of hepcidin with 
ferritin in the UC and CKD groups has also been reported in other studies (Ganz et al 
2008;Kemna et al 2007) and implies a high association of hepcidin with iron stores, in 
addition to supporting the biological relevance of the hepcidin levels measured by the assay. 
Details concerning the ethnicity of the healthy control group and patients were unavailable 
for this study. No data at present has found cellular iron flux to vary as a function of race, 
although race/ethnicity differences in iron status have previously been reported (Perry et al 
1992). Data from the second and third extensive National Health and Nutrition Examination 
Surveys (NHANES II and III), have consistently shown higher ferritin concentrations in the 
black population, despite their lower haemoglobin concentrations compared with whites 
(Perry et al 1992; Yang et al 2008). The results from the initial Perry et al study suggested 
that the differences in haemoglobin may be due to pathological processes that affect red cell 
production or genetic factors related to haemoglobin synthesis as in the thalassaemia traits. 
The Yang and Jackson study concluded that the difference in ferritin is a result of factors 
including overall nutrition, health, iron status, hepatic well-being and that the higher ferritin, 
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low haemoglobin and reduced total iron binding capacity observed in blacks is consistent 
with the definition of anaemia of chronic disease. Future studies are needed to confirm the 
role of ACD in the black-white ferritin difference, to determine whether there are differences 
in hepcidin concentrations between ethnicities, and, if so, whether these differences have 
any physiological impact in these populations. 
It has previously been suggested that circulating hepcidin levels change over a diurnal cycle, 
as is observed with Fe concentrations, (Ganz et al 2008;Kemna et al 2005). We have 
confirmed these findings, demonstrating a diurnal change in hepcidin concentrations, 
recording an afternoon peak and a 08:00am trough in hepcidin in healthy control samples. 
However, we did not conduct a control study in this same sample group to ascertain the 
effect of dietary iron on this diurnal fluctuation, as has been reported by Ganz et al. 2008 
study. This pattern is in contrast to iron levels during the day which show a peak at 12am 
and a trough level at 4pm. The factors regulating the circadian variation of plasma iron are 
only partially known (Zang et al 2009). The nuclear receptors REV-ERBalfa and REV-
ERBbeta are known to regulate a number of physiological functions including circadian 
rhythm. Recently, heme has been suggested to be the physiological ligand for REV-ERB 
(Raghuram et al 2007; Rogers et al 2008).  
Plasma iron also displays a large biological variation. The intra-individual variation from day 
to day is approximately 25–30% (CV %) (Borel et al 1991; Maes et al 1997). Extreme sleep 
deprivation for 5 days has also been shown to markedly reduce the amplitude and disturb 
the circadian rhythmicity of iron (Kuhn et al 1982).  
 
In a study by Fillet et al 1989, where the processing of erythrocyte iron by the 
reticuloendothelial (RE) system was studied after intravenous injections of Fe59 heat 
damaged RBCs and Fe59 transferrin in normal subjects, two distinct phases of Fe59 were 
observed, with partioning of iron between the early (release from heme catabolism) and late 
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(release from RE stores) phases dependent on the size of RE stores. Iron output from the 
RE system is responsible for the diurnal variations observed with serum iron levels (Fillet et 
al 1974; Uchida et al 1983). However, the total amount of iron leaving the RE system 
remains relatively constant over time under basal conditions. When body (marrow) 
requirements are enhanced, more iron is donated, particularly through an increase in the 
immediate output of heme iron. When body (marrow) requirements are decreased, iron 
supply is diminished. Plasma iron levels decrease when marrow requirements cannot be 
matched by iron mobilization and increase when marrow activity is insufficient to use the iron 
the RE cell is not able to retain. When the amount of iron entering the RE system is 
increased by transfusions and erythropoiesis is not stimulated to a similar extent, the RE cell 
will accumulate stored iron (Fillet et al 1989). 
However, abnormalities 
Hepatic hepcidin mRNA levels in mice increase in response to increased dietary iron 
(Anderson et al. 2002;Pigeon et al 2001). In analogous human studies, urinary hepcidin 
(corrected for creatinine) was markedly increased in response to an oral iron load (65mg as 
ferrous sulphate) (Lin et al 2007;Nemeth et al 2004;Piperno et al. 2007). All of these studies 
were limited by their reliance on measurement of urinary hepcidin, and the Nemeth et al. 
2004 and Piperno et al. 2007 studies were limited in the time points selected (days rather 
than hours post iron load). Lin et al. 2007 measured urinary hepcidin response over 48hrs 
and showed a peak hepcidin level at 12hrs and peak TSAT at 5hrs, with subsequent decline. 
In our study using plasma hepcidin, we observed a marked increase in hepcidin and TSAT 
levels at 2hrs in all subjects, peaking between 3-4hrs and declining to baseline at 24hrs. 
Although the previous studies show comparable responses, our study measured plasma 
rather than urine levels of iron-related parameters, which explains the much more rapid 
response of hepcidin and TSAT; the delay in response is likely due to the time required for 
clearance through the kidney. These observations suggest that hepcidin synthesis is 
stimulated by acute iron loading and that the iron load may be sensed by the hepcidin 
169 
 
producing hepatocytes through changes in TSAT and the resulting change in holotransferrin 
concentration. The kinetics of the hepcidin response to iron are complex, as hepatocytes are 
exposed to boluses of iron in portal blood as well as to changing iron concentrations in 
systemic blood, and hepcidin changes have a feedback effect on iron concentrations by 
affecting the release of iron from enterocytes and from macrophage and hepatocyte stores. 
We have also observed a significant increase in hepcidin levels in response to IV-Fe. As 
expected, this response is similar to the response with oral iron, although the marked 
increase was not observed until post-24hrs IV-Fe infusion. This delay in comparison to the 
healthy control response to oral iron is most probably due to the severity of the anaemia in 
this patient. Interestingly, this response was not observed with prohepcidin, suggesting that 
the prohormone does not have a functional role in Fe homeostasis, at least over such an 
acute timeline.  
The immunoreactive profile of hepcidin in HC plasma demonstrated a single peak eluting in 
the same fraction as a sample spiked with synthetic hepcidin. A small additional peak was 
detected in extracted HCKD plasma. This peak may represent hepcidin-20, which is not 
readily detectable in HC samples, but levels of which would be likely to increase and thus be 
measurable in renal failure, as it is a degradation product of mature hepcidin. Even in HCKD 
patients, however, over 90% of the immunoreactivity corresponded chromatographically to 
hepcidin-25.  
 
In summary, using the Hepcidin RIA I have developed I have been able to discriminate 
between altered hepcidin concentrations in specific disease populations, and to establish 
that hepcidin exhibits a diurnal variation and is responsive to oral iron and IV-Fe therapy. 
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Chapter 4 
Influence of Erythropoietin 
on Hepcidin in Kidney 
Disease and Healthy 
Controls 
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4.0 Introduction 
4.1.1 Renal anaemia 
Replacement of EPO is the mainstay of treatment of anaemia in kidney failure, reflecting the 
central role of renally produced EPO in regulating hematocrit (Hct). However, it is now 
recognized that sensitivity to EPO therapy in end stage kidney disease is often limited by a 
functional defect in iron availability, and that in most patients IV-Fe therapy improves the 
response (Macdougall 1998). Resistance to EPO has been associated with increased 
mortality in renal disease (Macdougall & Cooper 2005), and there are concerns that regular 
IV-Fe administration may have adverse consequences (Bishu and Agarwal 2006;Zager et al. 
2005).  
 
Prior to introduction of rHuEPO, also known as erythropoiesis-stimulating agents (ESAs), in 
the 1980s, most dialysis patients had Hb concentrations <10g/dL and often much lower. 
Diagnosis of anaemia early in the progression of CKD is clinically important as, if left 
untreated; it causes many of the side effects of CKD such as fatigue, breathlessness on 
exertion, intolerance to cold and decreased exercise capacity. Anaemia is also associated 
with development of cardiovascular disease (CVD) in patients with CKD, in particular left 
ventricular dysfunction (LVF) (Macdougall & Cooper 2005). The anaemia usually presents as 
a normochromic normocytic anaemia (normal RBCs with normal Hb content) that increases 
in severity as the eGFR (Figure 4.1.1).  
 
The National Kidney Foundation Disease Outcomes Quality Initiative (NKF K/DOQI) defines 
anaemia in CKD as an Hb concentration of <11g/dL in pre-menopausal females and pre-
pubertal patients, and <12g/dL in adult males and post- menopausal females (NKF KDOQI 
guidelines 2006). The UK Renal Association Standards recommend evaluation of anaemia, 
‗when Hb <13g/dL (adult males and post-menopausal females), <12g/dL (pre-menopausal 
females)‘ and advise that ‗anaemia is more likely to be the result of CKD if the eGFR is 
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<30mL/min/1.73m2 (<45mL/min/1.73m2 in diabetics) and no other cause, e.g. blood loss, 
folate or Vitamin B12 deficiency, is identified‘. (UK Renal Association 2009-2012). 
 
 
Figure 4.1.1 Prevalence of anaemia severity stratified by stage of chronic kidney disease 
(CKD). Anaemia of CKD increases in prevalence as eGFR declines (27% in Stage 1 to 76% in Stage 
5). (Adapted from Schmidt et al. 2007). 
 
 
Iron absorption is normally regulated by body iron stores and the rate of erythropoiesis, but 
is limited by the GI tract. Hepcidin prevents GI iron absorption and blocks release from the 
RES. Inflammatory states, such as infection, stimulate cytokine release (particularly IL-6) 
resulting in elevated hepcidin levels. This is the probable mechanism blocking effective iron 
utilization in the ACD which is commonly seen in the inflammatory CKD (Ganz 2003). 
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4.1.2 Management of renal anaemia 
Serum ferritin measurements are commonly used to determine iron stores, whereas 
measurement of TSAT gives an indication of iron ‗delivery‘. Patients with CKD Stage 5 can 
be diagnosed ID when serum ferritin <100μg/L. Patients with CKD Stage 3/4 can be 
categorised as ID when serum ferritin <100μg/L. ‗Functional‘ iron deficiency is defined by 
serum ferritin >100μg/L and TSAT <20%. However, serum ferritin does have limitations as a 
marker of disordered iron homeostasis. High ferritin concentrations may be secondary to 
inflammation, and Tf is also influenced by inflammation and nutritional status (Macdougall 
2012). The National Institute of Clinical Excellence (NICE) guidelines indicate management 
of anaemia in adult patients with CKD when the Hb is ≤11g/dL. Recommended treatment is 
aimed at maintaining a stable Hb 10.5-12.5g/dL (NICE guidelines 2011) 
 
Treatment of anaemia in CKD requires the maintenance of adequate iron stores and, where 
appropriate, the introduction of ESAs. Initial iron correction should maintain serum ferritin 
>200μg/L and TSAT >20%. Parental iron is most commonly used, as oral iron has low 
efficacy in CKD patients, especially in HD patients, due to GI malabsorption. Iron status 
should be regularly monitored (1-3 monthly) in patients receiving replacement treatment; a 
serum ferritin level >800μg/L may indicate iron overload (UK Renal Assoc. 2009-2012). 
 
Following optimisation of iron status, CKD patients should begin treatment with ESAs to treat 
the renal anaemia that develops. Current ESA therapies are; Epoetin alfa, Epoetin beta, 
Darbepoietin alfa and Methoxy polyethylene-glycol epoetin beta. These ESAs are inactive 
orally and are given either by IV or subcutaneously (sc). ESAs are effective in correcting the 
anaemia of CKD in 90-95% of patients. The Hb should be monitored regularly (1-3 monthly) 
with dosage adjusted accordingly (UK Renal Assoc. 2009-2012). The most common side-
effect with ESAs is hypertension, which may develop or worsen in some patients. Blood 
pressure should therefore be well controlled prior to introduction of treatment. Failure to 
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respond to ESAs (‗resistance‘, defined as either failure to reach target Hb or requirement for 
excessive dosages of ESAs) requires thorough investigation for potential causes (UK Renal 
Assoc. 2009-2012). 
 
4.1.3 Erythropoietin 
EPO is a large 165 amino-acid glycoprotein hormone (34 KDa) responsible for stimulating 
erythroid progenitor cells within the bone marrow to produce RBCs. EPO is mainly produced 
by highly specialized epithelial-like peritubular capillary lining cells of the renal cortex, with a 
small amount also being produced in the liver (Macdougall & Cooper 2005). Regulation 
relies on a feed-back loop responding to blood oxygenation. Constitutively synthesized 
transcription factors for EPO, known as HIFs, are hydroxylated and proteosomally digested 
in the presence of oxygen (Jelkman W 2007). EPO binds to the erythropoietin 
receptor (EpoR) on the RBC surface and activates a JAK2 cascade. The EpoR is also found 
in bone marrow cells and peripheral/central nerve cells, and intracellular signaling pathways 
are also activated in these cell types upon binding with EPO (Adamson 1996). 
EPO has its primary effect by promoting RBC survival through protecting these cells 
from apoptosis. It also cooperates with various growth factors involved in the development of 
precursor red cells, specifically, the colony forming unit-erythroid (CFU-E), which is 
completely dependent on EPO. The burst forming unit-erythroid (BFU-E) is also responsive 
to EPO (Figure 4.1.2). Under hypoxic conditions, the kidney will produce and secrete EPO to 
increase the production of RBCs by targeting CFU-E, pro-erythroblast and basophilic 
erythroblast subsets during differentiation. EPO has a range of other effects, including 
vasoconstriction-dependent hypertension, increased angiogenesis, and proliferation 
of smooth muscle fibres (Jelkman W 2007). 
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4.1.4 Hepcidin in CKD 
Elevated iron stores and inflammation induce hepcidin production, whereas hypoxia, 
anaemia, ID, increased erythropoiesis and ESAs attenuate hepcidin synthesis (Figure 4.1.3). 
Inflammation decreases the availability of iron, whereas hypoxia or anaemia increases iron 
release and absorption. Recent studies have demonstrated that HIF-1α contributes to the 
down-regulation of hepcidin, perhaps by a direct transcriptional mechanism (Peyssonnaux et 
al 2007) or possibly via muscle-derived sHJV, which may be increased by the HIF-
dependent induction of furin activity (Silvestri et al. 2008).  
 
 
 
Figure 4.1.2 Development of red blood cells (RBCs). RBCs take 25 days to completely develop. 
They initially form from stem cells in the bone marrow, developing into burst-forming erythrocytes 
(BFU-E). These cells require EPO for stimulation to develop into colony-forming erythrocytes, (CFU-
E). The cells are subsequently exposed to iron at the pro-erythroblast stage. Iron is sequestered into 
the RBCs to form Hb. (Adapted from (Adamson and Eschbach 1998). 
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ESAs increase erythropoietic activity, and iron is rapidly mobilized from stores to satisfy the 
requirements of erythrocyte production in the bone marrow. The relationship between 
hepcidin production and erythropoiesis suggests the presence of a regulator between the 
erythron and the liver, and several possible proteins have been proposed to act in this role, 
including sTfR (Kemna et al 2007), GDF15 and TWSG1 (Tanno et al 2007;Tanno et al 
2009). 
 
Recent studies have suggested that hepcidin, like β2M, is freely filtered and reabsorbed in 
the proximal tubule (Swinkels & Wetzels 2008). In this context, it has been suggested that 
the functional iron deficit that accompanies renal disease may be attributable to increased 
circulating levels of hepcidin due to impaired urinary excretion (Ganz 2007). Hepcidin 
expression is also induced by inflammatory cytokines such as IL-6 (Kemna et al 
2005;Nemeth et al 2004) and because the erythropoietic demand for iron is large in relation 
to the quantity normally available in the plasma (Hentze et al 2010;Rivera et al. 2005), it is 
believed that excess hepcidin in inflammatory states reduces the iron recycling that is 
necessary for erythropoiesis, leading to ACD, which is characterized by reduced 
erythropoiesis and reduced serum iron despite apparently normal stores (De, I, Ward, & 
Kaplan 2007;Ganz 2006). These features are similar to EPO resistance in CKD (Macdougall 
& Cooper 2005). 
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Figure 4.1.3 Proposed regulation of hepcidin in chronic kidney disease. The combined effect 
of the various pathways determines hepcidin levels (+ denotes transcriptional up regulation of 
hepcidin and – denotes transcriptional down regulation of hepcidin). (Adapted from (Swinkels & 
Wetzels 2008). 
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4.2 Hypothesis 
I hypothesise that iron therapy and erythropoietin therapy will alter circulating hepcidin levels 
in specific patient populations. 
 
4.3 Aims 
1. To determine levels of hepcidin in renal comprised patients with mild to moderate CKD 
and in clinical stable CKD patients requiring haemodialysis (HCKD).  
2. To investigate the hepcidin response to intravenous iron in anaemic renal patients and 
determine whether diurnal variation is still preserved in CKD and HCKD patients. 
3. To further characterise the response of hepcidin to EPO therapy in HCKD patients. 
4. To investigate the temporal association between plasma hepcidin and other iron indices 
in healthy humans after EPO administration and venesection. 
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4.4 Methods 
4.4.1 Patient samples 
To determine levels of hepcidin and influence of EPO therapy on hepcidin in patients with 
CKD and on HD for ESRF, patients were recruited from a regional center and were of mainly 
Caucasian and South Asian ethnicity. All patient sample studies were approved by the local 
NHS Research Ethics Committee (06/Q0406/134) and (08/Q0707/153) and all participants 
gave informed consent according to the Declaration of Helsinki principles. The CKD; n=44 
and HCKD; n=94 were recruited from the West London Renal Service, Hammersmith 
Hospital NHS Trust. Samples were collected over a three-month period and frozen at –20°C.  
The CKD group had varying degrees of renal impairment (eGFR 13–98 mL/min), and none 
were receiving rHuEPO or IV-Fe therapy, and had not yet begun regular dialysis, whereas 
those patients in the HCKD group were all treated with rHuEPO and IV-Fe intended to 
maintain Hb >11 g/dL and ferritin >400 ng/mL. The HCKD patients were dialyzed for 4 h 
using 2.1m2 low-flux acetate membranes with a minimum ultrafiltrate volume of 2 litres, 
delivering a haemodialysis dose (spKt/V) of over 1.5 in all patients.  The sixty-four sample 
controls recruited for the healthy control group (HC) were as previously described in Section 
2.4.9.1. 
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4.4.2 Hepcidin response to iron therapy in CKD patients 
To confirm that hepcidin responds to Fe status despite renal failure, samples were taken 
from four Fe-naive CKD patients before and after administration of a first dose of IV-Fe 
(Venofer™, (Fe complex 200mg IV infusion for 10mins).  
 
4.4.3 Diurnal variation of hepcidin in CKD patients 
To investigate whether the diurnal variation of hepcidin seen in healthy controls is 
maintained in CKD and HCKD patients, morning (08:00am) and afternoon (16:00pm) levels 
were measured in four CKD patients (eGFR 12–28 mL/min/1.73m2) and six HD patients on a 
non-dialysis day. 
 
4.4.4 Effect of EPO administration and venesection on hepcidin levels in 
healthy controls 
To investigate the temporal association between plasma hepcidin and other iron indices in 
healthy humans after EPO administration and venesection, a preliminary pilot study was 
conducted on one healthy volunteer to determine appropriate time frames between EPO 
administration and venesection and whether a wash-out period would be needed between 
the two study points, before a larger study was performed,.  
 
For this pilot study epoetin beta (5000 units) was administered sc at 10:00am on day 2, 
followed by removal of 250 mL blood by venesection at 10:00am on day 5. Based upon 
these results it was decided to include a washout period of four weeks in the larger study.  
 
For the larger study, six healthy volunteers were recruited, (5 male, ages 24- 38), with 
normal baseline blood tests, (Hb 12.1- 15.6 g/dL and ferritin 28-168 μg/L). Blood samples, 
(2.5 mL each, were taken into lithium heparin tubes with immediate centrifugation 670g for 
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10mins (GF720 RMS UK Ltd.) at R.T. and storage at –20°C), were taken from healthy 
volunteers four times per day during two separate weeks of study, separated by a washout 
period of four weeks. On the morning of the second day of each week, subjects received 
either a subcutaneous (Sc) injection of epoetin beta (5000 units), or had 250 mL blood 
removed by venesection. 
 
4.4.5 Biochemical assays 
Routine chemistry profile, ferritin, Fe, UIBC and CRP were measured using standard 
methods on the Abbott Architect ic8000 system, (Abbott Diagnostics, Ireland). TIBC is a 
calculated test; serum iron + UIBC. TSAT is calculated from; serum iron / TIBC x 100. Full 
blood counts were kindly processed by the Haematology department, using the Sysmex 
system, (Sysmex, USA), Hammersmith Hospital Trust. Hepcidin was measured using the 
competitive RIA previously described in Chapter 2, Section 2.5.7 (Busbridge, Griffiths, 
Ashby, Gale, Jayantha, Sanwaiya, & Chapman 2009). EPO, IL-6 and GDF15 were 
measured using a commercial ELISA (R & D Systems, UK). 
 
4.4.6 Statistical analysis  
Differences between groups were measured using Student‘s t-test, and associations 
between parameters were measured using Pearson‘s correlation coefficient. Variables that 
are normally distributed are expressed as mean, and those variables that are not normally 
distributed are expressed as median with range as indicated. Normality was assessed using 
the Shapiro-Wilk test and skewed data was log transformed before statistical analysis. SPSS 
16.0 (SPSS Inc., Chicago, IL, USA) was used for multivariate regression analysis using 
variables significant in bivariate correlations.  
 
For the data describing the effect of EPO and venesection on hepcidin, changes during the 
EPO administration week and the venesection week were analysed separately from diurnal 
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changes by fitting a linear mixed model in which repeated measurements were assigned an 
autoregressive covariance structure (SPSS, Chicago, IL, USA). This prevented 
overestimation of effects arising from the tendency of measurements separated by short 
time intervals to be similar. In addition, mid-afternoon hepcidin levels were compared 
between days 1 and 3 using the paired t test. Results are expressed as mean ± standard 
error. 
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4.5 Results 
4.5.1 Hepcidin levels in chronic kidney disease patients 
Elevated levels of hepcidin were observed in CKD and HCKD patients compared to HC 
(Figure 4.1.4). In the HC, plasma hepcidin levels (n=64 (34 men)) showed a log-normal 
distribution, with a median 28ng/ml and a range 2.1–58ng/ml (5th–95th percentiles), and 
significantly correlated with ferritin (R 0.57, p <0.0001). Hepcidin was log-normally 
distributed in both CKD groups: the CKD group exhibited elevated levels compared to HC, 
with a median 26ng/ml (5th–95th percentiles: 3.1–153 ng/ml, p <0.001). The relationship 
between hepcidin and ferritin was preserved in CKD patients and by multivariate regression, 
ferritin was a stronger predictor than eGFR, although significant correlations remained for 
eGFR after correction for ferritin (β 0.230, p 0.017) as well as for ferritin after correction for 
eGFR (β 0.745, p 0.001) as hepcidin was inversely correlated with eGFR in the CKD group 
(R 0.530, p 0.0002). Hepcidin was also positively correlated with creatinine, TSAT and 
inversely correlated with EPO; there was no significant correlation with Hb (Table 4.1 and 
Figure 4.1.5).  
 
The HCKD group also had significantly higher hepcidin levels compared to HC, with a 
median 58.5 ng/ml (5th–95th percentiles: 27.6–158 ng/ml, p <0.001). In the bivariate model 
the relationship with ferritin was no longer observed in the HCKD, which explains the poor 
correlation within the dialysis group possibly because there was less variation in ferritin 
levels, which were elevated due to target-driven treatment with IV-Fe. Although in the 
multivariate model adjusted for EPO and Hb (Table 4.2), significant partial correlations are 
observed in the multiple linear regression (MLR) model, (ferritin p 0.013 and cholesterol p 
0.018), that were not associated with hepcidin in the bivariate analysis in the HCKD group. 
Table 4.3 examines the association of gender and comorbidities, (residual renal function, 
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diabetes and cardiovascular disease) in the HCKD group with hepcidin levels, demonstrating 
that none of these factors were significant predictors of hepcidin levels. 
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Figure 4.1.4 Plasma hepcidin in Chronic Kidney Disease (CKD) and stable haemodialysis 
chronic kidney disease patients (HCKD): (Box and Whisker plot [2.5–97.5 percentile] with outliers). 
Groups include healthy controls (HC, n=64), CKD; (n=44) and HCKD; (n=94). CKD disease groups 
differed significantly from HC (*p <0.0001, one-way ANOVA, Dunnetts multiple comparison test p 
<0.05 for CKD groups compared to HC). 
 
 
 
 
 
 
 
185 
 
Table 4.1 Continuous clinical parameters in the Chronic Kidney Disease (CKD) group. 
Distributions of clinical parameters in the CKD (n=44) group, and correlation with hepcidin. 
 
Parameter 
(Reference Interval) 
Mean 5
th
 
percentile 
95
th
 
Percentile 
R p 
Creatinine (µmol/L) 
(Male: 60-125) 
(Female: 25-200) 
186 61 462 0.45 0.0046* 
Hb (g/dL) 
(Male: 13.8-17.2) 
(Female:12.1-15.1 ) 
12.3 9.9 14.8 -0.05 0.8 
hsCRP (mg/L) 
(0-5) 
10.2 2 82 0.23 0.156 
EPO (mIU/mL) 
(5-25)
+
 
15.5 5.1 32 -0.52 0.001* 
Iron (µmol/L) 
(Male: 9-29) 
(Female: 7-27) 
13 6 24 0.21 0.21 
Ferritin (µg/L) 
(Male: 20-300) 
(Female (16-50y): 10-120) 
(Female (>50y): 20-300) 
75 10.6 562 0.85 <0.0001* 
TSAT (%) 
(16-55%) 
22 8.7 44 0.49 0.0016* 
Hepcidin (ng/mL) 34 1.1 103 N/A N/A 
Hb; haemoglobin, hsCRP; high-sensitivity C-reactive protein, EPO; erythropoietin, (
+
when haematocrit 
is normal), TSAT; transferrin saturation. 
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Figure 4.1.5 Relationship between Hepcidin and measured parameters in the Healthy 
Control (HC) and Chronic Kidney Disease (CKD) groups. A) HC (n=64); correlation between 
hepcidin and ferritin (R 0.67, p <0.0001). B) CKD (n=44); correlation between hepcidin and ferritin (R 
0.85, p <0.0001). C) CKD; correlation between hepcidin and serum creatinine (R 0.45, p 0.0046). D) 
CKD; inverse correlation between hepcidin and EPO (R -0.52, p 0.001). (Pearsons Rank correlation p 
<0.05, considered significant). 
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Table 4.2 Continuous clinical parameters in the Stable Haemodialysis Chronic Kidney 
Disease (HCKD) group. Distributions of clinical parameters in the HCKD (n=94) group, and 
correlation with hepcidin in a model adjusted for EPO and Hb. 
 
Parameter 
(Reference Interval) 
Mean 5
th
 
percentile 
95
th
 
Percentile 
 
β 
 
p 
Age 64.6 39.2 83 -0.082 0.414 
Ferritin
#
 (µg/L) 
(Male: 20-300) 
(Female (16-50y): 10-120) 
(Female (>50y): 20-300) 
550 291 1014 0.247 0.013* 
BMI (Kg/m
2
) 
(18.5-24.9) 
25.2 19.3 32.1 -0.085 0.397 
Albumin (g/L) 
(35-50) 
34.4 28 41 0.101 0.319 
Cholesterol (mmol/L) 
(<5.0) 
3.55 2.4 5.2 -0.236 0.018* 
Creatinine (µmol/L) 
(Male: 60-125) 
(Female: 55-110) 
669 405 886 0.133 0.178 
spKt/V 1.81 1.47 2.13 0.051 0.632 
hsCRP
#
 (mg/L) 
(0-5) 
12.9 2.8 31.2 -0.016 0.874 
IL-6
#
  (pg/mL) 5.2 1.2 12.8 0.195 0.054 
GDF-15 (ng/mL) 4.25 2.27 7.28 0.072 0.467 
BMI, Body Mass Index; spKt/V, Hemodialysis Dose; hsCRP, high sensitivity C - reactive protein; IL-6, 
Interlukin-6; GDF-15, Growth Differeniation Factor-15, (*p <0.05 considered significant). (
#
Skewed 
variables that were normalized by log transformation for regression analysis). 
 
Table 4.3 Gender and comorbidity in the Stable Haemodialysis Chronic Kidney Disease 
(HCKD). Ratio of plasma hepcidin levels measured in men vs. women, and in the presence vs. 
absence of significant residual renal function and comorbid conditions, (p <0.05 considered 
significant). 
 % Hepcidin ratio p 
Sex (male) 66 0.74 0.079 
Residual renal function 37.9 1.09 0.739 
Diabetes 36.6 1.16 0.375 
Cardiovascular disease 52.1 1.23 0.217 
. 
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In the dialysis patients, I also examined whether elevated plasma hepcidin may be partly 
attributable to inflammatory signals, as these patients are usually in a generalised 
inflammatory state and in previous studies a positive correlation between inflammatory 
markers and hepcidin has been observed (Kemna et al 2005;Nemeth et al 2004). I 
measured CRP and IL-6, and identified no correlation with bivariate analysis with hepcidin in 
CKD (R 0.20, p 0.19 for CRP and R 0.28, p 0.07 for IL-6) or HCKD patients (R 0.04, p 0.69 
for CRP and R 0.12, p 0.26 for IL-6). 
 
4.5.2 Hepcidin response to intravenous iron therapy in CKD patients 
To confirm that hepcidin responds to Fe status despite renal failure, samples were taken 
from four iron-naive CKD patients before and after administration of a first dose of IV-Fe. 
Hepcidin levels in these patients were significantly increased from 18.1±9.6 to 59.3±18.6 
ng/ml 24hrs after infusion (p 0.047; Figure 4.1.6). 
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Figure 4.1.6 Hepcidin, iron and ferritin response to IV-Fe. In Chronic Kidney Disease (CKD) 
(n=4) patients receiving IV-Fe for the first time, hepcidin (p <0.05), iron (p <0.001) and ferritin (p 
<0.001) all rise promptly after infusion of 200mg Fe sucrose. 
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4.5.3 Diurnal Hepcidin levels in chronic kidney disease patients 
As demonstrated in Chapter 3, (Section 3.5.3, Figure 3.3), a diurnal cycle for hepcidin in HC 
is present, with peak levels in the afternoon (Busbridge et al 2009). Based on this finding we 
decided to investigate if this diurnal variation is preserved in CKD patients. Morning 
(08:00am) and afternoon (16:00pm) levels were measured in four CKD patients (eGFR 12–
28 mls/min/1.73m2) and six HCKD patients on a non-dialysis day (Figure 4.1.7), that showed 
no clear diurnal pattern (65.5 vs. 65.5 ng/ml in CKD group and 58.3 vs. 57.8 ng/ml in HCKD 
group). Pre- and post-dialysis samples were also taken from six patients, and showed no 
reduction following a standard dialysis session (68.7 vs. 69.7 ng/ml for pre- and post-
dialysis, respectively). 
 
 
H
e
p
c
id
in
 (
n
g
/m
L
)
0
10
20
30
40
50
60
70
80
90
08:00am 16:00pm
CKD (n=4)
HDCKD (n=6)
HC (n=15)
ns
ns
*
 
Figure 4.1.7 Diurnal profiles of plasma hepcidin in healthy controls and chronic kidney 
disease patients. Diurnal profile of plasma hepcidin in fifteen healthy controls, four chronic kidney 
disease (CKD) patients and six stable haemodialysis chronic kidney disease (HCKD) patients (on a 
non-dialysis day) the significant diurnal variation in hepcidin observed in the healthy controls (*p <0.05 
paired t-test between morning (8am) and afternoon (16pm) samples was not observed in the CKD 
and HDCKD patients, (ns indicates no significance). 
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4.5.4 Hepcidin levels and endogenous EPO in CKD patients 
We next investigated the possible relationship of hepcidin with endogenous EPO in stable 
CKD patients, who were not undergoing EPO therapy. As noted in Section 4.5.1, hepcidin 
levels were inversely correlated with endogenous EPO levels (R -0.52, p <0.001), implying 
that rather than reflecting impaired clearance, hepcidin levels may in part reflect EPO 
deficiency.  
 
4.5.5 Hepcidin and EPO dose in CKD patients 
It has been hypothesized that the elevated hepcidin levels seen in CKD patients may explain 
the reduced sensitivity to EPO observed in dialysis patients (Swinkels & Wetzels 2008). To 
investigate this, we compared hepcidin, Hb levels and EPO dose in the stable dialysis 
patients (HCKD group). In this group, log hepcidin levels were negatively correlated with Hb 
and EPO dose, (Figure 4.1.8),  and in multivariate analyses, only Hb and EPO dose were 
significant predictors of hepcidin levels, (β 0.290, p 0.004 and β 0.335, p 0.001 respectively), 
regardless of whether EPO dose was measured as an absolute value, or normalized by 
body weight or by Hb. This correlation was consistent across each tertile of Hb (Figure 
4.1.9).  
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Figure 4.1.8 Relationship between EPO dose and plasma hepcidin in stable haemodialysis 
chronic kidney disease (HCKD) patients. Inverse correlation between log hepcidin and EPO dose 
in HCKD (n=94) (R -0.30, p 0.0071 for univariate, β 0.335, p <0.001 for model including Hb). Dashed 
lines show 90% CI for linear regression. 
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Figure 4.1.9 Relationship between EPO dose and plasma hepcidin across Hb 
concentrations in stable haemodialysis chronic kidney disease (HCKD) (n=94). Plasma hepcidin 
by tertiles of EPO dose and Hb, showing that the association of higher EPO dose with lower hepcidin 
is conserved across Hb concentrations and that, within each EPO dose tertile, lower Hb is associated 
with higher hepcidin. 
 
 
To further investigate whether EPO therapy may be responsible for reducing hepcidin, we 
conducted a small pilot study and measured hepcidin levels in five CKD patients as they 
were starting EPO (20 mg darbepoietin alfa weekly) for the first time (Figure 4.2.1). Plasma 
hepcidin fell from 70.0±4.7 to 60.7±6.0 ng/ml during the first few days and remained at 
similar levels when patients were retested after 2–4 weeks of continued EPO therapy. A 
potential mechanism by which hepcidin might be reduced by EPO involves GDF15, which is 
thought to function as a signal from active bone marrow to suppress hepcidin expression 
(Tanno et al 2007). We found that in the HCKD group, plasma GDF15 was significantly 
correlated with EPO dose (R 0.205, p 0.047), consistent with its role as a marker of marrow 
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activity, but that there was no correlation between plasma GDF15 concentrations and 
hepcidin levels (R 0.002, p 0.98). However, GDF15 levels were positively correlated with 
hepcidin levels in the CKD group (R 0.593, p 0.002). Together, these results suggest that 
altered hepcidin levels in renal disease are not due to changes in circulating GDF15. 
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Figure 4.2.1 Effect of Erythropoietin (EPO) on hepcidin levels. On commencing EPO treatment 
in CKD, hepcidin falls 70.0±4.7 to 60.7±6.0 ng/ml at 2–4 days, (n=5) remaining at the lower level on 
continued therapy. All samples were taken at 15:00pm. 
 
 
 
 
4.5.6 Response of Hepcidin and to EPO administration and subsequent 
venesection in a healthy control 
 
The normal diurnal variation in hepcidin was observed on the first day of the study. There 
was an obvious suppression of hepcidin post 24hrs EPO administration, and these 
suppressed hepcidin levels did not return to day 1 levels before the venesection was 
conducted which also resulted in a subsequent suppression of hepcidin levels. Based on this 
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data we decided to include a 4 week washout period between EPO administration and 
subsequent venesection (Figure 4.2.2).  
 
Figure 4.2.2 Effect of Erythropoietin (EPO) administration and venesection on plasma 
hepcidin. Healthy control (n=1), receiving EPO (sc) (5000 units epoetin beta) at 10:00am on day 2 of 
study and venesection of 250mL of blood at 10:00am day 5. 
 
 
 
4.5.7 Erythropoietin administration in healthy controls; Week 1  
Throughout both study weeks, the expected diurnal variation in circulating hepcidin 
described in Chapter 3 (section 3.5.2, Figure 3.3) was observed (Ashby et al 2009;Busbridge 
et al 2009), with levels increasing during the day (p <0.001 for either afternoon time point 
compared with 09:00am time-point), reaching a plateau in the mid-afternoon, and falling 
slightly, but not significantly, between 15:00pm and 18:00pm hours. 
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During the first study week, subjects received a single sc injection of EPO (5000 unit‘s 
epoetin beta) at 09:00am on day 2. Profound suppression of hepcidin was observed starting 
from 24hrs after EPO administration, and continuing throughout the week, with incomplete 
recovery occurring over a two week period (Figure 4.2.3). Hepcidin suppression was near 
maximal during day 3, with peak (mid-afternoon) levels reduced by 73.2% (p 0.018).  
 
TSAT levels in this study demonstrated the expected diurnal pattern, with levels significantly 
lower at 15:00pm (p <0.001) and 18:00pm (p <0.001) than at 09:00am. Levels also gradually 
declined during the week. During day 2, however, prior to the change in hepcidin, mean 
TSAT levels were not significantly changed from baseline, (Figure 4.2.4) and in 4 of the 6 
subjects were slightly increased (Appendix II, Figure 1.1). TIBC levels were very stable 
during the study period, showing no diurnal variation or trend over the week; changes in 
circulating iron levels therefore closely reflect those seen with TSAT levels. Ferritin levels 
similarly exhibited a gradual decline during the week (Figure 4.2.5). 
 
A significant diurnal pattern to GDF15 was observed, with levels increasing slightly during 
each day, but the pattern remained constant during the week (Figure 4.2.6). After EPO 
administration, however, sTfR levels remained constant throughout the week, only beginning 
to rise from day 8 (Figure 4.2.7). Individual responses for all measured parameters in week 1 
are shown in Appendix II, Figures 1.1 to 1.3. 
 
 
196 
 
 
 
Figure 4.2.3 Effect of Erythropoietin (EPO) administration on plasma hepcidin. Healthy 
controls (n=6), received EPO (sc) (5000 units epoetin beta) at 09:00am on the second day of study. 
Plasma levels of Hepcidin (mean ±SE) and EPO (group mean, red line) are shown throughout the 
week. Hepcidin levels demonstrated normal diurnal variation through day 1, (*p <0.001 for mid-
afternoon time-point compared with 09:00am time-point). Significant suppression of hepcidin was 
observed starting from 24hrs after EPO administration, and continuing throughout the week, with 
incomplete recovery occurring over a two week period ,(*p 0.003 for 09:00am day 3, *p <0.001 for 
09:00am day 4 and *p <0.001 for 09:00am day 5 levels compared with 09:00am day 1). Hepcidin 
suppression was near maximal during day 3, with peak (mid-afternoon 15:00) levels reduced by 
73.2% compared to mid-afternoon levels on day 1 (*p 0.018). (*p <0.05 considered significant).  
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Figure 4.2.4 Effect of Erythropoietin (EPO) administration on plasma transferrin saturation 
(TSAT). Healthy controls (n=6), received EPO (sc) (5000 units epoetin beta) at 09:00am on the 
second day of study. Plasma levels of TSAT (mean ±SE) and EPO (group mean, red line) are shown 
throughout the week. The expected diurnal pattern was observed on day 1 with significant lower 
levels at 15pm (p <0.001) and 18pm (p <0.001) compared with 09:00am, with levels declining through 
the week. Day 2 mean TSAT levels were not significantly different from baseline, but 09:00am levels 
on day 3 (p 0.029), day 4 (p 0.028) and day 5 (p 0.001) were significantly different than day 1 
09:00am levels. (*p <0.05 considered significant). 
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Figure 4.2.5 Effect of Erythropoietin (EPO) administration on plasma Ferritin. Healthy 
controls (n=6), received EPO (sc) (5000 units epoetin beta) at 09:00am on the second day of study. 
Plasma levels of Ferritin (mean ±SE) and EPO (group mean, red line) are shown throughout the 
week. Ferritin levels exhibited a gradual and non-significant decline during the week. 
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Figure 4.2.6 Effect of Erythropoietin (EPO) administration on plasma Growth Differentiation 
Factor-15 (GDF15). Healthy controls (n=6), received EPO (sc) (5000 units epoetin beta) at 09:00am 
on the second day of study. Plasma levels of GDF15 (mean ±SE) and EPO (group mean, red line) are 
shown throughout the week. A significant diurnal variation was observed with levels increasing during 
the day, but the pattern remained constant during the week, peaking at 18pm compared to 09:00am 
levels, (day 1 p 0.018, day 2 p 0.019 and day 3 p <0.001). The peak level at day 3 appears to be 
exaggerated but is not significantly different to peak on day 1. (*p <0.05 considered significant). 
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Figure 4.2.7 Effect of Erythropoietin (EPO) administration on plasma Soluble Transferrin 
Receptor (sTfR). Healthy controls (n=6), received EPO (sc) (5000 units epoetin beta) at 09:00am on 
the second day of study. Plasma levels of sTfR (mean ±SE) and EPO (group mean, red line) are 
shown throughout the week. sTFR levels showed no significant change during the week only 
beginning to rise from day 8 (23.5±0.6 vs. 18.3±0.5 nmol/L, p 0.002). (*p <0.05 considered 
significant). 
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4.5.8 Venesection week 
 
After the 4 week washout period we commenced with the second study week, where 250 mL 
blood was removed from each subject at 09:00am on day 2. Hepcidin levels were again 
subsequently reduced, although the reduction was more gradual than that seen after EPO 
administration, with no apparent recovery even by day 15 (Figure 4.2.8). Analysis of related 
parameters demonstrated a more gradual decline in TSAT, but was otherwise similar to the 
first study week (Figure 4.2.9). Ferritin levels again similarly exhibited a gradual decline 
during the week (Figure 4.3.1).GDF15 and sTfR were also unchanged during the week 
(Figures 4.3.2 and 4.3.3). Individual responses for all measured parameters in week 1 are 
shown in Appendix II, Figures 1.4 to 1.6. 
 
 
 
202 
 
 
 
Figure 4.2.8 Effect of venesection (250mL) on plasma Hepcidin. Healthy controls (n=6) post 
venesection (250mL) at 09:00am on the second day of study. Plasma levels of Hepcidin (mean ±SE) 
and response of endogenous EPO production (group mean, red line) to venesection are shown 
throughout the week. Hepcidin levels demonstrated normal diurnal variation days 1, 2 and 3 with 
significantly reduced 09:00am levels on day 4 (p 0.020) and day 5 (p <0.001) compared to 09:00am 
levels on day 1. (*p <0.05 considered significant).   
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Figure 4.2.9 Effect of Venesection (250mL) on plasma Transferrin Saturation (TSAT). Healthy 
controls (n=6) post venesection (250mL) at 09:00am on the second day of study. Plasma levels of 
TSAT (mean ±SE) and response of endogenous EPO production (group mean, red line) to 
venesection are shown throughout the week. TSAT levels gradually declined through the week. Day 
2, 3 and 4 mean TSAT levels were not significantly different from baseline. Day 5 mean TSAT levels 
were significantly different to baseline on day 1 (p 0.006). (*p <0.05 considered significant). 
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Figure 4.3.1 Effect of Venesection (250mL) on plasma Ferritin. Healthy controls (n=6) post 
venesection (250mL) at 09:00am on the second day of study. Plasma levels of ferritin (mean ±SE) 
and response of endogenous EPO production (group mean, red line) to venesection are shown 
throughout the week. Ferritin levels did not significantly change during the week although there was 
an observed decline throughout the week with no significant recovery to baseline levels by Day 15 (p 
<0.001). (*p <0.05 considered significant). 
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Figure 4.3.2 Effect of Venesection (250mL) on plasma Growth Differentiation Factor-15 
(GDF15). Healthy controls (n=6) post venesection (250mL) at 09:00am on the second day of study. 
Plasma levels of GDF15 (mean ±SE) and responses of endogenous EPO production (group mean, 
red line) to venesection are shown throughout the week. The significant diurnal variation is still 
observed with levels increasing during the day, and the pattern remained constant during the week, 
peaking at 18pm compared to 09:00am levels, (day 1 p 0.018, day 2 p 0.019 and day 3 p 
0.021).Although the diurnal variation on day 4 and 5 is not significant. (*p <0.05 considered 
significant). 
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Figure 4.3.3 Effect of Venesection (250mL) on plasma Soluble Transferrin Receptor (sTfR). 
Healthy controls (n=6) post venesection (250mL) at 09:00am on the second day of study. Plasma 
levels of sTfR (mean ±SE) and response of endogenous EPO production (group mean, red line) to 
venesection are shown throughout the week. sTFR levels showed no significant change during the 
week. 
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4.6 Discussion 
 
Using an established hepcidin immunoassay I have demonstrated elevated circulating 
concentrations of hepcidin in patients with renal impairment. This observation has also been 
made by other groups (Ganz et al 2008;Swinkels & Wetzels 2008;Tomosugi et al 2006) and 
suggests a possible mechanism for the impaired iron absorption observed in renal disease 
(Macdougall et al. 2010). These findings also demonstrate a number of important additional 
points. Firstly, that normal diurnal variation in hepcidin is suppressed in these patients, with 
elevated hepcidin levels due to severe renal impairment and the ureamic inflammatory 
response.  Secondly, even in the presence of moderate renal impairment, hepcidin remains 
closely related to iron stores and responsive to changes in iron status, without any obvious 
relationship to the inflammatory mediators measured. The elevated circulating hepcidin 
levels in these patients would be expected to cause iron sequestration in macrophages of 
the RE system, and thus restrict iron flow to the erythropoietic marrow and contribute to the 
pathogenesis of anaemia. This would prevent the biphasic release of iron from the RE 
system and might lead to the lack of diurnal variation observed in renal patients, (Coyne 
2011). Short-term elevated hepcidin levels impair the release of storage iron, and long-term 
elevated hepcidin can result in iron deficiency. In vitro studies also suggest that elevated 
hepcidin may also directly contribute to anaemia in CKD by inhibiting erythroid colony 
formation when EPO concentrations are low, and thus impair red blood cell survival (Dallalio 
et al 2006; Coyne 2011). Consequently, lowering hepcidin or inhibiting its signaling would 
release iron from stores, promote erythropoiesis, and prolong red cell survival. Such an 
approach may be safer than using high doses of erythropoiesis-stimulating agents (ESAs) 
with repetitive parenteral iron. It may also be possible to use plasma hepcidin as a guide to 
anaemia therapy rather than traditional iron parameters such as ferritin, which lack suitable 
specificity due their response in inflammatory conditions. Larger longitudinal studies would 
be required to define appropriate hepcidin reference intervals in this disease population.  
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Thirdly, although high hepcidin is associated with low Hb, consistent with its role in restricting 
erythropoiesis, it is also strongly and independently associated with low EPO dosage. Rather 
than reflecting hepcidin‘s influence on EPO requirement, and potential as a marker of EPO 
resistance, these data are consistent with a model in which hepcidin levels are directly or 
indirectly suppressed by EPO. This concept is supported by the reduction in hepcidin seen in 
CKD patients starting EPO therapy. Such an effect on hepcidin expression is also suggested 
by animal experiments in which stimulation of erythropoiesis by venesection or EPO 
administration is sufficient to suppress hepcidin mRNA levels in the liver (Nicolas et al 
2002;Vokurka et al. 2006).  In the multivariate analysis adjusted for EPO and Hb, there was 
an association observed with ferritin (p 0.013) and cholesterol (p 0.018). Multivariate 
analysis is a useful technique for examining the manner in which a set of explanatory 
variables account for differences in hepcidin levels within the HCKD group. However, this 
analysis has significant drawbacks, being highly dependent on the set of explanatory 
variables available and the simultaneous interpretation of multiple p-values. Over-reliance, 
particularly when the ratio of observations to predictors is low, may lead to spurious 
associations while still missing real ones. Fluvastatin (80 mg per day) has been shown to 
decrease not only total cholesterol and high-sensitive C-reactive protein levels, but also 
prohepcidin serum levels in dyslipidemic dialysed patients, (Arabul et al 2008). Therefore it 
may be possible that statin use may account for the negative independent relationship 
between hepcidin and cholesterol levels in this study. However, the inverse relationship 
between cholesterol and hepcidin was not explained by statin use, which was not predictive 
of hepcidin level in the bivariate or multivariate analysis. Any cholesterol association is 
perhaps more likely to result from the inverse correlation between cholesterol and 
interleukin-6, although it should be emphasized that these associations, based on multiple 
comparisons, are relatively weak. 
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There was a significant hepcidin response to IV-Fe in the CKD patients. Parenteral iron, but 
not oral has also been shown in several studies to improve the anaemia-induced over 
expression of hepcidin (Nicolas et al 2002; Roy et al 2007; Finnberg 2008; Cui et al 2009). 
IV-Fe improved anaemia in most CKD and dialysis patients, including those with elevated 
hepcidin levels, (Tessitore et al 2010) and markedly elevated C-reactive protein levels, 
(Coyne et al 2007; Stancu et al 2010). Although consistent with continued dysregulation of 
iron metabolism following IV-Fe, studies show high liver-iron content in haemodialysis 
patients receiving IV-Fe. The long-term effects of IV-Fe and enhanced iron stores have not 
been rigorously investigated. Free iron increases after IV-Fe administration, which may 
promote infections and oxidative damage, whereas long-term, cellular iron could accumulate 
because of the persistently high hepcidin levels, (Sasu et al 2010). Administration of an anti-
hepcidin antibody has been shown in an animal model expressing human hepcidin to treat 
inflammation-induced anaemia when combined with EPO treatment, (Sasu et al 2010). 
However, these animals did not respond to IV-Fe in the absence of the neutralizing antibody, 
indicating that the effects of the antibody are mediated by factors beyond iron. Directly 
suppressing hepcidin transcription via small-interfering RNA has also been shown in 
preclinical studies to lower hepcidin, enhance erythropoiesis, and increase serum iron levels, 
(Sasu et al 2010).  
 
The suppression of hepcidin expression by EPO is thought to be mediated by increased 
bone marrow activity; prior bone marrow suppression by cytotoxic agents or irradiation 
abolishes the response (Nicolas et al 2002;Vokurka et al 2006), suggesting a circulating 
marrow-derived mediator is responsible. Rather than reflecting the pharmacokinetic profile of 
plasma EPO observed in week 1, the delay in the suppression and recovery of hepcidin 
levels found in this study are more in keeping with an effect mediated by a secondary factor.  
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EPO acts via cell membrane receptors expressed in erythroid progenitor cells, increasing 
mitosis and survival so that the number of cells entering the precursor pool is increased, 
(Macdougall & Cooper 2005). The putative factor responsible for hepcidin suppression might 
be released by cells in response to the EPO signal, or in proportion to the number of cells at 
a particular stage of maturation. This delay, which was consistent in all subjects (Appendix II 
Figures 1.1 to 1.3), may, therefore, reflect the time required for this proliferative response to 
occur. Following EPO administration in humans, reticulocyte numbers begin to increase after 
a dose-independent delay of around 1.7 days (Krzyzanski W & Perez-Ruxo JJ 2007).  
 
Three potential marrow-derived mediators of this effect were examined in this study. Firstly, 
it has been suggested that rather than a novel mediator, bone marrow iron utilization in 
response to EPO might lead directly to hepcidin suppression via a reduction in circulating 
TSAT, which would be sensed by hepatocytes. TSAT levels in this study demonstrated the 
expected diurnal pattern, with changes in circulating iron closely reflecting those in TSAT 
(Appendix II Figure 1.1), with ferritin levels similarly exhibiting a gradual decline during the 
week. However, the marked decrease in hepcidin seen in all subjects preceded the 
reduction in TSAT, suggesting that increased iron utilization by itself is not the mechanism 
driving the observed hepcidin suppression  
 
A possible candidate for a circulating indicator of marrow iron requirement is sTfR. The 
membrane bound form of this receptor binds holo-Tf leading to iron uptake by erythroid 
precursors and is subsequently shed during further RBC maturation. Its circulating levels are 
therefore generally proportional to iron uptake (Lin et al 2007). It has thus been suggested 
as a mediator of iron regulation in effective and ineffective erythropoiesis (Cazzola 2002). 
However, after EPO administration, sTfR levels remained constant throughout the week, 
indicating that there was no significant response to EPO administration and that it is unlikely 
to mediate the observed changes in hepcidin levels.  
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GDF15, a transforming growth factor-β (TGF-β) family cytokine, has been suggested as a 
possible mediator of hepcidin suppression in the context of ineffective erythropoiesis based 
on two observations. Firstly, GDF15 has been shown to suppress hepcidin expression in 
cultured hepatocytes, and secondly, it circulates at extremely high levels in patients with ß-
thalassemia, potentially explaining their inappropriate hepcidin suppression in spite of iron 
overload (Tanno et al 2007;Weizer-Stern et al 2006).This hypothesis was strengthened by 
the recent discovery that iron depletion in vitro induces GDF15 expression, and that infusion 
of the iron chelator deferoxamine increases plasma GDF15 in humans (Lakhal et al. 2009). 
In our study, a modest but significant diurnal pattern to GDF15 was observed, with levels 
increasing slightly during each day, but the pattern remained constant during the week. 
GDF15 therefore appears unlikely to mediate the hepcidin suppression resulting from EPO 
administration.  
 
During the second study week, hepcidin levels were again reduced, with TSAT 
demonstrating a more gradual decline but otherwise similar to the first study week. Soluble 
transferring receptor and GDF15 levels were again unchanged during the week. That these 
changes were similar but more gradual than those observed during the first week, may 
reflect the slower onset and lower amplitude of the plasma EPO profile following venesection 
compared to that seen after EPO administration. The degree of hepcidin suppression points 
towards EPO as a more useful therapy for the ACD than is currently recognised. Two key 
mechanisms underlying ACD are an insufficient EPO response to anaemia, and restricted 
iron transport, with the latter being due to increased hepcidin expression mediated by IL-6 
(Kemna et al 2005;Nemeth et al 2004). Both these mechanisms can be addressed by 
therapeutic EPO: in addition to augmenting insufficient endogenous hormone, the resulting 
suppression of circulating hepcidin levels is able to restore the delivery of iron to the marrow. 
The EPO administration in this study results in a profound and sustained suppression of 
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circulating hepcidin, which is not mediated by reduced circulating iron. This suggests that 
EPO improves disordered iron transport as well as supplementing a diminished EPO 
response when used in the treatment of ACD. This study also confirms the existence of a 
hepcidin-based mechanism for increasing the delivery of iron at times of increased 
utilization. However, the putative marrow derived mediator of this effect remains to be 
identified. 
 
In conclusion, we have shown that a raised plasma hepcidin level, with flattening of the 
normal diurnal variation, occurs in kidney disease. This increase in hepcidin level reflects 
both the degree of renal impairment and iron storage, but is independent of variation in 
markers of inflammation. The results also suggest that EPO therapy can suppress hepcidin, 
ameliorating disordered iron transport as well as treating EPO deficiency. As such, hepcidin 
could become an important tool to predict ESA responsiveness and to guide treatment with 
ESAs and IV-Fe. In addition, hepcidin has the potential to become a therapeutic target itself.  
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214 
 
5.0 General Discussion 
Although iron is essential for life, its reactive properties mean that levels within the body 
require tight regulation in order to prevent pathological side effects. Hepcidin, a hepatocyte 
produced peptide hormone, has been established as the central regulator of body iron 
metabolism (Ganz 2003;Nemeth & Ganz 2006). Hepcidin production is predominantly 
controlled by erythropoietic activity of the bone marrow, the amount of circulating and stored 
iron, and inflammation. Hepcidin exerts its regulatory function on iron metabolism by binding 
to the transmembrane iron exporter Fpn, which is present on macrophages, the basolateral 
site of enterocytes, and hepatocytes. This binding sequence then leads to the internalization 
and degradation of Fpn, which prevents subsequent iron release into the circulation (Nemeth 
et al 2004;Nemeth et al 2006). Although hepcidin was initially discovered in human urine and 
ultra filtrated serum, most published evidence on hepcidin regulation and mode of action 
comes from in vitro work and murine based studies that have used hepcidin mRNA 
expression as a measurable endpoint (Ganz 2003;Rivera et al 2005). Clinical human studies 
have been hampered due lack of suitable hepcidin assays. The major aim of this thesis was 
the development of a high through-put immunoassay for human hepcidin in order to study 
the regulation and role of this peptide in iron metabolism. 
 
Progress in developing a conventional immunochemical hepcidin assay has been hampered 
by difficulties in generating specific anti-hepcidin antibodies in host animals such as rabbits 
and mice (Nicolas et al 2002).  Due to these problems there has been a trend to develop 
alternative methods based upon mass-spectroscopy (MS) methods to quantify human 
hepcidin. The first published MS for hepcidin was based upon a SELDI-TOF MS method 
(Kemna et al 2005). This method gave comparable hepcidin results to an early immunoblot 
assay (Ganz 2003), was similarly based on urine and, due to changes in solvents and the 
sample matrix (e.g. sample dilution) which influenced the flight behaviour of the peptide 
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during the SELDI-TOF MS analysis, was also only semiquantitaive. This has led to the 
generation of a variety of published MS methods based upon LC-MS/MS (Bansal et al 
2009;Li, Rose et al 2009;Murao et al 2007;Murphy et al 2007), isotope dilution MS (Kobold 
et al 2008) and SELDI-TOF MS (Altamura et al  2009;Castagna et al 2010;Ward et al 2008). 
All these MS methods use a variety of external and internal calibrators based upon synthetic 
and stable isotope labelled analogues and a number of different extraction procedures 
based upon cation exchange resins and copper loaded immobilized metal-affinity capture 
ProteinChip arrays. 
 
More recently the Swinkels et al group has improved their initial SELDI-TOF MS method to 
enable quantification of hepcidin in human sera and urine (Kemna et al 2007;Swinkels et al 
2008) by using a synthetic 25 residue hepcidin as an external calibrator and an in-house 
synthesised 24 residue hepcidin as an internal calibrator. Although these MS methods have 
become increasingly popular in protein quantification they still remain expensive and 
technically challenging methods to develop and the instruments are not ideally suited for 
high through-put analysis (Kroot et al 2010). 
 
Although a number of MS methods have been described there has been a lack of specific 
immunoassays for hepcidin. The advantages of immunoassays include the potential for 
more widespread use in clinical laboratories compared to the expensive and technically 
demanding MS methods. Ganz et al were the first group to publish an immunoassay for 
hepcidin based upon a competitive ELISA format (Ganz et al 2008); this method was based 
upon the same anti-hepcidin antibody used in the original immunoblot assay. Compared to 
MS methods, the ELISA detected considerably higher levels of hepcidin in patients (Kroot et 
al 2009), possibly due to cross-reaction with prohepcidin or the recently described hepcidin 
isoforms (Campostrini et al 2010;Swinkels et al 2008). The MS assays have the advantage 
of distinguishing between mature hepcidin (hepcidin-25) and the -22 (hepcidin-22), and -20 
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(hepcidin-20) residues (Kroot et al 2010), whereas the interpretation of hepcidin results from 
the immunoassays may be hampered by cross-reaction with the various forms of 
physiological hepcidin, such as free or protein bound form, or by the presence of these 
hepcidin isoforms which may well interfere with hepcidin quantification. However, this 
concern might be overcome by exploiting antibodies that are hepcidin specific i.e. production 
of monoclonal anti-hepcidin antibodies generated against the 5-7 residue N-terminal region 
of hepcidin-25. However, it should be noted that the relevance of measuring hepcidin-25 
rather than total hepcidin for clinical decision-making has not been systematically 
investigated. 
 
As described in Chapter 2, I have produced a specific and well characterised polyclonal 
antibody to the synthetic 25 residue hepcidin. I was able to establish that the purified form of 
this antibody was able to recognise endogenous human hepcidin and using this antibody 
developed the first published competitive radioimmunoassay (RIA) for hepcidin (Busbridge et 
al 2009). Although there are obvious limitations to using radioisotopic labeled assays 
compared to ELISA, we decided on developing the hepcidin RIA as this assay format offers 
a number of advantages over the ELISA, such as the use of diluted antisera rather than 
purified antisera which ELISA requires to limit background interference. It is also easier to 
run large batches of samples in an RIA, and RIAs are largely unaffected by possible 
interference of signal end-point by highly coloured patient samples, such as those from 
haemolysed and icteric collections, temperature, pH of buffers and stability of the 
measurable end-point products.  
 
Using the validated hepcidin RIA, I was able to confirm the central role of hepcidin in iron 
regulation by its significant correlation with ferritin in healthy controls. I was able to define a 
preliminary plasma reference interval for hepcidin in a healthy control population. The high 
degree of inter-individual variance in plasma hepcidin concentrations as reflected by the 
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wide reference interval (2.1-58ng/mL) has been observed in a larger recent study of hepcidin 
concentrations in a healthy control population of mixed gender and age ranges (men; 
n=1066 (and women; n=882, (18-≥85yrs)) (Galesloot et al 2011), which may imply that 
population-based reference ranges has limitations when used for the interpretation of 
individual hepcidin concentrations. It would appear that hepcidin values, like other 
hormones, should be interpreted as (in) appropriate in the context of indices of iron 
metabolism. In a study by Thomas et al it has been proposed that hepcidin may have 
diagnostic utility when used in combination with sTfR measurement in discriminating altered 
states of anaemia (Thomas et al. 2011). Although sTfR is not directly related to hepcidin 
concentrations, this marker is an excellent indicator of iron uptake as it is not influenced by 
inflammation, thus the combination of sTfR and hepcidin as an index may have value in 
discriminating between absolute iron deficiency and anaemia of inflammation (Thomas et al. 
2011). Diagnostic use of hepcidin and sTfR in combination requires further validation and 
definition of appropriate cut-offs, but with the availability of an established sTfR international 
reference preparation (Thorpe et al. 2010), this could improve the diagnostic utility of the 
sTfR/hepcidin test combination. 
 
In the population study conducted by Galesloot et al it was also shown that ferritin was the 
most important associate of hepcidin concentrations, but it was not possible to define 
whether the ferritin concentration determines hepcidin concentration or vice versa.  
Galesloot et al also demonstrated in their study that variations in hepcidin concentrations 
with age differed between men and women. Men showed a stable hepcidin concentration, 
but in women, hepcidin concentrations were substantially higher for postmenopausal than for 
premenopausal women. This higher hepcidin concentration in postmenopausal women is in 
agreement with the observation that ferritin concentrations tend to increase sharply as 
women progress through menopause (Escobar-Morreale 2012). I also observed gender 
related differences in hepcidin with my RIA, as had been previously reported (Ganz et al 
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2008). These differences are likely related to the lower iron stores seen in women, which are 
also reflected in the lower ferritin concentrations. However Galesloot et al have reported a 
less pronounced gender difference in hepcidin concentrations which may be due to 
differences in the reference population, with a lower median age for women (32.6 years) in 
the Ganz et al and (37 years) in the Busbridge et al studies compared to the Galesloot et al 
population (55 years).  
 
Plasma and urine hepcidin in healthy controls also correlated significantly in the healthy 
controls, but urine hepcidin concentrations may not always accurately reflect plasma 
hepcidin concentrations. Interpretation of urinary hepcidin data is difficult because urine 
concentrations may also depend on glomerular filtration, tubular reabsorption, local 
production by tubular epithelial cells (Kulaksiz et al. 2005) and production by interstitial 
inflammatory cells (Zhang et al. 2008). In addition, Kroot et al reported relatively high 
(pre)analytical variation in urine hepcidin measurements (Kroot et al 2009). Urine hepcidin 
measurements are also sensitive to oxidation (Swinkels et al 2008) and the urine may 
contain relatively high concentrations of the smaller hepcidin fragments, which cannot be 
distinguished from mature hepcidin by most immunoassays.  
 
I was also able to compare the RIA directly against a published MS method and thus to 
demonstrate the similarity in the results achieved using both methods. I also participated in 
an international round robin of hepcidin methods organised by Swinkels et al in which the 
RIA I developed compared favourably with MS and other immunoassay methods (Kroot et al 
2009). In this study the correlations between the participating methods were generally high 
and the between-sample and analytical variation of most of the methods was similar. 
However, absolute hepcidin concentrations differed widely between the assays (Kroot et al 
2009). This latter variation is not surprising given the absence of a hepcidin reference 
method and a validated international reference standard for assay harmonization. These 
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differences in level assignment hindered the comparability of data and the definition of 
universal reference intervals and cut-off values for clinical decision making. Therefore, a 
second Round Robin for plasma hepcidin has been proposed by Swinkels et al to explore 
world-wide hepcidin harmonization by exchanging synthetic materials for assay 
harmonization. 
 
In the experiments described in Chapter 3 I was able to accurately detect the expected 
physiologic and pathologic variations in hepcidin concentrations using the validated hepcidin 
RIA. The selectivity of the hepcidin RIA is indicated by the low plasma hepcidin levels that 
were found in IDA and UC patients diagnosed with IDA, reflecting the low circulating or 
stored iron levels. I was also able to detect the expected elevated concentrations of plasma 
hepcidin in CKD and CKD patients on HD, which may be due to the decreased renal 
clearance of hepcidin, due to impaired glomerular function, augmented by the hepcidin 
induction by inflammation related to the underlying disease process or haemodialysis 
However, in this study, no association with inflammatory markers such as CRP or IL-6 was 
observed, I did not measure pro-inflammatory markers in the renal patients. Although the 
association between hepcidin and inflammatory markers has been demonstrated in other 
studies with CKD patients, (Tomosugi et al 2006; Zaritsky et al 2009; Peters et al 2010; 
Weiss et al 2009; Ford et al 2010). The uraemia observed in renal disease is considered an 
inflammatory state, even in the absence of apparent infection or obvious inflammatory 
conditions, with up regulated production of pro-inflammatory cytokines such as TNF-α, IL-1 
and IFN-γ contributing to the anaemia observed in CKD (Coyne 2011). These pro-
inflammatory cytokines are thought to act on erythroid progenitor cell proliferation thereby 
inhibiting erythroid colony formation and response to EPO, but also inhibiting EPO 
production, thus leading to the anaemia of inflammation, (Mahdavi et al 2011).  This 
anaemia is characterized by decreased iron and iron-binding capacity, increased ferritin and 
an abundance of iron in the bone marrow, (Mahdavi et al 2011). This actually represents a 
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state of iron sequestration in reticuloendothelial cells and suggests that the plasma iron 
levels are inadequate to support erythropoiesis, (Ganz et al 2009).This process is illustrated 
in Figure 5.1.1 as an updated overview of hepcidin mediated iron metabolism.  
 
 
  
 
Figure 5.1.1 Hepcidin as the main regulator of systemic iron homeostasis. Hepcidin synthesis 
is induced by iron loading and inflammation, principally the inflammatory cytokines IL-6, BMP-2, -4, -6 
and -9, and suppressed by erythropoiesis and tissue hypoxia. In the case of an iron load, increased 
hepcidin levels limit further enteral iron absorption and release of iron from the liver and the 
reticuloendothelial system to normalize plasma iron levels. With increased inflammation, elevated 
hepcidin levels cause the same sequence of events, leading to reticuloendothelial blockade and the 
anaemia of inflammation. Conversely, by suppressing hepcidin production, erythropoietic activity 
increases the availability of iron by enhancing enteral absorption and release of iron from the liver and 
the reticuloendothelial system. EPO from the kidney initiates the production of red blood cells from 
bone marrow tissue. Exogenous EPO administration has a suppressive effect on circulating hepcidin 
thereby inducing iron absorption. In chronic inflammatory conditions EPO response is blunted and this 
is thought to be mediated via inflammatory cytokines such as IL-1, TNF-α and IFN-γ.(IL-6; interlukin-6, 
BMP; bone morphogenic protein, EPO; erythropoietin, IL-1; interlukin-1, TNF-α; tumour necrosis-
alpha, IFN-γ; interferon-gamma, Fe-Tf, iron-transferrin complex). (Adapted from Cullis 2011). 
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Hepcidin levels in pretreated HH patients diagnosed with the HFE gene mutation and 
undergoing regular phlebotomy treatment were not low as might be expected, but rather 
were inappropriately normal, indicating that the mutation affects hepcidin signalling rather 
than hepcidin production. Unfortunately I was unable to collect post-treatment samples from 
these patients or from possibly affected family members which may have given more data on 
the role of hepcidin in HH-HFE. The hepcidin concentrations measured in the normal and 
pathological patient samples were largely consistent with the proposed mechanism and 
regulation of hepcidin action, and the range of measured plasma hepcidin concentrations 
(0.6 – 436ng/mL) was in accord with concentrations known to stimulate the internalization of 
Fpn (Nemeth et al 2004).  
 
Plasma hepcidin concentrations showed diurnal changes similar to plasma iron 
concentrations, indicating that clinical studies should be designed to avoid this potentially 
confounding influence. Hepcidin levels also increased markedly with acute changes in 
plasma iron as induced by an oral challenge with iron sulfate in healthy controls and by IV- 
Fe in a severely anaemic patient. The almost immediate effects of iron administration on 
hepcidin levels are consistent with hepcidin regulation occurring rapidly. The immunoreactive 
distribution of hepcidin in HC and CKD plasma indicated that the hepcidin RIA recognises 
endogenous hepcidin-25 and cross-reacts approximately 10% with the hepcidin-20 isoform. 
This isoform and the hepcidin-22 isoform are rare in reference populations (Kroot et al. 
2010), though the hepcidin-20 isoform is present at higher levels in CKD plasma.  The 
pathological role, if any, of these isoforms are currently unknown, as they are unable to bind 
to ferroportin (Nemeth et al 2006). 
 
In the studies described in Chapter 4 I have shown that the elevated hepcidin in CKD is still 
significantly associated with ferritin, indicating that the physiological regulation of hepcidin by 
222 
 
iron stores is maintained in CKD, though hepcidin concentrations are at higher levels than in 
healthy controls. However, this relationship is less pronounced in HD patients due to regular 
IV-Fe therapy. I also established that hepcidin levels in CKD patients were significantly 
correlated with eGFR, even when corrected for ferritin levels, although this finding is in 
contrast to a recent study by Peters et al which found that hepcidin levels were not related to 
eGFR in CKD patients (Peters et al. 2010). Using a SELDI-TOF MS method which is able to 
distinguish between two predominant isoforms, this study found that hepcidin-25 and 
hepcidin-20 were not significantly different in predialysis CKD patients compared to HC, but 
both hepcidin-25 and hepcidin-20 increased significantly in stable HD patients compared to 
the CKD and HC patients. But in contrast to our reported results, hepcidin-25 and hepcidin-
20 levels were both independent of eGFR, but similar to our study both isoforms 
demonstrated a significant negative relationship with eGFR. This apparent discrepancy 
between the two observations could be explained by the use of different assays, and in 
particular the inability of the hepcidin RIA to differentiate between the various isoforms, but 
also by the qualitative differences between the populations studied (for example, due to 
comorbidities). Another possibility is a type 1 error in our study, although the significance of 
eGFR as a predictor of hepcidin in our model makes this unlikely (p 0.017). It is also possible 
that the Peters et al result reflects a type 2 error, which may, in linear regression, be due to 
sample size or the number of predictors—particularly when, as in this case, the effect may 
be relatively weak (β -0.230 vs. 0.745 for ferritin in our model) (Ashby et al 2009). A similar 
study by Campostrini et al, using a similar MS method to discriminate between hepcidin 
isoforms, reported that hepcidin-20 was also significantly higher in CKD patients on HD 
similar to hepcidin-25, but the hepcidin-20 was not correlated with ferritin or inflammatory 
markers. This suggests that two possible mechanisms may be responsible for the increased 
hepcidin-20 levels; i) altered proteolytic processing and/or ii) reduced renal excretion of a 
catabolic product normally produced in small amounts. (Campostrini et al 2010). 
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In the CKD patients I detected a positive response to IV-Fe therapy similar to the HC 
response, but the diurnal variation was suppressed in these patients. A major diagnostic 
problem in managing CKD-related anaemia is determining whether patients need parenteral 
iron. Studies examining ferritin, transferrin saturation, combinations of these tests and other 
tests have failed to find a reliable predictor for iron response in dialysis and non-dialysis 
CKD, (Coyne et al 2007; Singh et al 2007; Stancu et al 2010). As hepcidin is the true 
regulator of iron stores, I hypothesize that serum hepcidin might better predict iron-restricted 
erythropoiesis. My data supports a potential role for hepcidin in clinical assessment of 
anaemia. I have observed a relationship with ferritin to hepcidin levels in dialysis patients, 
and an inverse relationship of hepcidin level to epoetin dose, and a decline in hepcidin upon 
initiating epoetin, as observed by Weiss et al, (Weiss et al 2009). These findings are 
consistent with hepcidin being reflective of iron status and iron demands in dialysis patients, 
and suggest hepcidin levels could have predictive value in individuals. 
 
Similar to hepcidin, ferritin also correlates with iron status, but ferritin levels have a high 
short-term intra-patient coefficient of variation and are affected by inflammation, (Ford et al 
2010). Ferritin has been repeatedly been shown to lack adequate predictive value for 
identifying a response to intravenous iron, (Ford et al 2009). In some studies, hepcidin levels 
in dialysis patients correlate with levels of C-reactive protein, a marker of inflammation, 
(Peters et al 2010; Ford et al 2010), which is unfortunate as it is in inflamed patients that the 
question of whether to administer iron arises. In addition, the intra-patient coefficient of 
variation for hepcidin is even higher than for ferritin, undermining the value of a single 
determination as indicative of iron status or iron needs, (Ford et al 2009; Ford et al 2010). 
However, further investigation into the relationship of the various hepcidin assay methods to 
predictive value is needed. In CKD stages 2–4, hepcidin may afford more diagnostic value, 
as values are lower and may be more stable 
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Interestingly, in a small study looking at pre- and post-dialysis hepcidin plasma levels in a 
single HD session, no significant reduction in hepcidin was seen post-dialysis. Considering 
the size of hepcidin (2789Da), perhaps a 20–30% reduction in hepcidin concentrations 
would be anticipated post-dialysis. Although this may simply reflect a type 2 error—with a 
sample of six patients a small reduction might not be detected (95% confidence interval = 
80–120% for the post–pre dialysis hepcidin ratio)—other explanations should not be 
overlooked. For example, hepcidin might be secreted into the circulation in appreciable 
quantities during dialysis, which is known to activate an inflammatory response due to the 
interaction of blood with the dialysis membranes and/or with a less-than-sterile dialysis fluid 
(Kaysen et al. 2001;Kaysen 2001). Alternatively, clearance may be lower than expected 
because of aggregation or binding to larger plasma proteins such as α-2-macroglobulin 
(Peslova et al 2009). This finding is also corroborated by Peters et al who reported that 
hepcidin levels decreased only slightly during HD (approximately 10–15%) (Peters et al 
2010). Campostrini et al in contrast reported that a single HD session appeared to 
significantly reduced hepcidin-25 levels in CKD patients (n=44), but that the extent of the 
reduction by dialysis showed a high inter-individual variability. This suggests that the lack of 
reduction in hepcidin levels seen in our small study (n=6) may reflect the large individual 
variability in hepcidin levels rather than a lack of effect. All the HD techniques evaluated in 
the Campostrini et al study showed a comparable removal of hepcidin-25 by dialysis, 
suggesting that the removal of this molecule is largely due to diffusion, but the large 
individual variability of the reduction ratio in patients treated by the same dialysis modality 
suggests that post-dialysis levels are influenced by factors other than removal by dialysis. 
The removal of hepcidin-20 and hepcidin-25 was similar by the different dialysis modalities 
investigated, suggesting that the different HD modalities remove the two isoforms through 
common mechanisms (Campostrini et al. 2010). Additional studies with larger sample sizes 
are needed to fully understand the effect of dialysis on levels of the two hepcidin isoforms. 
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Hyporesponsiveness to EPO treatment of anaemia in CKD is a difficult clinical issue to 
resolve, as resistance to exogenous EPO is associated with an increase in patient mortality. 
In early in vitro studies EPO was shown to down-regulate liver hepcidin mRNA expression, 
acting, therefore as a hepcidin inhibitory hormone (Nicolas et al. 2002), and in a more recent 
in vitro study, hepcidin was shown to inhibit erythroid progenitor proliferation and survival 
(Dallalio et al. 2006), suggesting that hepcidin may have a role in the EPO resistance 
observed in some patients. Although my studies show that elevated hepcidin is associated 
with anaemia, EPO was negatively correlated with hepcidin, suggesting that in vivo EPO 
suppresses circulating hepcidin levels. I confirmed this in CKD patients initiating EPO 
treatment, who demonstrated a significant decrease in hepcidin levels.  These important 
findings suggest that EPO therapy can suppress hepcidin, thus ameliorating the disordered 
iron transport as well as treating the EPO deficiency in renal patients. But the EPO does not 
appear to be a direct regulator of hepcidin, and the mechanisms by which erythropoiesis 
affects hepcidin production are not well understood, but both direct and indirect effects of 
anaemia and erythropoiesis could contribute. Possible mediators include soluble factors 
released by erythroid precursors and decreased circulating or stored iron. Hypoxia may alter 
hepcidin production directly through hypoxia inducible factor or indirectly via increased EPO 
production and erythropoiesis, (Goodnough et al 2011). 
 
Hepcidin has been evaluated as a predictor of EPO response in several relatively small 
studies in humans. One study found that hepcidin concentrations of EPO responders did not 
differ significantly from those of hypo responders (Kato et al. 2008), whereas cross-sectional 
studies among HD patients and a prospective study among patients with combined CKD and 
chronic heart failure found that non-responders had low hepcidin concentrations (Bratescu et 
al. 2010;Costa et al. 2009b;Valenti et al 2009). This has been corroborated in other studies 
where hepcidin seems to reflect iron load and response to EPO, rather than inflammation 
and EPO resistance (van der Putten et al. 2010).  
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In additional novel human studies, I confirmed the importance of a rapidly responsive 
marrow-hepcidin axis in regulating iron supply in vivo, where exogenous EPO had a rapid 
and prolonged effect on hepcidin levels in HC and phlebotomy had a similar, though less 
pronounced, effect. Other measured factors, such as sTfR and GDF15, were unaffected, 
suggesting that this axis is regulated by factors other than circulating iron and these marrow 
derived factors. This data adds to the underlying principle behind the use of EPO for the 
treatment of anaemia of chronic disease improving the disorder of iron transport as well as 
supplementing a diminished erythropoietin response. Similar studies have demonstrated that 
increased erythropoietic drive can inhibit both inflammatory and iron-sensing pathways via 
the suppression of STAT3 and SMAD4 signaling in vivo, thus down-regulating production of 
hepcidin, (Pinto et al 2008). 
 
The lack of an exogenous EPO effect on the erythropoietic factors, sTfR and GDF-15 in this 
study suggests the possible presence of an unknown circulating factor that mediates the 
action of EPO in down-regulating hepcidin production. A proposed study to investigate this 
potentially important finding will be the subject of a future in vitro study. The basis of the 
study would involve the use of primary human hepatocyte cell lines, passaged appropriately 
to allow quantification of basal hepcidin levels. These cell lines would then be cultured with 
healthy human sera, sera from HCKD patients currently undergoing EPO treatment and 
similar HCKD sera but with the EPO removed by immunoprecipitation. The direct effect of 
EPO and the possibility of a secondary effect could then be assessed by quantifying any 
subsequent change in hepcidin levels.   
 
Although hepcidin is a promising companion diagnostic for EPO therapy, patients with renal 
insufficiency are a complex population in which consistent results have been difficult to 
obtain (Ford et al. 2010). Clinical stability, time of sampling in relation to iron and EPO 
227 
 
therapy, and iron and EPO dosage and dialysis regimens differ between studies and are 
likely to influence results. Therefore, there is need for further studies on hepcidin 
concentrations in larger and well designed studies to resolve these discrepancies in the 
literature.  
 
The diagnostic and therapeutic implications for consideration in iron-restricted 
erythropoiesis, which is observed in CKD related anaemia, depend on the assessment of 
whether the patient has an absolute iron deficiency, an iron sequestration syndrome, and/or 
functional iron deficiency. Hepcidin levels are elevated in patients with anaemia of 
inflammation compared to normal values, and are low or undetectable in patients with 
absolute iron deficiency. However, in patients who have mixed pathologies such as anaemia 
of inflammation coexisting with absolute iron deficiency or functional iron deficiency, hepcidin 
levels may not reliably distinguish among iron deficiency syndromes (Goodnough et al 
2011). Expected changes in hepcidin levels and iron variables in various clinical conditions, 
and in the potential use of hepcidin-targeted and iron therapies in patients with various forms 
of anaemia, are summarized in Table 5.1.1. 
 
As the pathogenic mediator of inflammation, hepcidin would be expected to be high in iron 
sequestration syndromes. Additionally, as hepcidin levels are also affected by iron stores, 
the hepcidin assay could also identify patients most likely to respond to iron therapy or 
identify patients at risk for iron loading. For patients with mixed presentations, however more 
complex algorithms would be need to be generated and tested to provide optimal guidance 
in the evaluation and management of anaemia, (Goodnough et al 2011). For example, 
functional iron deficiency can occur in several different conditions, so the hepcidin levels 
may be variable: in resistance to EPO therapy due to CKD (which may be due to decreased 
hepcidin renal clearance and inflammation), hepcidin levels will be high; in conditions of 
accelerated erythropoiesis due to endogenous EPO or erythropoietic stimulating agents, 
228 
 
hepcidin levels will be suppressed. It is also important realise that several iron deficiency 
syndromes can coexist in patients: for example, if iron sequestration coexists with functional 
iron deficiency, hepcidin levels are variable (Table 5.1.1). For these patients, hepcidin levels 
may not help diagnostically but may give therapeutic guidance for the anaemia management 
(and, for example, hepcidin antagonists may be useful if hepcidin levels are high due to 
inflammation) or may identify patients who are likely to respond to iron (oral vs. intravenous) 
therapy (i.e. if hepcidin levels are low with insignificant storage iron or accelerated 
erythropoiesis), (Goodnough et al 2011). The relationship between these syndromes is 
shown in Figure. 5.1.1 
 
Table 5.1. Potential role of hepcidin in diagnosis and management of anaemia. 
Condition 
Expected 
hepcidin 
levels 
Iron variable 
Iron therapy 
strategies 
Potential 
hepcidin 
therapy 
 
Absolute iron 
deficiency anaemia (IDA) 
Low 
Low TSAT and 
ferritin 
PO or IV (if 
poorly tolerated 
or absorbed) 
No 
 
Functional iron deficiency 
(ESA therapy, CKD) 
Variable 
depending on 
± CKD 
Low TSAT, 
variable ferritin 
IV 
Antagonist (if 
hepcidin low) 
 
Iron sequestration (anaemia 
of inflammation (AI)) 
High 
Low TSAT, 
normal to 
elevated 
ferritin 
IV Antagonist 
 
Mixed anaemia (AI/IDA or 
AI/functional iron deficiency) 
Variable 
Low TSAT, 
normal to 
elevated 
ferritin 
IV† 
Antagonist (if 
hepcidin low) 
 
Iron loading anaemias (e.g. 
Ineffective erythropoiesis) 
Low 
High TSAT 
and ferritin 
Iron chelation 
therapy 
Agonist 
 
Iron loading anaemias 
treated with transfusion 
Normal to High 
High TSAT 
and ferritin 
Iron chelation 
therapy 
Agonist 
 
Updated from Goodnough et al 2010. †mixed anaemia is a diagnosis of exclusion without a 
therapeutic trial of iron. (PO; oral iron, IV; intravenous iron, CKD; chronic kidney disease; TSAT; 
transferrin saturation). 
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Figure 5.1.2 Iron deficiency syndromes. The relationship between absolute iron deficiency, iron 
sequestration, and functional iron deficiency. Patients can have one or more combinations that all 
result in iron-restricted erythropoiesis. (Adapted from Goodnough et al 2011). 
 
 
Since the discovery of hepcidin a decade ago, multiple studies have contributed insights into 
its regulation and its functional properties. The first reliable assays to quantify hepcidin in 
human body fluids have been developed, and proof-of-principle studies in human iron 
disorders highlight hepcidin as a promising novel tool in diagnostic medicine. However, the 
use of different assay technologies to assess hepcidin concentrations in patients with 
disorders of iron metabolism makes the interpretation of the results of these published 
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studies complex. For example, the relative inability of non-specific immunoassays unable to 
distinguish between the hepcidin isoforms implies that measured hepcidin concentrations in 
specific studies using particular immunoassays may not necessarily reflect only bioactive 
hepcidin-25 levels. The generation of specific antibodies to hepcidin-25 could possible avoid 
such technical issues (Butterfield et al. 2010;Troutt et al. 2012).  
 
In conclusion, hepcidin is a promising diagnostic tool. However, if the measurement of 
hepcidin is to be useful in diagnostic medicine, there is a need to assess the relevance of 
specifically measuring hepcidin-25, to harmonize the various assays to enable the 
establishment of world-wide reference intervals, to establish appropriate clinical decision 
limits, and to make assays more readily available to clinical laboratories.  
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Appendix I 
 
Table 1.1 Mean (±SD) urine and plasma hepcidin levels for the Round Robin method comparison study. Results presented by sample ID and method. (Method VI 
represents the Hepcidin RIA developed at Imperial College). Urine sample ‘5’ represents ‘spiked’ samples with synthetic hepcidin-25. Urine results in nmol/mmol creatinine, 
plasma results in nmol/L; 1 nmol hepcidin-25 =2.789 μg; < LLOD, below lower level of detection, for method I: signal/noise < 3, for method II : < 50 pM and < 0.5 nM for urine and 
plasma, respectively. Mass spectrometry methods are highlighted in black. Adapted from (Kroot, Kemna, Bansal, Busbridge, Campostrini, Girelli, Hider, Koliaraki, Mamalaki, 
Olbina, Tomosugi, Tselepis, Ward, Ganz, Hendriks, & Swinkels 2009b). 
 
 
Body 
Fluids 
 
Sample Method I* 
Mean    SD 
Method II 
Mean    SD 
Method III 
Mean     SD 
Method IV 
Mean     SD 
Method V 
Mean    SD 
Method VI 
Mean     SD 
Method VII 
Mean      SD 
Method VIII 
Mean       SD 
Urine 1 0.04     (0.01) <LLOD     - 0.6      (0.4) 1.0       (0.6) 1.5       (0.3) 0.2      (0.01)     -            -             -            -         
 2 0.2     (0.1) 0.4       (0.1) 4.4      (4.0) 2.2       (0.7) 14.1     (0.5) 3.2      (0.2) 
    -            -     -            - 
 3 0.5     (0.1) 0.6       (0.1) 1.9       (0.6) 2.4       (0.7) 19.0     (4.2) 2.3      (0.4)     -            -             -            -         
 4 0.6     (0.2) 1.9       (0.4) 7.0       (0.7) 3.7       (1.1) 105.8    (176) 8.3      (1.0) 
    -            -     -            - 
 ‘5’ 1.2     (0.4) 12.0     (3.0) 27.1     (6.7) 14.7     (1.9)   115.4   (14.9) 12.1     (0.9)     -            -             -            -         
 6 2.7     (0.5) 48.6     (6.3) 2.7      (0.6) 51.2      (14.7) 861.6   (308.2) 14.3      (1.6) 
    -            -     -            - 
 7 6.3     (1.2) 35.1     (6.5) 14.4     (3.3) 52.9      (11.5) 659.6   (176.4) 12.9     (1.2)     -            -             -            -         
 8 11.6   (2.7) 184.8    (36.0) 49.2    (8.7) 153.0    (21.9) 1646.9    (597.1) 13.7    (0.9) 
    -            -     -            - 
          
Plasma 9 <LLOD    - <LLOD     - 0.2      (0.6) 1.1       (0.4) 2.4       (3.8) 0.5     (0.1) 0.3     (0.1) 61.1     (6.6) 
 10 4.6       (1.8) 4.3       (0.3) 14.3     (2.7) 7.1      (0.6) 39.7      (10.7) 9.4     (0.5) 4.1     (0.7) 32.7     (4.9) 
 11 4.1       (1.0) 5.6       (1.1) 16.2     (2.6) 7.2      (0.5) 61.3      (12.9) 9.9     (0.8) 4.6     (0.7) 19.4     (2.7) 
 12 7.5       (3.2) 8.4       (0.6) 23.4      (3.4) 14.1     (0.7) 128.9     (46.2) 21.2    (1.4) 9.3     (1.7) 23.1    (2.8) 
 13 8.7       (3.6) 7.6       (2.4) 24.9      (3.9) 15.0     (1.0) 100.9     (53.5) 23.3    (0.9) 10.1    (1.8)  43.3    (5.4) 
 14 18.3     (5.6) 23.8     (3.6) 23.8      (3.6) 34.7     (1.6) 259.5     (37.0) 29.6    (1.5) 29.2    (5.9)  58.0    (5.2) 
 15 25.1     (6.0) 28.2     (2.6) 28.2      (2.6) 35.7     (1.5) 279.7     (44.2) 27.2    (2.0)  29.3    (4.0)  52.6    (6.7) 
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Table 1.2 Sample means and variations by method for urine and plasma hepcidin levels. (Method VI represents the Hepcidin RIA developed at Imperial College). 
Between-sample; variation between samples; analytical variation, repeated measurements; SD, standard deviation i.e. absolute error; CV: coefficient of variation, i.e. relative 
error; % of total variance, % of variance-segment to the total variance sample means and SDs in nmol/mmol creatinine and nmol/L for urine and plasma, respectively. Mass 
spectrometry methods are highlighted in black. Adapted from (Kroot, Kemna, Bansal, Busbridge, Campostrini, Girelli, Hider, Koliaraki, Mamalaki, Olbina, Tomosugi, Tselepis, 
Ward, Ganz, Hendriks, & Swinkels 2009b). 
 
 
 
Body 
Fluids 
 
 
Method 
 
Mean all 
sample 
 
 
SD 
 
Between-sample 
CV(%) 
 
% of total 
variance 
 
  
SD 
Analytical Variation 
Between-day 
CV(%) 
 
%of total 
variance 
 
 
SD 
Urine I 2.9 4.1 139.9 93.4 <0.1 <0.1 <0.1 1.1 
 II 44.4 66.1 148.8 95.9 4.9 11.0 0.5 12.8 
 III 13.4 16.9 125.9 93.7 1.8 13.3 1.1 4.0 
 IV 35.1 52.3 148.9 96.3 <0.1 <0.1 <0.1 10.2 
 V 427.1 587.8 137.6 85.4 102.8 24.1 2.6 220.6 
 VI 7.9 5.7 72.2 97.2 0.6 7.2 1.0 0.8 
          
Plasma I 11.4 8.4 73.6 81.3 1.6 14.4 3.1 3.7 
 II 13.0 10.3 79.1 96 0.4 3.2 0.2 2.1 
 III 27.4 21.3 77.9 92.1 0.7 2.6 0.1 6.2 
 IV 16.4 13.6 83.2 99.5 0.2 1.2 <0.1 1.0 
 V 124.6 107 85.8 89.4 26.1 20.9 5.3 26.0 
 VI 17.3 10.8 62.3 98.8 0.1 0.6 <0.1 1.2 
 VII 12.4 11.9 96.3 94.4 <0.1 <0.1 <0.1 2.9 
 VIII 41.5 16.7 40.2 90.9 3.1 7.5 3.1 4.3 
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Figure 1.1 Effect of Erythropoietin (EPO) administration on plasma A) Hepcidin and B) 
Transferrin saturation (TSAT). Individual responses to EPO (Sc) (5000 units epoetin beta) 
administration at 09:00 on day 2. Dotted lines represent reference intervals for hepcidin and TSAT 
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Figure 1.2 Effect of Erythropoietin administration on plasma A) Ferritin and B) Soluble 
Transferrin Receptor (sTfR). Individual responses to EPO (Sc) (5000 units epoetin beta) 
administration at 09:00 on day 2. Dotted lines represent reference intervals. 
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Figure 1.3 Effect of Erythropoietin (EPO) administration on plasma A) Growth 
differentiation factor-15 (GDF15) and B) Response to EPO. Individual responses to erythropoietin 
(Sc) (5000 units epoetin beta) administration at 09:00 on day 2. No defined reference intervals for 
GDF15. Dotted line represents upper reference interval for EPO at 20mIU/mL. 
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Figure 1.4 Effect of venesection on plasma A) Hepcidin and B) Transferrin saturation 
(TSAT). Individual responses to venesection (250mL) at 09:00 on day 2. Dotted lines represent 
reference intervals. 
237 
 
F
e
rr
iti
n
 (

g
/L
) 
L
o
g
0
9
:0
0
1
2
:0
0
1
5
:0
0
1
8
:0
0
0
9
:0
0
1
2
:0
0
1
5
:0
0
1
8
:0
0
0
9
:0
0
1
2
:0
0
1
5
:0
0
1
8
:0
0
0
9
:0
0
1
2
:0
0
1
5
:0
0
1
8
:0
0
0
9
:0
0
1
2
:0
0
1
5
:0
0
1
8
:0
0
1
5
:0
0
1
5
:0
0
1
10
100
1000
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7
Venesection
Male
Male
Male
Female
Male
Male
Group Mean
A
s
T
fR
 (
n
m
o
l/L
)
0
9
:0
0
1
2
:0
0
1
5
:0
0
1
8
:0
0
0
9
:0
0
1
2
:0
0
1
5
:0
0
1
8
:0
0
0
9
:0
0
1
2
:0
0
1
5
:0
0
1
8
:0
0
0
9
:0
0
1
2
:0
0
1
5
:0
0
1
8
:0
0
0
9
:0
0
1
2
:0
0
1
5
:0
0
1
8
:0
0
1
5
:0
0
1
5
:0
0
10
20
30
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7
Venesection
Male
Male
Male
Female
Male
Male
Group Mean
B
 
Figure 1.5 Effect of venesection on plasma A) Ferritin and B) Soluble transferrin receptor 
(sTfR). Individual responses to venesection (250mL) at 09:00 on day 2. Dotted lines represent 
reference intervals. 
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Figure 1.6 Effect of venesection on plasma A) Growth differentiation factor-15 (GDF15) 
and B) Erythropoietin (EPO). Individual responses to venesection (250mL) at 09:00 on day 2. No 
defined reference intervals for GDF15. Dotted line represents upper reference interval for EPO at 
20mIU/mL. 
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Appendix III 
 
Suppliers 
 
Abbott Diagnostic Ltd, Maidenhead, Berkshire, UK 
Bachem Ltd, Merseyside, UK 
Bayer, Newbury, Berkshire, UK 
Becton Dickson Healthcare, Oxford, Oxfordshire, UK 
BHD Chemicals Ltd, Poole Dorset, UK 
Ciphergen Biosystems Inc, Fremont, California, USA 
Diagnostic Scotland, Edinburgh, Midlothian, UK 
Eppendorf, Cambridge, Cambridgeshire, UK 
European Collection of Cell Cultures, Porton Down, Wiltshire, UK 
Fisher Scientific, Loughborough, Leicestershire, UK 
Gibco-BRL, Paisley, Renfrewshire, UK 
Graphpad Software, La Jolla, California, USA 
Imperial School of Medicine, London, UK 
Invitrogen Ltd, Paisley, Renfrewshire, UK 
Jasco, Peterborough, Cambridgeshire, UK 
Jouan SA, Saint-Herblan, France 
Microsoft Ltd, Reading, Berkshire, UK 
Millipore, Watford, Hertfordshire, UK 
Nalgene, Hereford, Herefordshire, UK 
Novex, Invitrogen Life Technologies, Paisley, Renfrewshire, UK 
Perkin Elmer, Chalfont, Buckinghamshire, UK 
Peptide Institute, PeptaNova, Sandhausen, Germany 
Pierce, Cramlington, Northumberland, UK 
Research & Medical Systems, Oxford, Oxfordshire, UK 
R&D Systems, Abingdon, UK 
Serotec Ltd, Oxford, Oxfordshire, UK 
Scipac Ltd, Sittingbourne, Kent, UK 
Siemens Healthcare, Camberley, Surrey, UK 
Sigma, Poole, Dorset, UK 
Sysmex Ltd, Milton Keynes, UK 
Wallac, Beaconsfield, Buckinghamshire, UK 
Waters, Elstree, Hertfordshire, UK 
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